全國服務咨詢熱線:
18501609238
18501609238
詳細介紹
| 品牌 | 其他品牌 | 供貨周期 | 現貨 |
|---|---|---|---|
| 應用領域 | 食品,化工,生物產業,制藥 |
Cayman Chemical
Cayman以幫助從事人類健康以及動物健康研究事業的科學家提供研究工具為使命，承諾為廣大科研人員提供優質的產品和實惠的價格政策。其擁有眾多從事化學化成、純化、生化分子的鑒定等領域的科學家。同時，在免疫檢測、抗體生產、蛋白表達、蛋白結晶和測定等方面也具有豐富的研發和生產經驗。在過去的30多年里，Cayman積淀了深厚的脂質化學知識，包括涉及花生四烯酸級聯，這些知識使得Cayman能夠生產出品質的試劑，用于癌癥、氧化損傷、表觀遺傳學、神經科學、炎癥、代謝等領域的研究。目前，Cayman可提供生化試劑，抗體，EIA，蛋白等多種產品。產品分類查詢：
Cayman提供眾多*的EIA, 助您科研更輕松！
Cayman不懈努力的目標就是要讓您的研究更簡便，同時幫您節省經費。目前，Cayman可提供200余種不同的，主要覆蓋類花生四烯酸、內分泌、氧化損傷、動脈粥樣硬化、代謝、神經生物學以及染色質修飾等方面。可提供多種使用便捷的試劑盒，包括
EIA (Enzyme Immunoassay) Non-EIA, small molecule detection Transcription Factors STEP Transfection
酶免分析 小分子檢測 轉錄因子
Prostaglandin E2 前列腺素E2 Antioxidant 抗氧化劑 ChREBP CYP3A4 Induction
Cyclic Nucleotides (cGMP Free Fatty Acid 游離脂肪酸 CREB (Phospho-Ser133) EP2 Receptor (rat)
and cAMP) 環核苷酸
8-Isoprostane 8-異前列烷 Nitrate/Nitrite 亞硝酸鹽 NF-κB (p50 and p65) EP4 Receptor (rat)
Estradiol 雌二醇 TBARS PPAR Melanocortin
See all EIA kits Thiol Detection 巰基檢測 p53 Orexin
See all Non-EIA, See all transcription factor assays See all STEP assays
small molecule detection kits
Cell-Based 基于細胞的檢測 Enzyme Activity 酶活性檢測 Inhibitor Screening 抑制劑篩選
Aoptotic Blebs COX Fluorescent Activity G9a Methyltransferase Inhibitor Screening Assay Kit
甲基轉移酶抑制劑篩選
Aldehyde Site (DNA Methyltransferase Fluorometric FAAH
and Protein) Detection 甲基轉移酶
Cell Cycle Phase Demethylase (Jumonji-type) HDAC1 組蛋白去乙酰化酶
Determination細胞周期 Activity 去甲基化酶
JC-1 Mitochondrial NOS activity 一氧化氮合酶 Monoacylglycerol Lipase 單酰甘油脂肪酶
Membrane
Potential 線粒體膜電位
WST-1 Cell Proliferation Myeloperoxidase Peroxidation Sluble Epoxide Hydrolase 水溶性環氧化合物水解酶
細胞分化 髓性過氧化酶
See all cell-based assays See all enzyme activity assays See all inhibitor screening assays
蛋白產品
Enzymes/酶 (121) Nitric Oxide Synthase 一氧化氮合酶 (2) DNA/Histone Modifying Enzymes 組蛋白修飾酶 (69)
Western Ready Controls (6) Eicosanoid Metabolism 類花生酸代謝 (23) Kinases/Phosphatases 激酶/磷酸酶 (0)
Binding Proteins/結合蛋白 Proteases 蛋白酶 (7) Peroxisome Proliferation-activated Receptor
(119) 過氧化物 酶體增殖物活化受體 (4)
Drug Metabolizing Enzymes Nuclear Receptors/Transcription Factors New Proteins (19)
藥物代謝酶 (18) 核受體/轉錄因子 (6)
| CAC-10000-1 | Cayman | Cyclopentenone Prostaglandin HPLC Mixture | 1 ea | 1631.8 |
| CAC-100000-1 | Cayman | Optineurin (C-Term) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100002-500 | Cayman | Optineurin (INT) Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10001-1 | Cayman | Primary Eicosanoid HPLC Mixture | 1 ea | 1031.8 |
| CAC-100011-1 | Cayman | CD36 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100012-100 | Cayman | Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK-4B3) | 100 µl | 4534.2 |
| CAC-100012-500 | Cayman | Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK-4B3) | 500 µl | 20413.8 |
| CAC-100017-100 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-8C4) | 100 µl | 4534.2 |
| CAC-100017-500 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-8C4) | 500 µl | 20413.8 |
| CAC-100018-100 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-7F2) | 100 µl | 4534.2 |
| CAC-100018-500 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-7F2) | 500 µl | 20413.8 |
| CAC-100019-1 | Cayman | BLT1 Receptor Polyclonal Antiserum | 1 ea | 3988.6 |
| CAC-10002-1 | Cayman | Prostaglandin HPLC Mixture | 1 ea | 1031.8 |
| CAC-100020-100 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-2B4) | 100 µl | 4534.2 |
| CAC-100020-500 | Cayman | Zona Radiata (salmon) Monoclonal Antibody (Clone MN-2B4) | 500 µl | 20413.8 |
| CAC-100022-500 | Cayman | Hepsin Polyclonal Antibody (aa 241-260) | 500 µl | 3988.6 |
| CAC-100023-1 | Cayman | Prostaglandin I Synthase (mouse) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100024-200 | Cayman | Hepsin Blocking Peptide (aa 241-260) | 200 µg | 1647.8 |
| CAC-100025-500 | Cayman | 5-OxoETE Receptor Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-100027-1 | Cayman | SOAT-2/ACAT-2 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100028-1 | Cayman | SOAT-1/ACAT-1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100029-500 | Cayman | β-Catenin Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10003-1 | Cayman | Vasoactive Eicosanoid HPLC Mixture | 1 ea | 1216.6 |
| CAC-100030-500 | Cayman | Endothelial Lipase Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-100033-100 | Cayman | Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK-1H11) | 100 µl | 4534.2 |
| CAC-100033-500 | Cayman | Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK-1H11) | 500 µl | 20413.8 |
| CAC-100034-1 | Cayman | Goat Anti-COX-2 (human) Affinity-Purified Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-100035-1 | Cayman | Monoacylglycerol Lipase Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004023-480 | Cayman | Thromboxane B2 Express ELISA Kit - Monoclonal | 480 solid wells | 15600.2 |
| CAC-10004023-480s | Cayman | Thromboxane B2 Express ELISA Kit - Monoclonal | 480 strip wells | 15600.2 |
| CAC-10004023-96 | Cayman | Thromboxane B2 Express ELISA Kit - Monoclonal | 96 solid wells | 4158 |
| CAC-10004023-96s | Cayman | Thromboxane B2 Express ELISA Kit - Monoclonal | 96 strip wells | 4158 |
| CAC-10004030-1 | Cayman | S-5751 | 1 mg | 1031.8 |
| CAC-10004030-5 | Cayman | S-5751 | 5 mg | 4312 |
| CAC-10004030-500 | Cayman | S-5751 | 500 µg | 539 |
| CAC-10004110-200 | Cayman | TP Receptor (mouse) Blocking Peptide | 200 µg | 1647.8 |
| CAC-10004111-200 | Cayman | Endothelial Lipase (human) Blocking Peptide | 200 µg | 1647.8 |
| CAC-10004161-10 | Cayman | Luteolin | 10 mg | 292.6 |
| CAC-10004161-100 | Cayman | Luteolin | 100 mg | 1170.4 |
| CAC-10004161-50 | Cayman | Luteolin | 50 mg | 662.2 |
| CAC-10004161-500 | Cayman | Luteolin | 500 mg | 5128.2 |
| CAC-10004174-1 | Cayman | 4-oxo-2-Nonenal-d3 | 1 mg | 17416.8 |
| CAC-10004174-100 | Cayman | 4-oxo-2-Nonenal-d3 | 100 µg | 2879.2 |
| CAC-10004174-50 | Cayman | 4-oxo-2-Nonenal-d3 | 50 µg | 1801.2 |
| CAC-10004174-500 | Cayman | 4-oxo-2-Nonenal-d3 | 500 µg | 10209.6 |
| CAC-10004176-10 | Cayman | Apoptosis Activator 2 | 10 mg | 816.2 |
| CAC-10004176-25 | Cayman | Apoptosis Activator 2 | 25 mg | 1940.4 |
| CAC-10004176-5 | Cayman | Apoptosis Activator 2 | 5 mg | 431.2 |
| CAC-10004176-50 | Cayman | Apoptosis Activator 2 | 50 mg | 3449.6 |
| CAC-10004177-10 | Cayman | CAY10443 | 10 mg | 1139.6 |
| CAC-10004177-25 | Cayman | CAY10443 | 25 mg | 2710.4 |
| CAC-10004177-5 | Cayman | CAY10443 | 5 mg | 600.6 |
| CAC-10004177-50 | Cayman | CAY10443 | 50 mg | 4866.4 |
| CAC-10004184-1 | Cayman | NESS 0327 | 1 mg | 2679.6 |
| CAC-10004184-10 | Cayman | NESS 0327 | 10 mg | 21436.8 |
| CAC-10004184-5 | Cayman | NESS 0327 | 5 mg | 12135.2 |
| CAC-10004185-10 | Cayman | 3,4',5-Trismethoxybenzophenone | 10 mg | 415.8 |
| CAC-10004185-100 | Cayman | 3,4',5-Trismethoxybenzophenone | 100 mg | 3326.4 |
| CAC-10004185-25 | Cayman | 3,4',5-Trismethoxybenzophenone | 25 mg | 985.6 |
| CAC-10004185-50 | Cayman | 3,4',5-Trismethoxybenzophenone | 50 mg | 1878.8 |
| CAC-10004197-100 | Cayman | Prostaglandin E2-1-glyceryl ester-d5 | 100 µg | 2310 |
| CAC-10004197-50 | Cayman | Prostaglandin E2-1-glyceryl ester-d5 | 50 µg | 1216.6 |
| CAC-10004197-500 | Cayman | Prostaglandin E2-1-glyceryl ester-d5 | 500 µg | 9732.8 |
| CAC-10004207-1 | Cayman | (S)-Flurbiprofen | 1 g | 9486.4 |
| CAC-10004207-100 | Cayman | (S)-Flurbiprofen | 100 mg | 1185.8 |
| CAC-10004207-250 | Cayman | (S)-Flurbiprofen | 250 mg | 2818.2 |
| CAC-10004207-500 | Cayman | (S)-Flurbiprofen | 500 mg | 5343.8 |
| CAC-10004219-1 | Cayman | SC-236 | 1 mg | 385 |
| CAC-10004219-10 | Cayman | SC-236 | 10 mg | 1925 |
| CAC-10004219-5 | Cayman | SC-236 | 5 mg | 1155 |
| CAC-10004219-50 | Cayman | SC-236 | 50 mg | 8670.2 |
| CAC-10004224-100 | Cayman | trans-EKODE-(E)-Ib | 100 µg | 2156 |
| CAC-10004224-25 | Cayman | trans-EKODE-(E)-Ib | 25 µg | 600.6 |
| CAC-10004224-50 | Cayman | trans-EKODE-(E)-Ib | 50 µg | 1139.6 |
| CAC-10004224-500 | Cayman | trans-EKODE-(E)-Ib | 500 µg | 9609.6 |
| CAC-10004235-10 | Cayman | cis-Resveratrol | 10 mg | 2355.6 |
| CAC-10004235-100 | Cayman | cis-Resveratrol | 100 mg | 13536 |
| CAC-10004235-5 | Cayman | cis-Resveratrol | 5 mg | 1524 |
| CAC-10004235-50 | Cayman | cis-Resveratrol | 50 mg | 7992 |
| CAC-10004236-1 | Cayman | Fluprostenol serinol amide | 1 mg | 739.2 |
| CAC-10004236-10 | Cayman | Fluprostenol serinol amide | 10 mg | 5913.6 |
| CAC-10004236-5 | Cayman | Fluprostenol serinol amide | 5 mg | 3326.4 |
| CAC-10004237-1 | Cayman | 17-phenyl trinor Prostaglandin F2α serinol amide | 1 mg | 908.6 |
| CAC-10004237-10 | Cayman | 17-phenyl trinor Prostaglandin F2α serinol amide | 10 mg | 7268.8 |
| CAC-10004237-5 | Cayman | 17-phenyl trinor Prostaglandin F2α serinol amide | 5 mg | 4096.4 |
| CAC-10004237-50 | Cayman | 17-phenyl trinor Prostaglandin F2α serinol amide | 50 mg | 31801 |
| CAC-10004257-1 | Cayman | trans-4,5-epoxy-2(E)-Decenal | 1 mg | 1724.8 |
| CAC-10004257-10 | Cayman | trans-4,5-epoxy-2(E)-Decenal | 10 mg | 13798.4 |
| CAC-10004257-5 | Cayman | trans-4,5-epoxy-2(E)-Decenal | 5 mg | 7761.6 |
| CAC-10004259-1 | Cayman | Abnormal Cannabidiol | 1 mg | 308 |
| CAC-10004259-10 | Cayman | Abnormal Cannabidiol | 10 mg | 2464 |
| CAC-10004259-25 | Cayman | Abnormal Cannabidiol | 25 mg | 5390 |
| CAC-10004259-5 | Cayman | Abnormal Cannabidiol | 5 mg | 1386 |
| CAC-10004272-1 | Cayman | GW 501516 | 1 mg | 539 |
| CAC-10004272-10 | Cayman | GW 501516 | 10 mg | 1894.2 |
| CAC-10004272-5 | Cayman | GW 501516 | 5 mg | 1078 |
| CAC-10004281-1 | Cayman | R-1 Methanandamide Phosphate | 1 mg | 847 |
| CAC-10004281-10 | Cayman | R-1 Methanandamide Phosphate | 10 mg | 6113.8 |
| CAC-10004281-5 | Cayman | R-1 Methanandamide Phosphate | 5 mg | 3819.2 |
| CAC-10004301-1 | Cayman | Goat Anti-Rabbit IgG HRP | 1 ea | 1155 |
| CAC-10004302-1 | Cayman | Goat Anti-Mouse IgG HRP | 1 ea | 1001 |
| CAC-10004303-1 | Cayman | 11β-Hydroxysteroid Dehydrogenase (Type 1) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004337-1 | Cayman | Prostaglandin D Synthase (hematopoietic-type; human) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004342-1 | Cayman | Prostaglandin D Synthase (lipocalin-type; human) Monoclonal Antibody (Clone 10A5) | 1 ea | 3988.6 |
| CAC-10004344-500 | Cayman | Prostaglandin D Synthase (lipocalin-type; mouse) Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10004345-1 | Cayman | Prostaglandin D Synthase (hematopoietic-type; human) Monoclonal Antibody (Clone 2A5) | 1 ea | 3988.6 |
| CAC-10004348-1 | Cayman | Prostaglandin D Synthase (hematopoietic-type; mouse) Polyclonal Antiserum | 1 ea | 3988.6 |
| CAC-10004349-100 | Cayman | Prostaglandin D Synthase (hematopoietic-type; mouse) Monoclonal Antibody | 100 µg | 3988.6 |
| CAC-10004350-1 | Cayman | Prostaglandin E Synthase-1 (microsomal) Monoclonal Antibody (Clone 6C6) | 1 ea | 3988.6 |
| CAC-10004372-1 | Cayman | (±)-Nutlin-3 | 1 mg | 446.6 |
| CAC-10004372-10 | Cayman | (±)-Nutlin-3 | 10 mg | 2510.2 |
| CAC-10004372-5 | Cayman | (±)-Nutlin-3 | 5 mg | 1355.2 |
| CAC-10004372-50 | Cayman | (±)-Nutlin-3 | 50 mg | 6206.2 |
| CAC-10004380-96 | Cayman | PAF Acetylhydrolase Inhibitor Screening Assay Kit | 96 wells | 3788.4 |
| CAC-10004384-100 | Cayman | 16(S)-HETE | 100 µg | 6652.8 |
| CAC-10004384-25 | Cayman | 16(S)-HETE | 25 µg | 1848 |
| CAC-10004384-50 | Cayman | 16(S)-HETE | 50 µg | 3511.2 |
| CAC-10004385-100 | Cayman | 16(R)-HETE | 100 µg | 6652.8 |
| CAC-10004385-25 | Cayman | 16(R)-HETE | 25 µg | 1848 |
| CAC-10004385-50 | Cayman | 16(R)-HETE | 50 µg | 3511.2 |
| CAC-10004386-1 | Cayman | Sulindac | 1 g | 138.6 |
| CAC-10004386-10 | Cayman | Sulindac | 10 g | 1108.8 |
| CAC-10004386-5 | Cayman | Sulindac | 5 g | 631.4 |
| CAC-10004386-50 | Cayman | Sulindac | 50 g | 4851 |
| CAC-10004387-1 | Cayman | Sulindac sulfide | 1 mg | 385 |
| CAC-10004387-10 | Cayman | Sulindac sulfide | 10 mg | 1078 |
| CAC-10004387-25 | Cayman | Sulindac sulfide | 25 mg | 2310 |
| CAC-10004387-5 | Cayman | Sulindac sulfide | 5 mg | 616 |
| CAC-10004412-1 | Cayman | Reversine | 1 mg | 431.2 |
| CAC-10004412-10 | Cayman | Reversine | 10 mg | 3449.6 |
| CAC-10004412-25 | Cayman | Reversine | 25 mg | 7546 |
| CAC-10004412-5 | Cayman | Reversine | 5 mg | 1940.4 |
| CAC-10004413-1 | Cayman | 4-hydroperoxy 2-Nonenal | 1 mg | 1832 |
| CAC-10004413-10 | Cayman | 4-hydroperoxy 2-Nonenal | 10 mg | 9655.2 |
| CAC-10004413-5 | Cayman | 4-hydroperoxy 2-Nonenal | 5 mg | 5774.4 |
| CAC-10004413-500 | Cayman | 4-hydroperoxy 2-Nonenal | 500 µg | 1246.8 |
| CAC-10004442-100 | Cayman | Vitellogenin (stickleback) Polyclonal Antibody (GA-306) | 100 µl | 4534.2 |
| CAC-10004442-500 | Cayman | Vitellogenin (stickleback) Polyclonal Antibody (GA-306) | 500 µl | 20413.8 |
| CAC-10004452-1 | Cayman | TP Receptor (human) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004454-1 | Cayman | 15-Lipoxygenase-2 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004457-200 | Cayman | 15-Lipoxygenase-2 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10004549-1 | Cayman | 11β-Hydroxysteroid Dehydrogenase (Type 2) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004597-1 | Cayman | CD45 Monoclonal Antibody (Clone BRA-55) | 1 ea | 3988.6 |
| CAC-10004599-1 | Cayman | CD4 Monoclonal Antibody (Clone RIV7) | 1 ea | 3988.6 |
| CAC-10004600-1 | Cayman | Cytokeratin Monoclonal Antibody (Clone C-11) | 1 ea | 3988.6 |
| CAC-10004604-1 | Cayman | CD95 Monoclonal Antibody (Clone IPO-4) | 1 ea | 3988.6 |
| CAC-10004675-1 | Cayman | NADP+ (sodium salt hydrate) | 1 g | 2679.6 |
| CAC-10004675-100 | Cayman | NADP+ (sodium salt hydrate) | 100 mg | 708.4 |
| CAC-10004675-250 | Cayman | NADP+ (sodium salt hydrate) | 250 mg | 1001 |
| CAC-10004675-50 | Cayman | NADP+ (sodium salt hydrate) | 50 mg | 446.6 |
| CAC-10004715-1 | Cayman | CD8 Monoclonal Antibody (Clone RIV11) | 1 ea | 3988.6 |
| CAC-10004716-1 | Cayman | CD19 Monoclonal Antibody (Clone CB19) | 1 ea | 3988.6 |
| CAC-10004718-1 | Cayman | CD37 Monoclonal Antibody (Clone IPO-24) | 1 ea | 3203.2 |
| CAC-10004800-1 | Cayman | PAF-AH Inhibitor Screening Assay Buffer (10X) | 1 ea | 154 |
| CAC-10004801-1 | Cayman | PAF-AH Inhibitor Screening Assay DTNB | 1 ea | 107.8 |
| CAC-10004802-1 | Cayman | 2-thio-PAF-AH Inhibitor Screening Assay (substrate) | 1 ea | 708.4 |
| CAC-10004803-1 | Cayman | Inhibitor Screening Human Plasma PAF-AH | 1 ea | 1093.4 |
| CAC-10004804-1 | Cayman | CD150 Monoclonal Antibody (Clone IPO-3) | 1 ea | 3110.8 |
| CAC-10004805-1 | Cayman | PCNA Monoclonal Antibody (Clone IPO-38) | 1 ea | 3988.6 |
| CAC-10004806-1 | Cayman | p53 Monoclonal Antibody (Clone BP53-12) | 1 ea | 3988.6 |
| CAC-10004807-1 | Cayman | p53 (Phospho-Ser392) Polyclonal Antibody | 1 ea | 6831 |
| CAC-10004835-1 | Cayman | CD34 Monoclonal Antibody (Clone ICO-115) | 1 ea | 3280.2 |
| CAC-10004837-1 | Cayman | CD27 Monoclonal Antibody (Clone 203.6) | 1 ea | 3911.6 |
| CAC-10004840-1 | Cayman | LPA3 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004873-1 | Cayman | Antioxidant Assay Chromogen | 1 ea | 477.4 |
| CAC-10004876-1 | Cayman | Antioxidant Assay Trolox | 1 ea | 292.6 |
| CAC-10004883-96 | Cayman | sPLA2 (Type V) Inhibitor Screening Assay Kit | 96 wells | 5990.6 |
| CAC-10004884-200 | Cayman | CRTH2/DP2 Receptor (N-Term) Blocking Peptide | 200 µg | 1647.8 |
| CAC-10004886-1 | Cayman | CRTH2/DP2 Receptor (N-Term) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004888-100 | Cayman | FMOC-L-Leucine | 100 g | 831.6 |
| CAC-10004888-25 | Cayman | FMOC-L-Leucine | 25 g | 231 |
| CAC-10004888-50 | Cayman | FMOC-L-Leucine | 50 g | 446.6 |
| CAC-10004910-1 | Cayman | Mouse Macrophage Microsomal Immunoblot Control | 1 ea | 1925 |
| CAC-10004914-1 | Cayman | O-1918 | 1 mg | 354.2 |
| CAC-10004914-10 | Cayman | O-1918 | 10 mg | 2125.2 |
| CAC-10004914-25 | Cayman | O-1918 | 25 mg | 3988.6 |
| CAC-10004914-5 | Cayman | O-1918 | 5 mg | 1416.8 |
| CAC-10004942-1 | Cayman | Nod2 Monoclonal Antibody (Clone 2D9) | 1 ea | 3988.6 |
| CAC-10004943-1 | Cayman | PEPCK Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004944-1 | Cayman | FABP4 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10004946-100 | Cayman | 14,15-EE-5(Z)-E | 100 µg | 1940.4 |
| CAC-10004946-25 | Cayman | 14,15-EE-5(Z)-E | 25 µg | 539 |
| CAC-10004946-50 | Cayman | 14,15-EE-5(Z)-E | 50 µg | 1031.8 |
| CAC-10004946-500 | Cayman | 14,15-EE-5(Z)-E | 500 µg | 8624 |
| CAC-10004970-1 | Cayman | (+)-5-trans Cloprostenol | 1 mg | 862.4 |
| CAC-10004970-10 | Cayman | (+)-5-trans Cloprostenol | 10 mg | 6899.2 |
| CAC-10004970-25 | Cayman | (+)-5-trans Cloprostenol | 25 mg | 15092 |
| CAC-10004970-5 | Cayman | (+)-5-trans Cloprostenol | 5 mg | 3880.8 |
| CAC-10004971-10 | Cayman | N,N'-Dicyclohexylurea | 10 g | 231 |
| CAC-10004971-25 | Cayman | N,N'-Dicyclohexylurea | 25 g | 385 |
| CAC-10004974-1 | Cayman | Ionomycin | 1 mg | 446.6 |
| CAC-10004974-10 | Cayman | Ionomycin | 10 mg | 3572.8 |
| CAC-10004974-25 | Cayman | Ionomycin | 25 mg | 7253.4 |
| CAC-10004974-5 | Cayman | Ionomycin | 5 mg | 2017.4 |
| CAC-10004976-10 | Cayman | Leptomycin B | 10 µg | 662.2 |
| CAC-10004976-25 | Cayman | Leptomycin B | 25 µg | 1447.6 |
| CAC-10004976-5 | Cayman | Leptomycin B | 5 µg | 385 |
| CAC-10004985-1 | Cayman | Caylin-1 | 1 mg | 770 |
| CAC-10004985-10 | Cayman | Caylin-1 | 10 mg | 6160 |
| CAC-10004985-5 | Cayman | Caylin-1 | 5 mg | 3465 |
| CAC-10004993-480 | Cayman | Vitellogenin (carp) ELISA Kit | 480 Well | 52430.4 |
| CAC-10004993-96 | Cayman | Vitellogenin (carp) ELISA Kit | 96 Well | 13978.8 |
| CAC-10004994-480 | Cayman | Vitellogenin (rainbow trout) ELISA Kit | 480 wells | 52430.4 |
| CAC-10004994-96 | Cayman | Vitellogenin (rainbow trout) ELISA Kit | 96 wells | 13978.8 |
| CAC-10004995-480 | Cayman | Vitellogenin (zebrafish) ELISA Kit | 480 wells | 52430.4 |
| CAC-10004995-96 | Cayman | Vitellogenin (zebrafish) ELISA Kit | 96 Well | 13978.8 |
| CAC-10005-1 | Cayman | Prostaglandin Metabolite HPLC Mixture | 1 ea | 1216.6 |
| CAC-10005000-1 | Cayman | Stearidonic Acid methyl ester | 1 mg | 1603.8 |
| CAC-10005000-10 | Cayman | Stearidonic Acid methyl ester | 10 mg | 14256 |
| CAC-10005000-5 | Cayman | Stearidonic Acid methyl ester | 5 mg | 7583.4 |
| CAC-10005000-500 | Cayman | Stearidonic Acid methyl ester | 500 µg | 891 |
| CAC-10005002-1 | Cayman | Caylin-2 | 1 mg | 770 |
| CAC-10005002-10 | Cayman | Caylin-2 | 10 mg | 6160 |
| CAC-10005002-5 | Cayman | Caylin-2 | 5 mg | 3465 |
| CAC-10005019-1 | Cayman | BML-210 | 1 mg | 708.4 |
| CAC-10005019-10 | Cayman | BML-210 | 10 mg | 5667.2 |
| CAC-10005019-25 | Cayman | BML-210 | 25 mg | 12397 |
| CAC-10005019-5 | Cayman | BML-210 | 5 mg | 3187.8 |
| CAC-10005020-96 | Cayman | Protein Carbonyl Colorimetric Assay Kit | 96 wells | 4235 |
| CAC-10005031-100 | Cayman | L-NMMA (acetate) | 100 mg | 2587.2 |
| CAC-10005031-25 | Cayman | L-NMMA (acetate) | 25 mg | 831.6 |
| CAC-10005031-5 | Cayman | L-NMMA (acetate) | 5 mg | 184.8 |
| CAC-10005031-50 | Cayman | L-NMMA (acetate) | 50 mg | 1478.4 |
| CAC-10005032-1 | Cayman | 5(S),6(R)-7-trihydroxymethyl Heptanoate | 1 mg | 693 |
| CAC-10005032-10 | Cayman | 5(S),6(R)-7-trihydroxymethyl Heptanoate | 10 mg | 5544 |
| CAC-10005032-5 | Cayman | 5(S),6(R)-7-trihydroxymethyl Heptanoate | 5 mg | 3126.2 |
| CAC-10005033-10 | Cayman | CAY10444 | 10 mg | 1232 |
| CAC-10005033-25 | Cayman | CAY10444 | 25 mg | 2910.6 |
| CAC-10005033-5 | Cayman | CAY10444 | 5 mg | 646.8 |
| CAC-10005033-50 | Cayman | CAY10444 | 50 mg | 5174.4 |
| CAC-10005056-1 | Cayman | Eicosapentaenoic Acid-d5 | 1 mg | 9763.6 |
| CAC-10005056-100 | Cayman | Eicosapentaenoic Acid-d5 | 100 µg | 1524.6 |
| CAC-10005056-50 | Cayman | Eicosapentaenoic Acid-d5 | 50 µg | 800.8 |
| CAC-10005056-500 | Cayman | Eicosapentaenoic Acid-d5 | 500 µg | 6098.4 |
| CAC-10005057-1 | Cayman | Docosahexaenoic Acid-d5 | 1 mg | 4989.6 |
| CAC-10005057-100 | Cayman | Docosahexaenoic Acid-d5 | 100 µg | 1108.8 |
| CAC-10005057-50 | Cayman | Docosahexaenoic Acid-d5 | 50 µg | 693 |
| CAC-10005057-500 | Cayman | Docosahexaenoic Acid-d5 | 500 µg | 4158 |
| CAC-10005059-500 | Cayman | PTEN Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10005064-100 | Cayman | Thromboxane B2 Express AChE Tracer | 100 dtn | 2325.4 |
| CAC-10005064-500 | Cayman | Thromboxane B2 Express AChE Tracer | 500 dtn | 8562.4 |
| CAC-10005065-100 | Cayman | Thromboxane B2 Express ELISA Monoclonal Antibody | 100 dtn | 785.4 |
| CAC-10005065-500 | Cayman | Thromboxane B2 Express ELISA Monoclonal Antibody | 500 dtn | 2941.4 |
| CAC-10005066-1 | Cayman | Thromboxane B2 Express ELISA Standard | 1 ea | 338.8 |
| CAC-10005067-1 | Cayman | CAY10434 | 1 mg | 292.6 |
| CAC-10005067-10 | Cayman | CAY10434 | 10 mg | 2340.8 |
| CAC-10005067-5 | Cayman | CAY10434 | 5 mg | 1324.4 |
| CAC-10005067-50 | Cayman | CAY10434 | 50 mg | 10241 |
| CAC-10005072-1 | Cayman | CAY10455 | 1 mg | 5544 |
| CAC-10005072-100 | Cayman | CAY10455 | 100 µg | 693 |
| CAC-10005072-500 | Cayman | CAY10455 | 500 µg | 3126.2 |
| CAC-10005090-200 | Cayman | SOAT-1/ACAT-1 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005091-200 | Cayman | SOAT-2/ACAT-2 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005092-200 | Cayman | LPA3 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005098-10 | Cayman | AMC Arachidonoyl Amide | 10 mg | 2509.6 |
| CAC-10005098-25 | Cayman | AMC Arachidonoyl Amide | 25 mg | 5112.2 |
| CAC-10005098-5 | Cayman | AMC Arachidonoyl Amide | 5 mg | 1601 |
| CAC-10005098-50 | Cayman | AMC Arachidonoyl Amide | 50 mg | 8608 |
| CAC-10005099-100 | Cayman | 17(R)-HDHA | 100 µg | 5097.4 |
| CAC-10005099-25 | Cayman | 17(R)-HDHA | 25 µg | 1416.8 |
| CAC-10005099-250 | Cayman | 17(R)-HDHA | 250 µg | 11334.4 |
| CAC-10005099-50 | Cayman | 17(R)-HDHA | 50 µg | 2695 |
| CAC-10005102-1 | Cayman | CAY10435 | 1 mg | 1262.8 |
| CAC-10005102-10 | Cayman | CAY10435 | 10 mg | 9270.8 |
| CAC-10005102-5 | Cayman | CAY10435 | 5 mg | 5297.6 |
| CAC-10005102-500 | Cayman | CAY10435 | 500 µg | 662.2 |
| CAC-10005166-100 | Cayman | Daidzein | 100 mg | 154 |
| CAC-10005166-1 | Cayman | Daidzein | 1 g | 1232 |
| CAC-10005166-500 | Cayman | Daidzein | 500 mg | 693 |
| CAC-10005166-5 | Cayman | Daidzein | 5 g | 5390 |
| CAC-10005167-100 | Cayman | Genistein | 100 mg | 369.6 |
| CAC-10005167-1 | Cayman | Genistein | 1 g | 2402.4 |
| CAC-10005167-250 | Cayman | Genistein | 250 mg | 877.8 |
| CAC-10005167-500 | Cayman | Genistein | 500 mg | 1293.6 |
| CAC-10005169-10 | Cayman | Quercetin | 10 g | 354.2 |
| CAC-10005169-100 | Cayman | Quercetin | 100 g | 2587.2 |
| CAC-10005169-50 | Cayman | Quercetin | 50 g | 1478.4 |
| CAC-10005169-5 | Cayman | Quercetin | 5 g | 184.8 |
| CAC-10005174-1 | Cayman | Matairesinol | 1 mg | 462 |
| CAC-10005174-10 | Cayman | Matairesinol | 10 mg | 2772 |
| CAC-10005174-25 | Cayman | Matairesinol | 25 mg | 5205.2 |
| CAC-10005174-5 | Cayman | Matairesinol | 5 mg | 1848 |
| CAC-10005186-1 | Cayman | CAY10441 | 1 mg | 785.4 |
| CAC-10005186-10 | Cayman | CAY10441 | 10 mg | 6283.2 |
| CAC-10005186-25 | Cayman | CAY10441 | 25 mg | 13752.2 |
| CAC-10005186-5 | Cayman | CAY10441 | 5 mg | 3542 |
| CAC-10005188-100 | Cayman | DAUDA | 100 mg | 1894.2 |
| CAC-10005188-25 | Cayman | DAUDA | 25 mg | 539 |
| CAC-10005188-50 | Cayman | DAUDA | 50 mg | 1078 |
| CAC-10005189-1 | Cayman | PX-478 | 1 mg | 462 |
| CAC-10005189-10 | Cayman | PX-478 | 10 mg | 3696 |
| CAC-10005189-25 | Cayman | PX-478 | 25 mg | 7284.2 |
| CAC-10005189-5 | Cayman | PX-478 | 5 mg | 1971.2 |
| CAC-10005190-1 | Cayman | EAF2 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005196-96 | Cayman | Fatty Acid Amide Hydrolase Inhibitor Screening Assay Kit | 96 wells | 4912 |
| CAC-10005223-10 | Cayman | AM1172 | 10 mg | 2048.2 |
| CAC-10005223-100 | Cayman | AM1172 | 100 mg | 15092 |
| CAC-10005223-5 | Cayman | AM1172 | 5 mg | 1078 |
| CAC-10005223-50 | Cayman | AM1172 | 50 mg | 8624 |
| CAC-10005228-1 | Cayman | S1P1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005229-10 | Cayman | 2,3-DCPE (hydrochloride) | 10 mg | 847 |
| CAC-10005229-5 | Cayman | 2,3-DCPE (hydrochloride) | 5 mg | 446.6 |
| CAC-10005229-50 | Cayman | 2,3-DCPE (hydrochloride) | 50 mg | 3572.8 |
| CAC-10005254-1 | Cayman | AFMK | 1 mg | 277.2 |
| CAC-10005254-10 | Cayman | AFMK | 10 mg | 1663.2 |
| CAC-10005254-5 | Cayman | AFMK | 5 mg | 1108.8 |
| CAC-10005254-50 | Cayman | AFMK | 50 mg | 5544 |
| CAC-10005256-200 | Cayman | GPx4 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005257-200 | Cayman | Prostaglandin I Synthase (mouse) Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005258-1 | Cayman | GPx4 Polyclonal Antibody | 1 ea | 4296.6 |
| CAC-10005260-1 | Cayman | Serine Palmitoyltransferase Polyclonal Antibody | 1 ea | 4296.6 |
| CAC-10005263-10 | Cayman | TOFA | 10 mg | 847 |
| CAC-10005263-100 | Cayman | TOFA | 100 mg | 6252.4 |
| CAC-10005263-5 | Cayman | TOFA | 5 mg | 446.6 |
| CAC-10005263-50 | Cayman | TOFA | 50 mg | 3572.8 |
| CAC-10005270-1 | Cayman | (±)-C75 | 1 mg | 677.6 |
| CAC-10005270-10 | Cayman | (±)-C75 | 10 mg | 2849 |
| CAC-10005270-5 | Cayman | (±)-C75 | 5 mg | 2032.8 |
| CAC-10005272-100 | Cayman | Cortisol AChE Tracer | 100 dtn | 2310 |
| CAC-10005272-500 | Cayman | Cortisol AChE Tracer | 500 dtn | 8670.2 |
| CAC-10005276-10 | Cayman | DL-threo-PDMP (hydrochloride) | 10 mg | 554.4 |
| CAC-10005276-100 | Cayman | DL-threo-PDMP (hydrochloride) | 100 mg | 4096.4 |
| CAC-10005276-5 | Cayman | DL-threo-PDMP (hydrochloride) | 5 mg | 292.6 |
| CAC-10005276-50 | Cayman | DL-threo-PDMP (hydrochloride) | 50 mg | 2340.8 |
| CAC-10005280-1 | Cayman | LPA1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005291-1 | Cayman | p53 Product Pack | 1 ea | 7900.2 |
| CAC-10005292-1 | Cayman | Atherosclerosis Product Pack | 1 ea | 6853 |
| CAC-10005315-1 | Cayman | Creatinine Color Reagent | 1 ea | 800.8 |
| CAC-10005315-5 | Cayman | Creatinine Color Reagent | 5 ea | 3003 |
| CAC-10005316-5 | Cayman | Creatinine Sodium Hydroxide | 5 ml | 154 |
| CAC-10005316-25 | Cayman | Creatinine Sodium Hydroxide | 25 ml | 585.2 |
| CAC-10005317-1 | Cayman | Creatinine Acid Solution | 1 ea | 184.8 |
| CAC-10005317-5 | Cayman | Creatinine Acid Solution | 5 ea | 693 |
| CAC-10005368-1 | Cayman | Fenofibrate | 1 g | 138.6 |
| CAC-10005368-10 | Cayman | Fenofibrate | 10 g | 1108.8 |
| CAC-10005368-5 | Cayman | Fenofibrate | 5 g | 631.4 |
| CAC-10005368-50 | Cayman | Fenofibrate | 50 g | 4851 |
| CAC-10005371-1 | Cayman | 384-Well Solid Plate (black; non-binding) | 1 ea | 261.8 |
| CAC-10005371-5 | Cayman | 384-Well Solid Plate (black; non-binding) | 5 ea | 985.6 |
| CAC-10005372-1 | Cayman | 96-Well Solid Plate (black; non-binding) | 1 ea | 261.8 |
| CAC-10005372-5 | Cayman | 96-Well Solid Plate (black; non-binding) | 5 ea | 985.6 |
| CAC-10005375-1 | Cayman | Lysophospholipase D Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005388-200 | Cayman | Prostaglandin Transporter Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005426-100 | Cayman | Orlistat | 100 mg | 708.4 |
| CAC-10005426-250 | Cayman | Orlistat | 250 mg | 1663.2 |
| CAC-10005426-50 | Cayman | Orlistat | 50 mg | 369.6 |
| CAC-10005426-500 | Cayman | Orlistat | 500 mg | 2956.8 |
| CAC-10005428-1 | Cayman | JWH 133 | 1 mg | 539 |
| CAC-10005428-10 | Cayman | JWH 133 | 10 mg | 3080 |
| CAC-10005428-25 | Cayman | JWH 133 | 25 mg | 6745.2 |
| CAC-10005428-5 | Cayman | JWH 133 | 5 mg | 1894.2 |
| CAC-10005432-10 | Cayman | DDA | 10 mL | 816.2 |
| CAC-10005432-25 | Cayman | DDA | 25 mL | 1940.4 |
| CAC-10005432-5 | Cayman | DDA | 5 mL | 431.2 |
| CAC-10005432-50 | Cayman | DDA | 50 mL | 3449.6 |
| CAC-10005439-1 | Cayman | Tafluprost (free acid) | 1 mg | 1432.2 |
| CAC-10005439-10 | Cayman | Tafluprost (free acid) | 10 mg | 11457.6 |
| CAC-10005439-25 | Cayman | Tafluprost (free acid) | 25 mg | 25071.2 |
| CAC-10005439-5 | Cayman | Tafluprost (free acid) | 5 mg | 6452.6 |
| CAC-10005440-1 | Cayman | Tafluprost | 1 mg | 1401.4 |
| CAC-10005440-10 | Cayman | Tafluprost | 10 mg | 11211.2 |
| CAC-10005440-25 | Cayman | Tafluprost | 25 mg | 17525.2 |
| CAC-10005440-5 | Cayman | Tafluprost | 5 mg | 6314 |
| CAC-10005455-1 | Cayman | N-Arachidonoyl-L-Serine | 1 mg | 231 |
| CAC-10005455-10 | Cayman | N-Arachidonoyl-L-Serine | 10 mg | 924 |
| CAC-10005455-25 | Cayman | N-Arachidonoyl-L-Serine | 25 mg | 2002 |
| CAC-10005455-5 | Cayman | N-Arachidonoyl-L-Serine | 5 mg | 616 |
| CAC-10005459-1 | Cayman | Oleoyl Ethyl Amide | 1 mg | 169.4 |
| CAC-10005459-10 | Cayman | Oleoyl Ethyl Amide | 10 mg | 1355.2 |
| CAC-10005459-25 | Cayman | Oleoyl Ethyl Amide | 25 mg | 2972.2 |
| CAC-10005459-5 | Cayman | Oleoyl Ethyl Amide | 5 mg | 770 |
| CAC-10005516-200 | Cayman | Doppel Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005517-1 | Cayman | Doppel Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005518-1 | Cayman | IP Receptor (human) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10005519-200 | Cayman | IP Receptor (human) Blocking Peptide | 200 µg | 1647.8 |
| CAC-10005537-1 | Cayman | N-Arachidonoyl Taurine | 1 mg | 1601 |
| CAC-10005537-10 | Cayman | N-Arachidonoyl Taurine | 10 mg | 7930.4 |
| CAC-10005537-5 | Cayman | N-Arachidonoyl Taurine | 5 mg | 4788.8 |
| CAC-10005537-500 | Cayman | N-Arachidonoyl Taurine | 500 µg | 1123.6 |
| CAC-10005583-1 | Cayman | Y-27632 (hydrochloride) | 1 mg | 693 |
| CAC-10005583-10 | Cayman | Y-27632 (hydrochloride) | 10 mg | 2433.2 |
| CAC-10005583-5 | Cayman | Y-27632 (hydrochloride) | 5 mg | 1740.2 |
| CAC-10005583-50 | Cayman | Y-27632 (hydrochloride) | 50 mg | 8316 |
| CAC-10005609-1 | Cayman | N-Oleoyl Taurine | 1 mg | 1001 |
| CAC-10005609-10 | Cayman | N-Oleoyl Taurine | 10 mg | 7330.4 |
| CAC-10005609-5 | Cayman | N-Oleoyl Taurine | 5 mg | 4188.8 |
| CAC-10005609-500 | Cayman | N-Oleoyl Taurine | 500 µg | 523.6 |
| CAC-10005610-1 | Cayman | N-Stearoyl Taurine | 1 mg | 1031.8 |
| CAC-10005610-10 | Cayman | N-Stearoyl Taurine | 10 mg | 8254.4 |
| CAC-10005610-5 | Cayman | N-Stearoyl Taurine | 5 mg | 4650.8 |
| CAC-10005611-1 | Cayman | N-Palmitoyl Taurine | 1 mg | 1031.8 |
| CAC-10005611-10 | Cayman | N-Palmitoyl Taurine | 10 mg | 8254.4 |
| CAC-10005611-5 | Cayman | N-Palmitoyl Taurine | 5 mg | 4650.8 |
| CAC-10005615-100 | Cayman | PtdIns-(4,5)-P2 (1,2-dipamitoyl)-d62 (sodium salt) | 100 µg | 4158 |
| CAC-10005615-25 | Cayman | PtdIns-(4,5)-P2 (1,2-dipamitoyl)-d62 (sodium salt) | 25 µg | 1155 |
| CAC-10005615-50 | Cayman | PtdIns-(4,5)-P2 (1,2-dipamitoyl)-d62 (sodium salt) | 50 µg | 2202.2 |
| CAC-10005616-100 | Cayman | PtdIns-(3)-P1 (1,2-dipalmitoyl)-d62 (ammonium salt) | 100 µg | 4158 |
| CAC-10005616-25 | Cayman | PtdIns-(3)-P1 (1,2-dipalmitoyl)-d62 (ammonium salt) | 25 µg | 1155 |
| CAC-10005616-50 | Cayman | PtdIns-(3)-P1 (1,2-dipalmitoyl)-d62 (ammonium salt) | 50 µg | 2202.2 |
| CAC-10005633-1 | Cayman | CAY10448 | 1 mg | 246.4 |
| CAC-10005633-10 | Cayman | CAY10448 | 10 mg | 1971.2 |
| CAC-10005633-5 | Cayman | CAY10448 | 5 mg | 1108.8 |
| CAC-10005633-50 | Cayman | CAY10448 | 50 mg | 8624 |
| CAC-10005647-10 | Cayman | Cerulenin | 10 mg | 1925 |
| CAC-10005647-5 | Cayman | Cerulenin | 5 mg | 1001 |
| CAC-10005647-50 | Cayman | Cerulenin | 50 mg | 8008 |
| CAC-10005673-1 | Cayman | HU-331 | 1 mg | 739.2 |
| CAC-10005673-10 | Cayman | HU-331 | 10 mg | 5913.6 |
| CAC-10005673-25 | Cayman | HU-331 | 25 mg | 12936 |
| CAC-10005673-5 | Cayman | HU-331 | 5 mg | 3326.4 |
| CAC-10005705-1 | Cayman | NO-Indomethacin | 1 mg | 246.4 |
| CAC-10005705-10 | Cayman | NO-Indomethacin | 10 mg | 1971.2 |
| CAC-10005705-5 | Cayman | NO-Indomethacin | 5 mg | 1108.8 |
| CAC-10005705-50 | Cayman | NO-Indomethacin | 50 mg | 8624 |
| CAC-10005707-1 | Cayman | (2S)-OMPT | 1 mg | 1663.2 |
| CAC-10005707-10 | Cayman | (2S)-OMPT | 10 mg | 12289.2 |
| CAC-10005707-5 | Cayman | (2S)-OMPT | 5 mg | 7022.4 |
| CAC-10005707-500 | Cayman | (2S)-OMPT | 500 µg | 877.8 |
| CAC-10005728-1 | Cayman | DL-α-Lipoic Acid | 1 g | 107.8 |
| CAC-10005728-10 | Cayman | DL-α-Lipoic Acid | 10 g | 862.4 |
| CAC-10005728-25 | Cayman | DL-α-Lipoic Acid | 25 g | 1894.2 |
| CAC-10005728-5 | Cayman | DL-α-Lipoic Acid | 5 g | 492.8 |
| CAC-10005729-1 | Cayman | 11β-Hydroxysteroid Dehydrogenase (Type 1) Blocking Peptide | 1 ea | 1647.8 |
| CAC-10005732-1 | Cayman | EAF2 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10005764-1 | Cayman | 8-iso Prostaglandin F2α Ethanolamide | 1 mg | 5174.4 |
| CAC-10005764-100 | Cayman | 8-iso Prostaglandin F2α Ethanolamide | 100 µg | 646.8 |
| CAC-10005764-500 | Cayman | 8-iso Prostaglandin F2α Ethanolamide | 500 µg | 2910.6 |
| CAC-10005765-10 | Cayman | Arachidoyl Ethanolamide | 10 mg | 847 |
| CAC-10005765-100 | Cayman | Arachidoyl Ethanolamide | 100 mg | 6391 |
| CAC-10005765-25 | Cayman | Arachidoyl Ethanolamide | 25 mg | 2002 |
| CAC-10005765-5 | Cayman | Arachidoyl Ethanolamide | 5 mg | 446.6 |
| CAC-10005823-10 | Cayman | Docosanoyl Ethanolamide | 10 mg | 1432.2 |
| CAC-10005823-100 | Cayman | Docosanoyl Ethanolamide | 100 mg | 10564.4 |
| CAC-10005823-5 | Cayman | Docosanoyl Ethanolamide | 5 mg | 754.6 |
| CAC-10005823-50 | Cayman | Docosanoyl Ethanolamide | 50 mg | 6036.8 |
| CAC-10005836-10 | Cayman | bis(7)-Tacrine | 10 mg | 1878.8 |
| CAC-10005836-100 | Cayman | bis(7)-Tacrine | 100 mg | 13798.4 |
| CAC-10005836-5 | Cayman | bis(7)-Tacrine | 5 mg | 985.6 |
| CAC-10005836-50 | Cayman | bis(7)-Tacrine | 50 mg | 7884.8 |
| CAC-10005845-1 | Cayman | Protein Carbonyl Hydrochloric Acid | 1 ea | 292.6 |
| CAC-10005846-1 | Cayman | Protein Carbonyl DNPH | 1 ea | 477.4 |
| CAC-10005847-1 | Cayman | Protein Carbonyl TCA Solution | 1 ea | 385 |
| CAC-10005848-1 | Cayman | Protein Carbonyl Guanidine Hydrochloride | 1 ea | 385 |
| CAC-10005849-1 | Cayman | Protein Carbonyl Ethanol | 1 ea | 292.6 |
| CAC-10005850-1 | Cayman | Protein Carbonyl Ethyl Acetate | 1 ea | 292.6 |
| CAC-10005851-10 | Cayman | N-Decanoyl p-Nitroaniline | 10 mg | 354.2 |
| CAC-10005851-25 | Cayman | N-Decanoyl p-Nitroaniline | 25 mg | 831.6 |
| CAC-10005851-5 | Cayman | N-Decanoyl p-Nitroaniline | 5 mg | 184.8 |
| CAC-10005851-50 | Cayman | N-Decanoyl p-Nitroaniline | 50 mg | 1478.4 |
| CAC-10005913-1 | Cayman | CAY10449 | 1 mg | 708.4 |
| CAC-10005913-10 | Cayman | CAY10449 | 10 mg | 5667.2 |
| CAC-10005913-25 | Cayman | CAY10449 | 25 mg | 12397 |
| CAC-10005913-5 | Cayman | CAY10449 | 5 mg | 3187.8 |
| CAC-10005983-1 | Cayman | Pentafluorobenzenesulfonyl fluorescein | 1 mg | 508.2 |
| CAC-10005983-10 | Cayman | Pentafluorobenzenesulfonyl fluorescein | 10 mg | 4065.6 |
| CAC-10005983-25 | Cayman | Pentafluorobenzenesulfonyl fluorescein | 25 mg | 8901.2 |
| CAC-10005983-5 | Cayman | Pentafluorobenzenesulfonyl fluorescein | 5 mg | 2294.6 |
| CAC-10006045-1 | Cayman | (R)-Butaprost (free acid) | 1 mg | 2017.4 |
| CAC-10006045-10 | Cayman | (R)-Butaprost (free acid) | 10 mg | 14876.4 |
| CAC-10006045-5 | Cayman | (R)-Butaprost (free acid) | 5 mg | 8500.8 |
| CAC-10006045-500 | Cayman | (R)-Butaprost (free acid) | 500 µg | 1062.6 |
| CAC-10006084-100 | Cayman | Hesperetin | 100 g | 1771 |
| CAC-10006084-25 | Cayman | Hesperetin | 25 g | 492.8 |
| CAC-10006084-50 | Cayman | Hesperetin | 50 g | 939.4 |
| CAC-10006084-500 | Cayman | Hesperetin | 500 g | 7884.8 |
| CAC-10006120-10 | Cayman | Valdecoxib | 10 mg | 1601.6 |
| CAC-10006120-25 | Cayman | Valdecoxib | 25 mg | 3803.8 |
| CAC-10006120-5 | Cayman | Valdecoxib | 5 mg | 893.2 |
| CAC-10006120-50 | Cayman | Valdecoxib | 50 mg | 7145.6 |
| CAC-10006148-10 | Cayman | Leelamine | 10 mg | 847 |
| CAC-10006148-25 | Cayman | Leelamine | 25 mg | 2017.4 |
| CAC-10006148-5 | Cayman | Leelamine | 5 mg | 446.6 |
| CAC-10006148-50 | Cayman | Leelamine | 50 mg | 3572.8 |
| CAC-10006170-1 | Cayman | DMPO Nitrone Adduct Polyclonal Antiserum | 1 ea | 4604.6 |
| CAC-10006197-100 | Cayman | Leukotriene A4-d5 methyl ester | 100 µg | 5866.8 |
| CAC-10006197-25 | Cayman | Leukotriene A4-d5 methyl ester | 25 µg | 2063 |
| CAC-10006197-50 | Cayman | Leukotriene A4-d5 methyl ester | 50 µg | 3387.4 |
| CAC-10006198-100 | Cayman | Leukotriene C4-d5 | 100 µg | 13289.6 |
| CAC-10006198-25 | Cayman | Leukotriene C4-d5 | 25 µg | 4126.6 |
| CAC-10006198-50 | Cayman | Leukotriene C4-d5 | 50 µg | 7299 |
| CAC-10006199-100 | Cayman | Leukotriene D4-d5 | 100 µg | 13289.6 |
| CAC-10006199-25 | Cayman | Leukotriene D4-d5 | 25 µg | 4126.6 |
| CAC-10006199-50 | Cayman | Leukotriene D4-d5 | 50 µg | 7299 |
| CAC-10006211-1 | Cayman | Silybin | 1 g | 123.2 |
| CAC-10006211-10 | Cayman | Silybin | 10 g | 985.6 |
| CAC-10006211-5 | Cayman | Silybin | 5 g | 554.4 |
| CAC-10006211-50 | Cayman | Silybin | 50 g | 4312 |
| CAC-10006212-1 | Cayman | AN-7 | 1 mg | 385 |
| CAC-10006212-10 | Cayman | AN-7 | 10 mg | 2310 |
| CAC-10006212-5 | Cayman | AN-7 | 5 mg | 1247.4 |
| CAC-10006217-25 | Cayman | Renin (human recombinant) | 25 µg | 4912 |
| CAC-10006247-1 | Cayman | PPARδ Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006248-1 | Cayman | FABP4 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006270-96 | Cayman | Renin Inhibitor Screening Assay Kit | 96 wells | 7098.8 |
| CAC-10006283-1 | Cayman | PINK1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006284-1 | Cayman | PINK1 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006292-1 | Cayman | FTY720 | 1 g | 6036.8 |
| CAC-10006292-100 | Cayman | FTY720 | 100 mg | 1355.2 |
| CAC-10006292-250 | Cayman | FTY720 | 250 mg | 2648.8 |
| CAC-10006292-50 | Cayman | FTY720 | 50 mg | 754.6 |
| CAC-10006295-1 | Cayman | Cimicoxib | 1 mg | 754.6 |
| CAC-10006295-10 | Cayman | Cimicoxib | 10 mg | 4912.6 |
| CAC-10006295-5 | Cayman | Cimicoxib | 5 mg | 3018.4 |
| CAC-10006305-1 | Cayman | D-NMAPPD | 1 mg | 277.2 |
| CAC-10006305-10 | Cayman | D-NMAPPD | 10 mg | 2217.6 |
| CAC-10006305-5 | Cayman | D-NMAPPD | 5 mg | 1247.4 |
| CAC-10006305-50 | Cayman | D-NMAPPD | 50 mg | 9702 |
| CAC-10006306-96 | Cayman | Acylated Ghrelin (human) Express EIA Kit | 96 wells | 9979.2 |
| CAC-10006306-384 | Cayman | Acylated Ghrelin (human) Express EIA Kit | 384 wells | 24453 |
| CAC-10006307-96 | Cayman | Acylated Ghrelin (mouse, rat) Express EIA Kit | 96 wells | 9979.2 |
| CAC-10006309-10 | Cayman | BCTC | 10 mg | 970.2 |
| CAC-10006309-5 | Cayman | BCTC | 5 mg | 508.2 |
| CAC-10006309-50 | Cayman | BCTC | 50 mg | 4065.6 |
| CAC-10006315-1 | Cayman | 17β-Estradiol | 1 g | 369.6 |
| CAC-10006315-10 | Cayman | 17β-Estradiol | 10 g | 2079 |
| CAC-10006315-500 | Cayman | 17β-Estradiol | 500 mg | 231 |
| CAC-10006315-5 | Cayman | 17β-Estradiol | 5 g | 1278.2 |
| CAC-10006317-100 | Cayman | Mifepristone | 100 mg | 385 |
| CAC-10006317-1 | Cayman | Mifepristone | 1 g | 1925 |
| CAC-10006317-500 | Cayman | Mifepristone | 500 mg | 1062.6 |
| CAC-10006317-5 | Cayman | Mifepristone | 5 g | 7515.2 |
| CAC-10006318-100 | Cayman | Levonorgestrel | 100 mg | 292.6 |
| CAC-10006318-1 | Cayman | Levonorgestrel | 1 g | 2340.8 |
| CAC-10006318-500 | Cayman | Levonorgestrel | 500 mg | 1324.4 |
| CAC-10006318-5 | Cayman | Levonorgestrel | 5 g | 10241 |
| CAC-10006319-100 | Cayman | Norgestrel | 100 mg | 292.6 |
| CAC-10006319-1 | Cayman | Norgestrel | 1 g | 2340.8 |
| CAC-10006319-500 | Cayman | Norgestrel | 500 mg | 1324.4 |
| CAC-10006319-5 | Cayman | Norgestrel | 5 g | 10241 |
| CAC-10006320-1 | Cayman | Quinestrol | 1 g | 3449.6 |
| CAC-10006320-100 | Cayman | Quinestrol | 100 mg | 431.2 |
| CAC-10006320-250 | Cayman | Quinestrol | 250 mg | 1031.8 |
| CAC-10006320-500 | Cayman | Quinestrol | 500 mg | 1940.4 |
| CAC-10006321-100 | Cayman | Tibolone | 100 mg | 231 |
| CAC-10006321-1 | Cayman | Tibolone | 1 g | 1386 |
| CAC-10006321-500 | Cayman | Tibolone | 500 mg | 924 |
| CAC-10006321-5 | Cayman | Tibolone | 5 g | 4620 |
| CAC-10006329-10 | Cayman | EUK 134 | 10 mg | 785.4 |
| CAC-10006329-100 | Cayman | EUK 134 | 100 mg | 5544 |
| CAC-10006329-5 | Cayman | EUK 134 | 5 mg | 462 |
| CAC-10006329-50 | Cayman | EUK 134 | 50 mg | 3003 |
| CAC-10006330-100 | Cayman | 2,3-dinor Thromboxane B1 | 100 µg | 5266.8 |
| CAC-10006330-25 | Cayman | 2,3-dinor Thromboxane B1 | 25 µg | 1463 |
| CAC-10006330-50 | Cayman | 2,3-dinor Thromboxane B1 | 50 µg | 2787.4 |
| CAC-10006341-10 | Cayman | PDM 11 | 10 mg | 308 |
| CAC-10006341-100 | Cayman | PDM 11 | 100 mg | 2464 |
| CAC-10006341-25 | Cayman | PDM 11 | 25 mg | 739.2 |
| CAC-10006341-50 | Cayman | PDM 11 | 50 mg | 1386 |
| CAC-10006342-10 | Cayman | PDM 2 | 10 mg | 539 |
| CAC-10006342-100 | Cayman | PDM 2 | 100 mg | 4312 |
| CAC-10006342-50 | Cayman | PDM 2 | 50 mg | 2433.2 |
| CAC-10006350-1 | Cayman | HU-211 | 1 mg | 554.4 |
| CAC-10006350-10 | Cayman | HU-211 | 10 mg | 4435.2 |
| CAC-10006350-25 | Cayman | HU-211 | 25 mg | 9702 |
| CAC-10006350-5 | Cayman | HU-211 | 5 mg | 2494.8 |
| CAC-10006355-1 | Cayman | Melanocortin-4 Receptor Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006356-1 | Cayman | Melanocortin-4 Receptor Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006371-500 | Cayman | Hormone-Sensitive Lipase Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10006372-1 | Cayman | Hormone-Sensitive Lipase Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006373-1 | Cayman | S1P3 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006374-200 | Cayman | S1P3 Blocking Peptide | 200 µg | 1647.8 |
| CAC-10006389-1 | Cayman | HDAC Assay Buffer (10X) | 1 ea | 261.8 |
| CAC-10006391-1 | Cayman | HDAC Trichostatin A | 1 ea | 184.8 |
| CAC-10006392-1 | Cayman | HDAC Substrate | 1 ea | 1817.2 |
| CAC-10006393-1 | Cayman | HDAC Deacetylated Standard | 1 ea | 184.8 |
| CAC-10006394-1 | Cayman | HDAC Developer | 1 ea | 261.8 |
| CAC-10006400-1 | Cayman | CAY10462 | 1 mg | 292.6 |
| CAC-10006400-10 | Cayman | CAY10462 | 10 mg | 2340.8 |
| CAC-10006400-5 | Cayman | CAY10462 | 5 mg | 1324.4 |
| CAC-10006400-50 | Cayman | CAY10462 | 50 mg | 10241 |
| CAC-10006407-1 | Cayman | FTY720 (R)-Phosphate | 1 mg | 1432.2 |
| CAC-10006407-10 | Cayman | FTY720 (R)-Phosphate | 10 mg | 10564.4 |
| CAC-10006407-5 | Cayman | FTY720 (R)-Phosphate | 5 mg | 6036.8 |
| CAC-10006407-500 | Cayman | FTY720 (R)-Phosphate | 500 µg | 754.6 |
| CAC-10006408-1 | Cayman | FTY720 (S)-Phosphate | 1 mg | 1632.4 |
| CAC-10006408-10 | Cayman | FTY720 (S)-Phosphate | 10 mg | 12073.6 |
| CAC-10006408-5 | Cayman | FTY720 (S)-Phosphate | 5 mg | 6899.2 |
| CAC-10006408-500 | Cayman | FTY720 (S)-Phosphate | 500 µg | 862.4 |
| CAC-10006409-1 | Cayman | Adipose Triglyceride Lipase Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006410-100 | Cayman | (±)14(15)-EET-d11 | 100 µg | 8038.8 |
| CAC-10006410-25 | Cayman | (±)14(15)-EET-d11 | 25 µg | 2233 |
| CAC-10006410-250 | Cayman | (±)14(15)-EET-d11 | 250 µg | 17864 |
| CAC-10006410-50 | Cayman | (±)14(15)-EET-d11 | 50 µg | 4250.4 |
| CAC-10006413-10 | Cayman | (±)11(12)-EET-d11 | 10 µg | 2032.8 |
| CAC-10006413-100 | Cayman | (±)11(12)-EET-d11 | 100 µg | 16262.4 |
| CAC-10006413-25 | Cayman | (±)11(12)-EET-d11 | 25 µg | 4835.6 |
| CAC-10006413-50 | Cayman | (±)11(12)-EET-d11 | 50 µg | 9147.6 |
| CAC-10006415-10 | Cayman | Ro 48-8071 | 10 mg | 970.2 |
| CAC-10006415-100 | Cayman | Ro 48-8071 | 100 mg | 7114.8 |
| CAC-10006415-5 | Cayman | Ro 48-8071 | 5 mg | 508.2 |
| CAC-10006415-50 | Cayman | Ro 48-8071 | 50 mg | 4065.6 |
| CAC-10006421-1 | Cayman | HIF-1α (C-Term) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006426-1 | Cayman | RITA | 1 mg | 785.4 |
| CAC-10006426-10 | Cayman | RITA | 10 mg | 2587.2 |
| CAC-10006426-5 | Cayman | RITA | 5 mg | 1647.8 |
| CAC-10006426-50 | Cayman | RITA | 50 mg | 12181.4 |
| CAC-10006427-1 | Cayman | Berberine | 1 g | 231 |
| CAC-10006427-10 | Cayman | Berberine | 10 g | 693 |
| CAC-10006427-50 | Cayman | Berberine | 50 g | 1848 |
| CAC-10006427-5 | Cayman | Berberine | 5 g | 462 |
| CAC-10006436-1 | Cayman | DMPO | 1 g | 2202.2 |
| CAC-10006436-5 | Cayman | DMPO | 5 g | 9240 |
| CAC-10006436-500 | Cayman | DMPO | 500 mg | 1155 |
| CAC-10006438-2 | Cayman | Myeloperoxidase Chlorination Fluorometric Assay Kit | 2 x 96 wells | 3372.6 |
| CAC-10006440-10 | Cayman | SEW2871 | 10 mg | 261.8 |
| CAC-10006440-25 | Cayman | SEW2871 | 25 mg | 631.4 |
| CAC-10006440-5 | Cayman | SEW2871 | 5 mg | 138.6 |
| CAC-10006440-50 | Cayman | SEW2871 | 50 mg | 1108.8 |
| CAC-10006451-100 | Cayman | Pentacosanoic Acid methyl ester | 100 mg | 693 |
| CAC-10006451-250 | Cayman | Pentacosanoic Acid methyl ester | 250 mg | 1647.8 |
| CAC-10006451-500 | Cayman | Pentacosanoic Acid methyl ester | 500 mg | 3126.2 |
| CAC-10006452-10 | Cayman | CAY10486 | 10 mg | 646.8 |
| CAC-10006452-5 | Cayman | CAY10486 | 5 mg | 338.8 |
| CAC-10006452-50 | Cayman | CAY10486 | 50 mg | 2710.4 |
| CAC-10006452-500 | Cayman | CAY10486 | 500 mg | 20328 |
| CAC-10006454-1 | Cayman | ω-3 Arachidonic Acid methyl ester | 1 mg | 1742.4 |
| CAC-10006454-10 | Cayman | ω-3 Arachidonic Acid methyl ester | 10 mg | 14810.4 |
| CAC-10006454-5 | Cayman | ω-3 Arachidonic Acid methyl ester | 5 mg | 8177.4 |
| CAC-10006454-500 | Cayman | ω-3 Arachidonic Acid methyl ester | 500 µg | 1089 |
| CAC-10006456-1 | Cayman | NO-Losartan A | 1 mg | 215.6 |
| CAC-10006456-10 | Cayman | NO-Losartan A | 10 mg | 1724.8 |
| CAC-10006456-5 | Cayman | NO-Losartan A | 5 mg | 970.2 |
| CAC-10006456-50 | Cayman | NO-Losartan A | 50 mg | 7546 |
| CAC-10006480-10 | Cayman | CAY10487 | 10 mg | 646.8 |
| CAC-10006480-5 | Cayman | CAY10487 | 5 mg | 338.8 |
| CAC-10006480-50 | Cayman | CAY10487 | 50 mg | 2710.4 |
| CAC-10006480-500 | Cayman | CAY10487 | 500 mg | 20328 |
| CAC-10006482-10 | Cayman | CAY10485 | 10 mg | 816.2 |
| CAC-10006482-100 | Cayman | CAY10485 | 100 mg | 6036.8 |
| CAC-10006482-5 | Cayman | CAY10485 | 5 mg | 431.2 |
| CAC-10006482-50 | Cayman | CAY10485 | 50 mg | 3449.6 |
| CAC-10006484-100 | Cayman | Estriol | 100 mg | 138.6 |
| CAC-10006484-1 | Cayman | Estriol | 1 g | 1108.8 |
| CAC-10006484-500 | Cayman | Estriol | 500 mg | 631.4 |
| CAC-10006484-5 | Cayman | Estriol | 5 g | 4851 |
| CAC-10006485-1 | Cayman | Estrone | 1 g | 231 |
| CAC-10006485-10 | Cayman | Estrone | 10 g | 1724.8 |
| CAC-10006485-500 | Cayman | Estrone | 500 mg | 123.2 |
| CAC-10006485-5 | Cayman | Estrone | 5 g | 985.6 |
| CAC-10006486-1 | Cayman | Ethynyl Estradiol | 1 g | 693 |
| CAC-10006486-500 | Cayman | Ethynyl Estradiol | 500 mg | 385 |
| CAC-10006486-5 | Cayman | Ethynyl Estradiol | 5 g | 2310 |
| CAC-10006487-1 | Cayman | Estradiol Benzoate | 1 g | 693 |
| CAC-10006487-500 | Cayman | Estradiol Benzoate | 500 mg | 385 |
| CAC-10006487-5 | Cayman | Estradiol Benzoate | 5 g | 2125.2 |
| CAC-10006488-100 | Cayman | Gestrinone | 100 mg | 1370.6 |
| CAC-10006488-1 | Cayman | Gestrinone | 1 g | 10964.8 |
| CAC-10006488-500 | Cayman | Gestrinone | 500 mg | 5821.2 |
| CAC-10006515-96 | Cayman | HAT Inhibitor Screening Assay Kit | 96 wells | 4620 |
| CAC-10006518-1 | Cayman | S-Nitrosylated Protein Detection Kit (Biotin Switch) | 1 ea | 4081 |
| CAC-10006519-1 | Cayman | S-Nitrosylation Wash Buffer (10X) | 1 ea | 215.6 |
| CAC-10006520-1 | Cayman | S-Nitrosylation Buffer A | 1 ea | 277.2 |
| CAC-10006521-1 | Cayman | S-Nitrosylation Buffer B (5X) | 1 ea | 292.6 |
| CAC-10006522-1 | Cayman | S-Nitrosylation Reducing Reagent | 1 ea | 1031.8 |
| CAC-10006523-1 | Cayman | S-Nitrosylation Labeling Reagent | 1 ea | 354.2 |
| CAC-10006524-1 | Cayman | S-Nitrosylation Detection Reagent I (HRP) | 1 ea | 862.4 |
| CAC-10006525-1 | Cayman | S-Nitrosylation Detection Reagent II (Fluorescein) | 1 ea | 862.4 |
| CAC-10006529-10 | Cayman | Oleyl Anilide | 10 mg | 415.8 |
| CAC-10006529-100 | Cayman | Oleyl Anilide | 100 mg | 3018.4 |
| CAC-10006529-5 | Cayman | Oleyl Anilide | 5 mg | 215.6 |
| CAC-10006529-50 | Cayman | Oleyl Anilide | 50 mg | 1724.8 |
| CAC-10006545-10 | Cayman | CAY10464 | 10 mg | 261.8 |
| CAC-10006545-100 | Cayman | CAY10464 | 100 mg | 2094.4 |
| CAC-10006545-25 | Cayman | CAY10464 | 25 mg | 616 |
| CAC-10006545-50 | Cayman | CAY10464 | 50 mg | 1185.8 |
| CAC-10006546-1 | Cayman | CAY10465 | 1 mg | 261.8 |
| CAC-10006546-10 | Cayman | CAY10465 | 10 mg | 2094.4 |
| CAC-10006546-5 | Cayman | CAY10465 | 5 mg | 1185.8 |
| CAC-10006546-50 | Cayman | CAY10465 | 50 mg | 9163 |
| CAC-10006556-1 | Cayman | Latanoprost-d4 | 1 mg | 7653.8 |
| CAC-10006556-100 | Cayman | Latanoprost-d4 | 100 µg | 1031.8 |
| CAC-10006556-50 | Cayman | Latanoprost-d4 | 50 µg | 539 |
| CAC-10006556-500 | Cayman | Latanoprost-d4 | 500 µg | 4312 |
| CAC-10006577-1 | Cayman | Normal Goat Serum | 1 ea | 1155 |
| CAC-10006579-100 | Cayman | γ-Linolenic Acid methyl ester | 100 mg | 739.2 |
| CAC-10006579-1 | Cayman | γ-Linolenic Acid methyl ester | 1 g | 4620 |
| CAC-10006579-250 | Cayman | γ-Linolenic Acid methyl ester | 250 mg | 1740.2 |
| CAC-10006579-50 | Cayman | γ-Linolenic Acid methyl ester | 50 mg | 385 |
| CAC-10006580-10 | Cayman | Dihomo-γ-Linolenic Acid methyl ester | 10 mg | 308 |
| CAC-10006580-100 | Cayman | Dihomo-γ-Linolenic Acid methyl ester | 100 mg | 1817.2 |
| CAC-10006580-50 | Cayman | Dihomo-γ-Linolenic Acid methyl ester | 50 mg | 939.4 |
| CAC-10006588-1 | Cayman | Goat Anti-Rabbit IgG FITC | 1 ea | 1155 |
| CAC-10006590-1ea | Cayman | CB1 Receptor (C-Term) Polyclonal Antibody | 1ea | 4296.6 |
| CAC-10006591-1 | Cayman | CB1 Receptor (C-Term) Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006593-100 | Cayman | Prostaglandin D Synthase (hematopoietic-type; human recombinant) | 100 µg | 2324.8 |
| CAC-10006593-250 | Cayman | Prostaglandin D Synthase (hematopoietic-type; human recombinant) | 250 µg | 4681 |
| CAC-10006593-50 | Cayman | Prostaglandin D Synthase (hematopoietic-type; human recombinant) | 50 µg | 1508.6 |
| CAC-10006594-10 | Cayman | Losartan (potassium salt) | 10 mg | 184.8 |
| CAC-10006594-100 | Cayman | Losartan (potassium salt) | 100 mg | 1478.4 |
| CAC-10006594-50 | Cayman | Losartan (potassium salt) | 50 mg | 831.6 |
| CAC-10006594-500 | Cayman | Losartan (potassium salt) | 500 mg | 6468 |
| CAC-10006606-1 | Cayman | Retreversine | 1 mg | 816.2 |
| CAC-10006606-10 | Cayman | Retreversine | 10 mg | 6036.8 |
| CAC-10006606-5 | Cayman | Retreversine | 5 mg | 3449.6 |
| CAC-10006606-500 | Cayman | Retreversine | 500 µg | 431.2 |
| CAC-10006607-100 | Cayman | Arachidonic Acid (sodium salt) | 100 mg | 1940.4 |
| CAC-10006607-25 | Cayman | Arachidonic Acid (sodium salt) | 25 mg | 539 |
| CAC-10006607-50 | Cayman | Arachidonic Acid (sodium salt) | 50 mg | 1031.8 |
| CAC-10006607-500 | Cayman | Arachidonic Acid (sodium salt) | 500 mg | 8085 |
| CAC-10006610-1 | Cayman | Thromboxane B1 | 1 mg | 1694 |
| CAC-10006610-10 | Cayman | Thromboxane B1 | 10 mg | 13552 |
| CAC-10006610-5 | Cayman | Thromboxane B1 | 5 mg | 7623 |
| CAC-10006611-1 | Cayman | GW 4064 | 1 mg | 385 |
| CAC-10006611-10 | Cayman | GW 4064 | 10 mg | 1663.2 |
| CAC-10006611-5 | Cayman | GW 4064 | 5 mg | 1062.6 |
| CAC-10006616-1 | Cayman | S1P1 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006617-1 | Cayman | Goat Anti-Mouse (IgG+IgM) FITC | 1 ea | 1001 |
| CAC-10006618-1 | Cayman | 5-OxoETE Receptor Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006620-1 | Cayman | Serine Palmitoyltransferase Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006626-100 | Cayman | Lauric Acid | 100 g | 369.6 |
| CAC-10006626-25 | Cayman | Lauric Acid | 25 g | 154 |
| CAC-10006626-250 | Cayman | Lauric Acid | 250 g | 770 |
| CAC-10006626-50 | Cayman | Lauric Acid | 50 g | 215.6 |
| CAC-10006627-10 | Cayman | Palmitic Acid | 10 g | 308 |
| CAC-10006627-100 | Cayman | Palmitic Acid | 100 g | 1848 |
| CAC-10006627-25 | Cayman | Palmitic Acid | 25 g | 539 |
| CAC-10006627-50 | Cayman | Palmitic Acid | 50 g | 1001 |
| CAC-10006654-10 | Cayman | 5-iPF2α-VI-d11 | 10 µg | 5035.8 |
| CAC-10006654-25 | Cayman | 5-iPF2α-VI-d11 | 25 µg | 11996.6 |
| CAC-10006661-1 | Cayman | Ketoprofen | 1 g | 123.2 |
| CAC-10006661-10 | Cayman | Ketoprofen | 10 g | 985.6 |
| CAC-10006661-25 | Cayman | Ketoprofen | 25 g | 2156 |
| CAC-10006661-5 | Cayman | Ketoprofen | 5 g | 554.4 |
| CAC-10006692-1 | Cayman | (+)-15-epi Cloprostenol | 1 mg | 600.6 |
| CAC-10006692-10 | Cayman | (+)-15-epi Cloprostenol | 10 mg | 4804.8 |
| CAC-10006692-5 | Cayman | (+)-15-epi Cloprostenol | 5 mg | 2710.4 |
| CAC-10006692-50 | Cayman | (+)-15-epi Cloprostenol | 50 mg | 21021 |
| CAC-10006695-10 | Cayman | HEPC | 10 mg | 3742.2 |
| CAC-10006695-25 | Cayman | HEPC | 25 mg | 8870.4 |
| CAC-10006695-5 | Cayman | HEPC | 5 mg | 1971.2 |
| CAC-10006695-50 | Cayman | HEPC | 50 mg | 15769.6 |
| CAC-10006697-1 | Cayman | Prostaglandin D2-biotin | 1 mg | 10364.2 |
| CAC-10006697-100 | Cayman | Prostaglandin D2-biotin | 100 µg | 1694 |
| CAC-10006697-50 | Cayman | Prostaglandin D2-biotin | 50 µg | 893.2 |
| CAC-10006697-500 | Cayman | Prostaglandin D2-biotin | 500 µg | 5898.2 |
| CAC-10006726-1 | Cayman | PD 98059 | 1 mg | 184.8 |
| CAC-10006726-10 | Cayman | PD 98059 | 10 mg | 1001 |
| CAC-10006726-5 | Cayman | PD 98059 | 5 mg | 693 |
| CAC-10006726-50 | Cayman | PD 98059 | 50 mg | 4004 |
| CAC-10006727-1 | Cayman | PD 169316 | 1 mg | 754.6 |
| CAC-10006727-10 | Cayman | PD 169316 | 10 mg | 2109.8 |
| CAC-10006727-25 | Cayman | PD 169316 | 25 mg | 4527.6 |
| CAC-10006727-5 | Cayman | PD 169316 | 5 mg | 1201.2 |
| CAC-10006731-10 | Cayman | VDM11 | 10 mg | 970.2 |
| CAC-10006731-25 | Cayman | VDM11 | 25 mg | 2294.6 |
| CAC-10006731-5 | Cayman | VDM11 | 5 mg | 508.2 |
| CAC-10006731-50 | Cayman | VDM11 | 50 mg | 4065.6 |
| CAC-10006734-1 | Cayman | QNZ | 1 mg | 446.6 |
| CAC-10006734-10 | Cayman | QNZ | 10 mg | 3234 |
| CAC-10006734-5 | Cayman | QNZ | 5 mg | 1848 |
| CAC-10006734-500 | Cayman | QNZ | 500 µg | 231 |
| CAC-10006735-1 | Cayman | CAY10471 | 1 mg | 831.6 |
| CAC-10006735-10 | Cayman | CAY10471 | 10 mg | 6652.8 |
| CAC-10006735-5 | Cayman | CAY10471 | 5 mg | 3742.2 |
| CAC-10006735-50 | Cayman | CAY10471 | 50 mg | 29106 |
| CAC-10006758-1 | Cayman | Arachidonic Acid-d11 | 1 mg | 2510.2 |
| CAC-10006758-100 | Cayman | Arachidonic Acid-d11 | 100 µg | 385 |
| CAC-10006758-500 | Cayman | Arachidonic Acid-d11 | 500 µg | 1447.6 |
| CAC-10006778-500 | Cayman | Nitrotyrosine (Peptide) Polyclonal Antibody | 500 µl | 3526.6 |
| CAC-10006782-10 | Cayman | Oleic Acid-2,6-diisopropylanilide | 10 mg | 785.4 |
| CAC-10006782-5 | Cayman | Oleic Acid-2,6-diisopropylanilide | 5 mg | 415.8 |
| CAC-10006782-50 | Cayman | Oleic Acid-2,6-diisopropylanilide | 50 mg | 3326.4 |
| CAC-10006788-250 | Cayman | Prostaglandin D Synthase (lipocalin-type; human recombinant) | 250 µg | 4681 |
| CAC-10006790-1 | Cayman | ChREBP Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006797-100 | Cayman | Araguspongin B | 100 µg | 5035.8 |
| CAC-10006797-250 | Cayman | Araguspongin B | 250 µg | 11965.8 |
| CAC-10006798-10 | Cayman | GW 0742 | 10 mg | 1909.6 |
| CAC-10006798-25 | Cayman | GW 0742 | 25 mg | 4512.2 |
| CAC-10006798-5 | Cayman | GW 0742 | 5 mg | 1001 |
| CAC-10006798-50 | Cayman | GW 0742 | 50 mg | 7007 |
| CAC-10006800-1 | Cayman | (R)-Bromoenol lactone | 1 mg | 693 |
| CAC-10006800-10 | Cayman | (R)-Bromoenol lactone | 10 mg | 4620 |
| CAC-10006800-5 | Cayman | (R)-Bromoenol lactone | 5 mg | 2895.2 |
| CAC-10006800-500 | Cayman | (R)-Bromoenol lactone | 500 µg | 385 |
| CAC-10006801-1 | Cayman | (S)-Bromoenol lactone | 1 mg | 693 |
| CAC-10006801-10 | Cayman | (S)-Bromoenol lactone | 10 mg | 4620 |
| CAC-10006801-5 | Cayman | (S)-Bromoenol lactone | 5 mg | 2895.2 |
| CAC-10006801-500 | Cayman | (S)-Bromoenol lactone | 500 µg | 385 |
| CAC-10006803-1 | Cayman | O-1602 | 1 mg | 338.8 |
| CAC-10006803-10 | Cayman | O-1602 | 10 mg | 2032.8 |
| CAC-10006803-25 | Cayman | O-1602 | 25 mg | 3819.2 |
| CAC-10006803-5 | Cayman | O-1602 | 5 mg | 1355.2 |
| CAC-10006804-1 | Cayman | O-1821 | 1 mg | 308 |
| CAC-10006804-10 | Cayman | O-1821 | 10 mg | 2464 |
| CAC-10006804-5 | Cayman | O-1821 | 5 mg | 1386 |
| CAC-10006804-50 | Cayman | O-1821 | 50 mg | 10780 |
| CAC-10006809-10 | Cayman | Heptanoyl thio-PC | 10 mg | 3603.6 |
| CAC-10006809-25 | Cayman | Heptanoyl thio-PC | 25 mg | 8531.6 |
| CAC-10006809-5 | Cayman | Heptanoyl thio-PC | 5 mg | 1894.2 |
| CAC-10006809-50 | Cayman | Heptanoyl thio-PC | 50 mg | 15153.6 |
| CAC-10006822-1 | Cayman | Sphingosine Kinase 1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10006823-1 | Cayman | Sphingosine Kinase 1 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006829-1 | Cayman | Docosahexaenoic Acid Quant-PAK | 1 ea | 1062.6 |
| CAC-10006830-1 | Cayman | 6-keto Prostaglandin F1α Quant-PAK | 1 ea | 6868.4 |
| CAC-10006831-1 | Cayman | 11-dehydro Thromboxane B2 Quant-PAK | 1 ea | 16339.4 |
| CAC-10006832-1 | Cayman | Thromboxane B2 Quant-PAK | 1 ea | 8115.8 |
| CAC-10006833-1 | Cayman | ω-3 Arachidonic Acid Quant-PAK | 1 ea | 4881.8 |
| CAC-10006834-1 | Cayman | Linoleic Acid Quant-PAK | 1 ea | 508.2 |
| CAC-10006835-1 | Cayman | Arachidonic Acid Quant-PAK | 1 ea | 1524.6 |
| CAC-10006840-1 | Cayman | Prostaglandin A2 Quant-PAK | 1 ea | 2725.8 |
| CAC-10006841-1 | Cayman | Prostaglandin B2 Quant-PAK | 1 ea | 4450.6 |
| CAC-10006842-1 | Cayman | Prostaglandin D1 Quant-PAK | 1 ea | 6514.2 |
| CAC-10006843-1 | Cayman | Prostaglandin D2 Quant-PAK | 1 ea | 4851 |
| CAC-10006844-1 | Cayman | Prostaglandin E1 Quant-PAK | 1 ea | 2294.6 |
| CAC-10006845-1 | Cayman | 13,14-dihydro Prostaglandin E1 Quant-PAK | 1 ea | 8131.2 |
| CAC-10006846-1 | Cayman | Prostaglandin E2 Quant-PAK | 1 ea | 2356.2 |
| CAC-10006848-1 | Cayman | Prostaglandin F2α Quant-PAK | 1 ea | 2310 |
| CAC-10006850-1 | Cayman | 15-deoxy-Δ12,14-Prostaglandin J2 Quant-PAK | 1 ea | 6699 |
| CAC-10006855-96 | Cayman | PPARγ Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10006856-1 | Cayman | Stearidonic Acid ethyl ester | 1 mg | 1603.8 |
| CAC-10006856-10 | Cayman | Stearidonic Acid ethyl ester | 10 mg | 14256 |
| CAC-10006856-5 | Cayman | Stearidonic Acid ethyl ester | 5 mg | 7583.4 |
| CAC-10006856-500 | Cayman | Stearidonic Acid ethyl ester | 500 µg | 891 |
| CAC-10006861-1 | Cayman | nor-NOHA (acetate) | 1 mg | 261.8 |
| CAC-10006861-10 | Cayman | nor-NOHA (acetate) | 10 mg | 2094.4 |
| CAC-10006861-5 | Cayman | nor-NOHA (acetate) | 5 mg | 1185.8 |
| CAC-10006861-50 | Cayman | nor-NOHA (acetate) | 50 mg | 9163 |
| CAC-10006862-1 | Cayman | ABH | 1 mg | 539 |
| CAC-10006862-10 | Cayman | ABH | 10 mg | 4312 |
| CAC-10006862-5 | Cayman | ABH | 5 mg | 2433.2 |
| CAC-10006864-10 | Cayman | cis-7-Hexadecenoic Acid methyl ester | 10 mg | 1524.6 |
| CAC-10006864-25 | Cayman | cis-7-Hexadecenoic Acid methyl ester | 25 mg | 3388 |
| CAC-10006864-5 | Cayman | cis-7-Hexadecenoic Acid methyl ester | 5 mg | 847 |
| CAC-10006864-50 | Cayman | cis-7-Hexadecenoic Acid methyl ester | 50 mg | 5929 |
| CAC-10006865-100 | Cayman | Docosahexaenoic Acid methyl ester | 100 mg | 739.2 |
| CAC-10006865-1 | Cayman | Docosahexaenoic Acid methyl ester | 1 g | 5390 |
| CAC-10006865-50 | Cayman | Docosahexaenoic Acid methyl ester | 50 mg | 385 |
| CAC-10006865-500 | Cayman | Docosahexaenoic Acid methyl ester | 500 mg | 2895.2 |
| CAC-10006866-1 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid methyl ester | 1 mg | 385 |
| CAC-10006866-10 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid methyl ester | 10 mg | 2695 |
| CAC-10006866-5 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid methyl ester | 5 mg | 1447.6 |
| CAC-10006870-1 | Cayman | Renin Assay Buffer (10X) | 1 ea | 938.8 |
| CAC-10006872-1 | Cayman | Renin Substrate | 1 ea | 2833 |
| CAC-10006874-10 | Cayman | Ethyl Tricosanoate | 10 mg | 323.4 |
| CAC-10006874-100 | Cayman | Ethyl Tricosanoate | 100 mg | 2371.6 |
| CAC-10006874-5 | Cayman | Ethyl Tricosanoate | 5 mg | 169.4 |
| CAC-10006874-50 | Cayman | Ethyl Tricosanoate | 50 mg | 1355.2 |
| CAC-10006876-1 | Cayman | Diethylstilbestrol | 1 g | 308 |
| CAC-10006876-10 | Cayman | Diethylstilbestrol | 10 g | 2464 |
| CAC-10006876-25 | Cayman | Diethylstilbestrol | 25 g | 5390 |
| CAC-10006876-5 | Cayman | Diethylstilbestrol | 5 g | 1386 |
| CAC-10006878-10 | Cayman | 8,12-iso-iPF2α-VI-d11 | 10 µg | 3002.4 |
| CAC-10006878-25 | Cayman | 8,12-iso-iPF2α-VI-d11 | 25 µg | 6313.4 |
| CAC-10006878-50 | Cayman | 8,12-iso-iPF2α-VI-d11 | 50 µg | 11410.8 |
| CAC-10006880-1 | Cayman | Transcription Factor Binding Assay Buffer (4X) | 1 ea | 508.2 |
| CAC-10006881-1 | Cayman | Transcription Factor PPARγ Positive Control | 1 ea | 1601 |
| CAC-10006882-1 | Cayman | Transcription Factor Antibody Binding Buffer (10X) | 1 ea | 508.2 |
| CAC-10006883-1 | Cayman | Transcription Factor PPARγ Primary Antibody | 1 ea | 1570.8 |
| CAC-10006884-1 | Cayman | Transcription Factor Goat Anti-Rabbit HRP Conjugate | 1 ea | 631.4 |
| CAC-10006885-1 | Cayman | Transcription Factor PPAR Competitor dsDNA | 1 ea | 754.6 |
| CAC-10006887-1 | Cayman | Transcription Factor PPAR 96-Well Strip Plate | 1 ea | 985.6 |
| CAC-10006888-1 | Cayman | Transcription Factor Developing Solution | 1 ea | 508.2 |
| CAC-10006889-1 | Cayman | Transcription Factor Stop Solution | 1 ea | 508.2 |
| CAC-10006906-1 | Cayman | Renin Fluorogenic Substrate | 1 mg | 4950 |
| CAC-10006908-1 | Cayman | Adipogenesis Assay Kit | 1 ea | 3911.6 |
| CAC-10006910-96 | Cayman | HIF-1α Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10006912-96 | Cayman | NF-κB (human p50) Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10006914-96 | Cayman | PPARδ Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10006915-96 | Cayman | PPARα Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10006943-480 | Cayman | Vitellogenin (fathead minnow) ELISA Kit | 480 wells | 52430.4 |
| CAC-10006943-96 | Cayman | Vitellogenin (fathead minnow) ELISA Kit | 96 wells | 13978.8 |
| CAC-10006966-100 | Cayman | Nitrotyrosine Monoclonal Antibody - Biotinylated | 100 µg | 4450.6 |
| CAC-10006967-10 | Cayman | Zileuton | 10 mg | 462 |
| CAC-10006967-25 | Cayman | Zileuton | 25 mg | 1108.8 |
| CAC-10006967-5 | Cayman | Zileuton | 5 mg | 246.4 |
| CAC-10006967-50 | Cayman | Zileuton | 50 mg | 1971.2 |
| CAC-10006972-1 | Cayman | AM281 | 1 mg | 385 |
| CAC-10006972-10 | Cayman | AM281 | 10 mg | 1925 |
| CAC-10006972-5 | Cayman | AM281 | 5 mg | 1062.6 |
| CAC-10006973-10 | Cayman | Pravadoline | 10 mg | 1617 |
| CAC-10006973-25 | Cayman | Pravadoline | 25 mg | 3819.2 |
| CAC-10006973-5 | Cayman | Pravadoline | 5 mg | 847 |
| CAC-10006974-10 | Cayman | AM630 | 10 mg | 1139.6 |
| CAC-10006974-100 | Cayman | AM630 | 100 mg | 8408.4 |
| CAC-10006974-5 | Cayman | AM630 | 5 mg | 600.6 |
| CAC-10006974-50 | Cayman | AM630 | 50 mg | 4512.2 |
| CAC-10006976-100 | Cayman | Thiocarlide | 100 mg | 646.8 |
| CAC-10006976-1 | Cayman | Thiocarlide | 1 g | 4743.2 |
| CAC-10006976-50 | Cayman | Thiocarlide | 50 mg | 338.8 |
| CAC-10006976-500 | Cayman | Thiocarlide | 500 mg | 2710.4 |
| CAC-10006984-1 | Cayman | LPA1 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10006987-1 | Cayman | Prostaglandin E2-biotin | 1 mg | 11426.8 |
| CAC-10006987-100 | Cayman | Prostaglandin E2-biotin | 100 µg | 1555.4 |
| CAC-10006987-50 | Cayman | Prostaglandin E2-biotin | 50 µg | 816.2 |
| CAC-10006987-500 | Cayman | Prostaglandin E2-biotin | 500 µg | 6529.6 |
| CAC-10006988-100 | Cayman | Prostaglandin F2α-biotin | 100 µg | 1555.4 |
| CAC-10006988-50 | Cayman | Prostaglandin F2α-biotin | 50 µg | 816.2 |
| CAC-10006988-500 | Cayman | Prostaglandin F2α-biotin | 500 µg | 6529.6 |
| CAC-10006995-1 | Cayman | Piloty's Acid | 1 g | 231 |
| CAC-10006995-10 | Cayman | Piloty's Acid | 10 g | 1724.8 |
| CAC-10006995-500 | Cayman | Piloty's Acid | 500 mg | 123.2 |
| CAC-10006995-5 | Cayman | Piloty's Acid | 5 g | 985.6 |
| CAC-10006998-100 | Cayman | (±)14(15)-DiHETE | 100 µg | 4219.6 |
| CAC-10006998-25 | Cayman | (±)14(15)-DiHETE | 25 µg | 1170.4 |
| CAC-10006998-50 | Cayman | (±)14(15)-DiHETE | 50 µg | 2217.6 |
| CAC-10006999-100 | Cayman | (±)17(18)-DiHETE | 100 µg | 4219.6 |
| CAC-10006999-25 | Cayman | (±)17(18)-DiHETE | 25 µg | 1170.4 |
| CAC-10006999-50 | Cayman | (±)17(18)-DiHETE | 50 µg | 2217.6 |
| CAC-10007001-1 | Cayman | (±)19(20)-DiHDPA | 1 mg | 14876.4 |
| CAC-10007001-100 | Cayman | (±)19(20)-DiHDPA | 100 µg | 2017.4 |
| CAC-10007001-50 | Cayman | (±)19(20)-DiHDPA | 50 µg | 1062.6 |
| CAC-10007001-500 | Cayman | (±)19(20)-DiHDPA | 500 µg | 8500.8 |
| CAC-10007002-1 | Cayman | CRTH2/DP2 Receptor (C-Term) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10007003-1 | Cayman | CRTH2/DP2 Receptor (C-Term) Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007012-100 | Cayman | 12-oxo Stearic Acid methyl ester | 100 mg | 2186.8 |
| CAC-10007012-25 | Cayman | 12-oxo Stearic Acid methyl ester | 25 mg | 908.6 |
| CAC-10007012-250 | Cayman | 12-oxo Stearic Acid methyl ester | 250 mg | 5005 |
| CAC-10007012-50 | Cayman | 12-oxo Stearic Acid methyl ester | 50 mg | 1447.6 |
| CAC-10007048-100 | Cayman | Vitellogenin (bird) Monoclonal Antibody (ND-3C3) | 100 µl | 5128.2 |
| CAC-10007048-500 | Cayman | Vitellogenin (bird) Monoclonal Antibody (ND-3C3) | 500 µl | 23086.8 |
| CAC-10007049-100 | Cayman | Vitellogenin (bird) Monoclonal Antibody (ND-3G6) | 100 µl | 5128.2 |
| CAC-10007049-500 | Cayman | Vitellogenin (bird) Monoclonal Antibody (ND-3G6) | 500 µl | 23086.8 |
| CAC-10007055-1 | Cayman | 3-keto Petromyzonol | 1 mg | 871.2 |
| CAC-10007055-10 | Cayman | 3-keto Petromyzonol | 10 mg | 6098.4 |
| CAC-10007055-5 | Cayman | 3-keto Petromyzonol | 5 mg | 3267 |
| CAC-10007061-1 | Cayman | Calmodulin (1 µM) | 1 ea | 277.2 |
| CAC-10007062-1 | Cayman | Reaction Buffer (2X) | 1 ea | 277.2 |
| CAC-10007063-1 | Cayman | Homogenization Buffer (10X) | 1 ea | 277.2 |
| CAC-10007064-1 | Cayman | Stop Buffer | 1 ea | 277.2 |
| CAC-10007065-1 | Cayman | Equilibrated Resin | 1 ea | 492.8 |
| CAC-10007066-1 | Cayman | Calcium Chloride (6 mM) | 1 ea | 277.2 |
| CAC-10007067-1 | Cayman | L-NNA (10 mM) | 1 ea | 985.6 |
| CAC-10007068-1 | Cayman | iNOS Positive Control | 1 ea | 1832 |
| CAC-10007072-10 | Cayman | 1-Palmitoyl-2-linoleoyl PE | 10 mg | 908.6 |
| CAC-10007072-100 | Cayman | 1-Palmitoyl-2-linoleoyl PE | 100 mg | 6683.6 |
| CAC-10007072-5 | Cayman | 1-Palmitoyl-2-linoleoyl PE | 5 mg | 477.4 |
| CAC-10007072-50 | Cayman | 1-Palmitoyl-2-linoleoyl PE | 50 mg | 3819.2 |
| CAC-10007073-1 | Cayman | PTEN Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007075-1 | Cayman | 4-(1-piperazinyl)-1H-Indole (hydrochloride) | 1 g | 2692.8 |
| CAC-10007075-100 | Cayman | 4-(1-piperazinyl)-1H-Indole (hydrochloride) | 100 mg | 336.6 |
| CAC-10007075-250 | Cayman | 4-(1-piperazinyl)-1H-Indole (hydrochloride) | 250 mg | 792 |
| CAC-10007075-500 | Cayman | 4-(1-piperazinyl)-1H-Indole (hydrochloride) | 500 mg | 1425.6 |
| CAC-10007076-1 | Cayman | CAY10491 | 1 g | 7286.4 |
| CAC-10007076-100 | Cayman | CAY10491 | 100 mg | 910.8 |
| CAC-10007076-500 | Cayman | CAY10491 | 500 mg | 4019.4 |
| CAC-10007077-1 | Cayman | CAY10492 | 1 g | 4158 |
| CAC-10007077-100 | Cayman | CAY10492 | 100 mg | 495 |
| CAC-10007077-5 | Cayman | CAY10492 | 5 g | 17325 |
| CAC-10007077-500 | Cayman | CAY10492 | 500 mg | 2237.4 |
| CAC-10007078-1 | Cayman | CAY10493 | 1 g | 7128 |
| CAC-10007078-100 | Cayman | CAY10493 | 100 mg | 891 |
| CAC-10007078-500 | Cayman | CAY10493 | 500 mg | 4019.4 |
| CAC-10007079-1 | Cayman | 5-Bromoisoquinoline | 1 g | 1247.4 |
| CAC-10007079-5 | Cayman | 5-Bromoisoquinoline | 5 g | 3821.4 |
| CAC-10007079-500 | Cayman | 5-Bromoisoquinoline | 500 mg | 693 |
| CAC-10007080-1 | Cayman | 6-Bromoisoquinoline | 1 g | 1247.4 |
| CAC-10007080-5 | Cayman | 6-Bromoisoquinoline | 5 g | 3821.4 |
| CAC-10007080-500 | Cayman | 6-Bromoisoquinoline | 500 mg | 693 |
| CAC-10007081-1 | Cayman | 7-Bromoisoquinoline | 1 g | 1386 |
| CAC-10007081-5 | Cayman | 7-Bromoisoquinoline | 5 g | 4257 |
| CAC-10007081-500 | Cayman | 7-Bromoisoquinoline | 500 mg | 772.2 |
| CAC-10007082-1 | Cayman | 8-Bromoisoquinoline | 1 g | 1247.4 |
| CAC-10007082-5 | Cayman | 8-Bromoisoquinoline | 5 g | 3821.4 |
| CAC-10007082-500 | Cayman | 8-Bromoisoquinoline | 500 mg | 693 |
| CAC-10007083-1 | Cayman | 5,6,7,8-tetrahydro-2-Quinolone | 1 g | 14968.8 |
| CAC-10007083-100 | Cayman | 5,6,7,8-tetrahydro-2-Quinolone | 100 mg | 2039.4 |
| CAC-10007083-50 | Cayman | 5,6,7,8-tetrahydro-2-Quinolone | 50 mg | 1069.2 |
| CAC-10007083-500 | Cayman | 5,6,7,8-tetrahydro-2-Quinolone | 500 mg | 8395.2 |
| CAC-10007084-1 | Cayman | 4-Cyanoindole | 1 g | 1188 |
| CAC-10007084-10 | Cayman | 4-Cyanoindole | 10 g | 9504 |
| CAC-10007084-5 | Cayman | 4-Cyanoindole | 5 g | 5346 |
| CAC-10007084-500 | Cayman | 4-Cyanoindole | 500 mg | 613.8 |
| CAC-10007085-1 | Cayman | 4-Aminomethylindole | 1 g | 1762.2 |
| CAC-10007085-5 | Cayman | 4-Aminomethylindole | 5 g | 7603.2 |
| CAC-10007085-500 | Cayman | 4-Aminomethylindole | 500 mg | 1168.2 |
| CAC-10007086-1 | Cayman | 4-formyl Indole | 1 g | 1742.4 |
| CAC-10007086-10 | Cayman | 4-formyl Indole | 10 g | 13939.2 |
| CAC-10007086-5 | Cayman | 4-formyl Indole | 5 g | 7840.8 |
| CAC-10007086-500 | Cayman | 4-formyl Indole | 500 mg | 891 |
| CAC-10007087-1 | Cayman | (1H-Indol-4-yl)-Carbamic Acid tert-butyl ester | 1 g | 1346.4 |
| CAC-10007087-5 | Cayman | (1H-Indol-4-yl)-Carbamic Acid tert-butyl ester | 5 g | 5801.4 |
| CAC-10007087-500 | Cayman | (1H-Indol-4-yl)-Carbamic Acid tert-butyl ester | 500 mg | 891 |
| CAC-10007089-1 | Cayman | N-(diphenylmethylene) Glycine benzyl ester | 1 g | 613.8 |
| CAC-10007089-10 | Cayman | N-(diphenylmethylene) Glycine benzyl ester | 10 g | 4910.4 |
| CAC-10007089-5 | Cayman | N-(diphenylmethylene) Glycine benzyl ester | 5 g | 2772 |
| CAC-10007089-500 | Cayman | N-(diphenylmethylene) Glycine benzyl ester | 500 mg | 316.8 |
| CAC-10007090-1 | Cayman | (S)-(+)-2-hydroxy-3-Methylbutyric Acid | 1 g | 514.8 |
| CAC-10007090-10 | Cayman | (S)-(+)-2-hydroxy-3-Methylbutyric Acid | 10 g | 4118.4 |
| CAC-10007090-5 | Cayman | (S)-(+)-2-hydroxy-3-Methylbutyric Acid | 5 g | 2316.6 |
| CAC-10007090-500 | Cayman | (S)-(+)-2-hydroxy-3-Methylbutyric Acid | 500 mg | 257.4 |
| CAC-10007091-1 | Cayman | N,N-dimethyl-L-Valine | 1 g | 1108.8 |
| CAC-10007091-100 | Cayman | N,N-dimethyl-L-Valine | 100 mg | 138.6 |
| CAC-10007091-5 | Cayman | N,N-dimethyl-L-Valine | 5 g | 4851 |
| CAC-10007091-500 | Cayman | N,N-dimethyl-L-Valine | 500 mg | 534.6 |
| CAC-10007092-1 | Cayman | N-Pivaloylaniline | 1 g | 475.2 |
| CAC-10007092-10 | Cayman | N-Pivaloylaniline | 10 g | 3801.6 |
| CAC-10007092-5 | Cayman | N-Pivaloylaniline | 5 g | 2138.4 |
| CAC-10007092-500 | Cayman | N-Pivaloylaniline | 500 mg | 237.6 |
| CAC-10007093-10 | Cayman | 2-Aminopyrazine | 10 g | 534.6 |
| CAC-10007093-25 | Cayman | 2-Aminopyrazine | 25 g | 1247.4 |
| CAC-10007093-5 | Cayman | 2-Aminopyrazine | 5 g | 277.2 |
| CAC-10007093-50 | Cayman | 2-Aminopyrazine | 50 g | 2217.6 |
| CAC-10007094-1 | Cayman | 7-chlorothieno[2,3-c]Pyridine | 1 g | 3484.8 |
| CAC-10007094-100 | Cayman | 7-chlorothieno[2,3-c]Pyridine | 100 mg | 435.6 |
| CAC-10007094-5 | Cayman | 7-chlorothieno[2,3-c]Pyridine | 5 g | 15246 |
| CAC-10007094-500 | Cayman | 7-chlorothieno[2,3-c]Pyridine | 500 mg | 1881 |
| CAC-10007102-1 | Cayman | 3-thio-Pheneacrylic Acid methyl ester | 1 g | 277.2 |
| CAC-10007102-10 | Cayman | 3-thio-Pheneacrylic Acid methyl ester | 10 g | 2217.6 |
| CAC-10007102-25 | Cayman | 3-thio-Pheneacrylic Acid methyl ester | 25 g | 4851 |
| CAC-10007102-5 | Cayman | 3-thio-Pheneacrylic Acid methyl ester | 5 g | 1247.4 |
| CAC-10007103-1 | Cayman | 3-thio-Pheneacrylic Acid | 1 g | 277.2 |
| CAC-10007103-10 | Cayman | 3-thio-Pheneacrylic Acid | 10 g | 2217.6 |
| CAC-10007103-25 | Cayman | 3-thio-Pheneacrylic Acid | 25 g | 4851 |
| CAC-10007103-5 | Cayman | 3-thio-Pheneacrylic Acid | 5 g | 1247.4 |
| CAC-10007106-1 | Cayman | 2-Aminomethylpyrimidine (hydrochloride) | 1 g | 14968.8 |
| CAC-10007106-100 | Cayman | 2-Aminomethylpyrimidine (hydrochloride) | 100 mg | 2039.4 |
| CAC-10007106-50 | Cayman | 2-Aminomethylpyrimidine (hydrochloride) | 50 mg | 1069.2 |
| CAC-10007106-500 | Cayman | 2-Aminomethylpyrimidine (hydrochloride) | 500 mg | 8395.2 |
| CAC-10007108-1 | Cayman | 2-Pyrimidin-2-yl-Propionic Acid | 1 g | 8553.6 |
| CAC-10007108-100 | Cayman | 2-Pyrimidin-2-yl-Propionic Acid | 100 mg | 1069.2 |
| CAC-10007108-500 | Cayman | 2-Pyrimidin-2-yl-Propionic Acid | 500 mg | 4732.2 |
| CAC-10007109-1 | Cayman | 3-Pyrimidin-2-yl-Propionic Acid | 1 g | 14968.8 |
| CAC-10007109-100 | Cayman | 3-Pyrimidin-2-yl-Propionic Acid | 100 mg | 2039.4 |
| CAC-10007109-50 | Cayman | 3-Pyrimidin-2-yl-Propionic Acid | 50 mg | 1069.2 |
| CAC-10007109-500 | Cayman | 3-Pyrimidin-2-yl-Propionic Acid | 500 mg | 8395.2 |
| CAC-10007110-1 | Cayman | 3-Pyrimidin-2-yl-2-pyrimidin-2-ylmethyl-Propionic Acid | 1 g | 8553.6 |
| CAC-10007110-100 | Cayman | 3-Pyrimidin-2-yl-2-pyrimidin-2-ylmethyl-Propionic Acid | 100 mg | 1069.2 |
| CAC-10007110-500 | Cayman | 3-Pyrimidin-2-yl-2-pyrimidin-2-ylmethyl-Propionic Acid | 500 mg | 4732.2 |
| CAC-10007111-1 | Cayman | Pyrimidin-4-yl-Methanol | 1 g | 14968.8 |
| CAC-10007111-100 | Cayman | Pyrimidin-4-yl-Methanol | 100 mg | 2039.4 |
| CAC-10007111-50 | Cayman | Pyrimidin-4-yl-Methanol | 50 mg | 1069.2 |
| CAC-10007111-500 | Cayman | Pyrimidin-4-yl-Methanol | 500 mg | 8395.2 |
| CAC-10007112-1 | Cayman | 2-(hydroxymethyl)-Pyrimidine | 1 g | 14968.8 |
| CAC-10007112-100 | Cayman | 2-(hydroxymethyl)-Pyrimidine | 100 mg | 2039.4 |
| CAC-10007112-50 | Cayman | 2-(hydroxymethyl)-Pyrimidine | 50 mg | 1069.2 |
| CAC-10007112-500 | Cayman | 2-(hydroxymethyl)-Pyrimidine | 500 mg | 8395.2 |
| CAC-10007113-1 | Cayman | Pyrimidine-4-Carboxylic Acid (sodium salt) | 1 g | 8553.6 |
| CAC-10007113-100 | Cayman | Pyrimidine-4-Carboxylic Acid (sodium salt) | 100 mg | 1069.2 |
| CAC-10007113-500 | Cayman | Pyrimidine-4-Carboxylic Acid (sodium salt) | 500 mg | 4732.2 |
| CAC-10007114-1 | Cayman | methyl 4-Pyrimidine Carboxylate | 1 g | 8553.6 |
| CAC-10007114-100 | Cayman | methyl 4-Pyrimidine Carboxylate | 100 mg | 1069.2 |
| CAC-10007114-500 | Cayman | methyl 4-Pyrimidine Carboxylate | 500 mg | 4732.2 |
| CAC-10007116-1 | Cayman | 2-Pyrimidine Acetic Acid | 1 g | 8553.6 |
| CAC-10007116-100 | Cayman | 2-Pyrimidine Acetic Acid | 100 mg | 1069.2 |
| CAC-10007116-500 | Cayman | 2-Pyrimidine Acetic Acid | 500 mg | 4732.2 |
| CAC-10007118-1 | Cayman | 2-methyl-3-Pyrimidin-2-yl-Propionic Acid | 1 g | 12751.2 |
| CAC-10007118-100 | Cayman | 2-methyl-3-Pyrimidin-2-yl-Propionic Acid | 100 mg | 1722.6 |
| CAC-10007118-50 | Cayman | 2-methyl-3-Pyrimidin-2-yl-Propionic Acid | 50 mg | 910.8 |
| CAC-10007118-500 | Cayman | 2-methyl-3-Pyrimidin-2-yl-Propionic Acid | 500 mg | 7128 |
| CAC-10007119-1 | Cayman | methyl 2-Pyrimidine Carboxylate | 1 g | 752.4 |
| CAC-10007119-500 | Cayman | methyl 2-Pyrimidine Carboxylate | 500 mg | 495 |
| CAC-10007120-1 | Cayman | 4-Pyrimidinecarboxaldehyde, dimethyl acetal | 1 g | 5860.8 |
| CAC-10007120-100 | Cayman | 4-Pyrimidinecarboxaldehyde, dimethyl acetal | 100 mg | 732.6 |
| CAC-10007120-5 | Cayman | 4-Pyrimidinecarboxaldehyde, dimethyl acetal | 5 g | 25641 |
| CAC-10007120-500 | Cayman | 4-Pyrimidinecarboxaldehyde, dimethyl acetal | 500 mg | 3207.6 |
| CAC-10007121-1 | Cayman | 2-cyano-Pyrimidine | 1 g | 215.6 |
| CAC-10007121-10 | Cayman | 2-cyano-Pyrimidine | 10 g | 1724.8 |
| CAC-10007121-5 | Cayman | 2-cyano-Pyrimidine | 5 g | 970.2 |
| CAC-10007121-500 | Cayman | 2-cyano-Pyrimidine | 500 mg | 107.8 |
| CAC-10007122-1 | Cayman | 2-(chloromethyl)-Pyrimidine (hydrochloride) | 1 g | 8870.4 |
| CAC-10007122-100 | Cayman | 2-(chloromethyl)-Pyrimidine (hydrochloride) | 100 mg | 1207.8 |
| CAC-10007122-50 | Cayman | 2-(chloromethyl)-Pyrimidine (hydrochloride) | 50 mg | 633.6 |
| CAC-10007122-500 | Cayman | 2-(chloromethyl)-Pyrimidine (hydrochloride) | 500 mg | 5068.8 |
| CAC-10007123-1 | Cayman | 2-carboxy-Pyrimidine | 1 g | 1108.8 |
| CAC-10007123-5 | Cayman | 2-carboxy-Pyrimidine | 5 g | 5207.4 |
| CAC-10007123-500 | Cayman | 2-carboxy-Pyrimidine | 500 mg | 693 |
| CAC-10007124-1 | Cayman | 4-Pyrimidine Methanamine (hydrochloride) | 1 g | 14968.8 |
| CAC-10007124-100 | Cayman | 4-Pyrimidine Methanamine (hydrochloride) | 100 mg | 2039.4 |
| CAC-10007124-50 | Cayman | 4-Pyrimidine Methanamine (hydrochloride) | 50 mg | 1069.2 |
| CAC-10007124-500 | Cayman | 4-Pyrimidine Methanamine (hydrochloride) | 500 mg | 8395.2 |
| CAC-10007125-100 | Cayman | 8-Isoquinoline methanamine (hydrochloride) | 100 mg | 4336.2 |
| CAC-10007125-50 | Cayman | 8-Isoquinoline methanamine (hydrochloride) | 50 mg | 2277 |
| CAC-10007125-500 | Cayman | 8-Isoquinoline methanamine (hydrochloride) | 500 mg | 18216 |
| CAC-10007126-1 | Cayman | CAY10494 | 1 g | 7286.4 |
| CAC-10007126-100 | Cayman | CAY10494 | 100 mg | 910.8 |
| CAC-10007126-500 | Cayman | CAY10494 | 500 mg | 4019.4 |
| CAC-10007127-10 | Cayman | 5-Chlororesorcinol dimethyl ether | 10 g | 376.2 |
| CAC-10007127-25 | Cayman | 5-Chlororesorcinol dimethyl ether | 25 g | 891 |
| CAC-10007127-5 | Cayman | 5-Chlororesorcinol dimethyl ether | 5 g | 198 |
| CAC-10007127-50 | Cayman | 5-Chlororesorcinol dimethyl ether | 50 g | 1584 |
| CAC-10007128-100 | Cayman | R-(-)-Mandelic Acid | 100 g | 3425.4 |
| CAC-10007128-25 | Cayman | R-(-)-Mandelic Acid | 25 g | 950.4 |
| CAC-10007128-250 | Cayman | R-(-)-Mandelic Acid | 250 g | 7603.2 |
| CAC-10007128-50 | Cayman | R-(-)-Mandelic Acid | 50 g | 1801.8 |
| CAC-10007129-1 | Cayman | tert-butyl p-(bromomethyl) Benzoate | 1 g | 1029.6 |
| CAC-10007129-5 | Cayman | tert-butyl p-(bromomethyl) Benzoate | 5 g | 4633.2 |
| CAC-10007130-1 | Cayman | tert-butyl p-Toluate | 1 g | 138.6 |
| CAC-10007130-10 | Cayman | tert-butyl p-Toluate | 10 g | 1108.8 |
| CAC-10007130-5 | Cayman | tert-butyl p-Toluate | 5 g | 633.6 |
| CAC-10007130-50 | Cayman | tert-butyl p-Toluate | 50 g | 4851 |
| CAC-10007131-1 | Cayman | 5,6,7,8-tetrahydro-2-Naphthoic Acid | 1 g | 3960 |
| CAC-10007131-5 | Cayman | 5,6,7,8-tetrahydro-2-Naphthoic Acid | 5 g | 16632 |
| CAC-10007131-500 | Cayman | 5,6,7,8-tetrahydro-2-Naphthoic Acid | 500 mg | 2079 |
| CAC-10007132-1 | Cayman | (R)-(-)-2-Phenylglycinol | 1 g | 178.2 |
| CAC-10007132-10 | Cayman | (R)-(-)-2-Phenylglycinol | 10 g | 1425.6 |
| CAC-10007132-25 | Cayman | (R)-(-)-2-Phenylglycinol | 25 g | 3128.4 |
| CAC-10007132-5 | Cayman | (R)-(-)-2-Phenylglycinol | 5 g | 811.8 |
| CAC-10007133-1 | Cayman | CMPF | 1 mg | 1001 |
| CAC-10007133-10 | Cayman | CMPF | 10 mg | 7330.4 |
| CAC-10007133-5 | Cayman | CMPF | 5 mg | 4188.8 |
| CAC-10007133-500 | Cayman | CMPF | 500 µg | 523.6 |
| CAC-10007134-100 | Cayman | 5-Bromotetralone | 100 mg | 376.2 |
| CAC-10007134-250 | Cayman | 5-Bromotetralone | 250 mg | 891 |
| CAC-10007134-50 | Cayman | 5-Bromotetralone | 50 mg | 198 |
| CAC-10007134-500 | Cayman | 5-Bromotetralone | 500 mg | 1584 |
| CAC-10007135-100 | Cayman | 7-Bromotetralone | 100 mg | 376.2 |
| CAC-10007135-250 | Cayman | 7-Bromotetralone | 250 mg | 891 |
| CAC-10007135-50 | Cayman | 7-Bromotetralone | 50 mg | 198 |
| CAC-10007135-500 | Cayman | 7-Bromotetralone | 500 mg | 1584 |
| CAC-10007136-100 | Cayman | 7-Piperazin-1-yl-thieno[2,3-c] Pyridine (hydrochloride) | 100 mg | 752.4 |
| CAC-10007136-250 | Cayman | 7-Piperazin-1-yl-thieno[2,3-c] Pyridine (hydrochloride) | 250 mg | 1782 |
| CAC-10007136-50 | Cayman | 7-Piperazin-1-yl-thieno[2,3-c] Pyridine (hydrochloride) | 50 mg | 396 |
| CAC-10007136-500 | Cayman | 7-Piperazin-1-yl-thieno[2,3-c] Pyridine (hydrochloride) | 500 mg | 3168 |
| CAC-10007138-1 | Cayman | 2-methyl-1,3-Cyclohexanedione | 1 g | 138.6 |
| CAC-10007138-10 | Cayman | 2-methyl-1,3-Cyclohexanedione | 10 g | 1108.8 |
| CAC-10007138-5 | Cayman | 2-methyl-1,3-Cyclohexanedione | 5 g | 633.6 |
| CAC-10007138-50 | Cayman | 2-methyl-1,3-Cyclohexanedione | 50 g | 4851 |
| CAC-10007142-1 | Cayman | S-Nitrosylation Blocking Reagent | 1 ea | 385 |
| CAC-10007143-100 | Cayman | Vitellogenin (alligator) Monoclonal Antibody (ND-1E8) | 100 µL | 5128.2 |
| CAC-10007143-500 | Cayman | Vitellogenin (alligator) Monoclonal Antibody (ND-1E8) | 500 µL | 23086.8 |
| CAC-10007145-1 | Cayman | (R)-benzyl Mandelate | 1 g | 138.6 |
| CAC-10007145-10 | Cayman | (R)-benzyl Mandelate | 10 g | 1108.8 |
| CAC-10007145-5 | Cayman | (R)-benzyl Mandelate | 5 g | 633.6 |
| CAC-10007145-50 | Cayman | (R)-benzyl Mandelate | 50 g | 4851 |
| CAC-10007146-1 | Cayman | 8-piperazin-1-yl-Isoquinoline (hydrochloride) | 1 g | 23284.8 |
| CAC-10007146-100 | Cayman | 8-piperazin-1-yl-Isoquinoline (hydrochloride) | 100 mg | 3168 |
| CAC-10007146-50 | Cayman | 8-piperazin-1-yl-Isoquinoline (hydrochloride) | 50 mg | 1663.2 |
| CAC-10007146-500 | Cayman | 8-piperazin-1-yl-Isoquinoline (hydrochloride) | 500 mg | 12988.8 |
| CAC-10007147-1 | Cayman | 7-piperazin-1-yl-Isoquinoline (hydrochloride) | 1 g | 23839.2 |
| CAC-10007147-100 | Cayman | 7-piperazin-1-yl-Isoquinoline (hydrochloride) | 100 mg | 3227.4 |
| CAC-10007147-50 | Cayman | 7-piperazin-1-yl-Isoquinoline (hydrochloride) | 50 mg | 1702.8 |
| CAC-10007147-500 | Cayman | 7-piperazin-1-yl-Isoquinoline (hydrochloride) | 500 mg | 13622.4 |
| CAC-10007148-1 | Cayman | 6-piperazin-1-yl-Isoquinoline (hydrochloride) | 1 g | 23284.8 |
| CAC-10007148-100 | Cayman | 6-piperazin-1-yl-Isoquinoline (hydrochloride) | 100 mg | 3168 |
| CAC-10007148-50 | Cayman | 6-piperazin-1-yl-Isoquinoline (hydrochloride) | 50 mg | 1663.2 |
| CAC-10007148-500 | Cayman | 6-piperazin-1-yl-Isoquinoline (hydrochloride) | 500 mg | 12988.8 |
| CAC-10007164-100 | Cayman | Leukotriene C4 methyl ester | 100 µg | 7145 |
| CAC-10007164-25 | Cayman | Leukotriene C4 methyl ester | 25 µg | 2417.2 |
| CAC-10007164-50 | Cayman | Leukotriene C4 methyl ester | 50 µg | 4049.6 |
| CAC-10007165-100 | Cayman | Leukotriene D4 methyl ester | 100 µg | 7145 |
| CAC-10007165-25 | Cayman | Leukotriene D4 methyl ester | 25 µg | 2417.2 |
| CAC-10007165-50 | Cayman | Leukotriene D4 methyl ester | 50 µg | 4049.6 |
| CAC-10007166-100 | Cayman | Leukotriene E4 methyl ester | 100 µg | 4973.6 |
| CAC-10007166-25 | Cayman | Leukotriene E4 methyl ester | 25 µg | 1816.6 |
| CAC-10007166-50 | Cayman | Leukotriene E4 methyl ester | 50 µg | 2910 |
| CAC-10007171-10 | Cayman | Cetaben | 10 mg | 816.2 |
| CAC-10007171-100 | Cayman | Cetaben | 100 mg | 6036.8 |
| CAC-10007171-5 | Cayman | Cetaben | 5 mg | 431.2 |
| CAC-10007171-50 | Cayman | Cetaben | 50 mg | 3449.6 |
| CAC-10007185-500 | Cayman | PCSK9 (human) Polyclonal Antibody | 500 μl | 3988.6 |
| CAC-10007186-1 | Cayman | PCSK9 (human) Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007187-100 | Cayman | Microcystin-LA | 100 µg | 3696 |
| CAC-10007187-25 | Cayman | Microcystin-LA | 25 µg | 2310 |
| CAC-10007187-500 | Cayman | Microcystin-LA | 500 µg | 16170 |
| CAC-10007188-1 | Cayman | Microcystin-LR | 1 mg | 5005 |
| CAC-10007188-100 | Cayman | Microcystin-LR | 100 µg | 693 |
| CAC-10007188-50 | Cayman | Microcystin-LR | 50 µg | 385 |
| CAC-10007188-500 | Cayman | Microcystin-LR | 500 µg | 2895.2 |
| CAC-10007190-100 | Cayman | Nodularin | 100 µg | 1216.6 |
| CAC-10007191-1 | Cayman | PH Domain Leucine-rich Repeat Protein Phosphatase 1 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10007192-1 | Cayman | PH Domain Leucine-rich Repeat Protein Phosphatase Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007193-1 | Cayman | Lysophospholipase D Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007205-1 | Cayman | FFAR1 (GPR40) Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10007206-1 | Cayman | GPR40 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007207-100 | Cayman | tetranor-12(S)-HETE | 100 µg | 5651.8 |
| CAC-10007207-25 | Cayman | tetranor-12(S)-HETE | 25 µg | 1570.8 |
| CAC-10007207-50 | Cayman | tetranor-12(S)-HETE | 50 µg | 2987.6 |
| CAC-10007279-10 | Cayman | Resolvin D2 | 10 µg | 2525 |
| CAC-10007279-100 | Cayman | Resolvin D2 | 100 µg | 15815.2 |
| CAC-10007279-25 | Cayman | Resolvin D2 | 25 µg | 5173.8 |
| CAC-10007279-50 | Cayman | Resolvin D2 | 50 µg | 9270.2 |
| CAC-10007280-10 | Cayman | Resolvin D5 | 10 µg | 2525 |
| CAC-10007280-100 | Cayman | Resolvin D5 | 100 µg | 15815.2 |
| CAC-10007280-25 | Cayman | Resolvin D5 | 25 µg | 5173.8 |
| CAC-10007280-50 | Cayman | Resolvin D5 | 50 µg | 9270.2 |
| CAC-10007286-1 | Cayman | N-Lignoceroyl Taurine | 1 mg | 985.6 |
| CAC-10007286-10 | Cayman | N-Lignoceroyl Taurine | 10 mg | 7884.8 |
| CAC-10007286-5 | Cayman | N-Lignoceroyl Taurine | 5 mg | 4435.2 |
| CAC-10007287-1 | Cayman | N-Nervonoyl Taurine | 1 mg | 1031.8 |
| CAC-10007287-10 | Cayman | N-Nervonoyl Taurine | 10 mg | 8254.4 |
| CAC-10007287-5 | Cayman | N-Nervonoyl Taurine | 5 mg | 4650.8 |
| CAC-10007288-1 | Cayman | N-Docosanoyl Taurine | 1 mg | 1031.8 |
| CAC-10007288-10 | Cayman | N-Docosanoyl Taurine | 10 mg | 8254.4 |
| CAC-10007288-5 | Cayman | N-Docosanoyl Taurine | 5 mg | 4650.8 |
| CAC-10007289-1 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid | 1 mg | 985 |
| CAC-10007289-10 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid | 10 mg | 3295 |
| CAC-10007289-5 | Cayman | cis-4,10,13,16-Docosatetraenoic Acid | 5 mg | 2047.6 |
| CAC-10007290-10 | Cayman | cis-7-Hexadecenoic Acid | 10 mg | 1108.8 |
| CAC-10007290-100 | Cayman | cis-7-Hexadecenoic Acid | 100 mg | 8192.8 |
| CAC-10007290-5 | Cayman | cis-7-Hexadecenoic Acid | 5 mg | 585.2 |
| CAC-10007290-50 | Cayman | cis-7-Hexadecenoic Acid | 50 mg | 4681.6 |
| CAC-10007293-10 | Cayman | Arachidonoyl-N,N-dimethyl amide | 10 mg | 970.2 |
| CAC-10007293-100 | Cayman | Arachidonoyl-N,N-dimethyl amide | 100 mg | 7114.8 |
| CAC-10007293-5 | Cayman | Arachidonoyl-N,N-dimethyl amide | 5 mg | 508.2 |
| CAC-10007293-50 | Cayman | Arachidonoyl-N,N-dimethyl amide | 50 mg | 4065.6 |
| CAC-10007294-10 | Cayman | Arachidonoyl-N-methyl amide | 10 mg | 970.2 |
| CAC-10007294-100 | Cayman | Arachidonoyl-N-methyl amide | 100 mg | 7114.8 |
| CAC-10007294-5 | Cayman | Arachidonoyl-N-methyl amide | 5 mg | 508.2 |
| CAC-10007294-50 | Cayman | Arachidonoyl-N-methyl amide | 50 mg | 4065.6 |
| CAC-10007295-10 | Cayman | Arachidonoyl amide | 10 mg | 970.2 |
| CAC-10007295-25 | Cayman | Arachidonoyl amide | 25 mg | 2294.6 |
| CAC-10007295-5 | Cayman | Arachidonoyl amide | 5 mg | 508.2 |
| CAC-10007295-50 | Cayman | Arachidonoyl amide | 50 mg | 4065.6 |
| CAC-10007311-100 | Cayman | Salinosporamide A | 100 µg | 2849 |
| CAC-10007349-1 | Cayman | TGX-221 | 1 mg | 539 |
| CAC-10007349-10 | Cayman | TGX-221 | 10 mg | 1925 |
| CAC-10007349-5 | Cayman | TGX-221 | 5 mg | 1155 |
| CAC-10007349-500 | Cayman | TGX-221 | 500 µg | 385 |
| CAC-10007358-1 | Cayman | Palmitic Acid methyl ester | 1 g | 154 |
| CAC-10007358-10 | Cayman | Palmitic Acid methyl ester | 10 g | 1078 |
| CAC-10007358-25 | Cayman | Palmitic Acid methyl ester | 25 g | 2510.2 |
| CAC-10007358-5 | Cayman | Palmitic Acid methyl ester | 5 g | 585.2 |
| CAC-10007412-10 | Cayman | Combrestatin A4 | 10 mg | 1463 |
| CAC-10007412-25 | Cayman | Combrestatin A4 | 25 mg | 3465 |
| CAC-10007412-5 | Cayman | Combrestatin A4 | 5 mg | 770 |
| CAC-10007412-50 | Cayman | Combrestatin A4 | 50 mg | 6160 |
| CAC-10007415-1 | Cayman | Combrestatin A4 3'-O-Phosphate (sodium salt) | 1 mg | 446.6 |
| CAC-10007415-10 | Cayman | Combrestatin A4 3'-O-Phosphate (sodium salt) | 10 mg | 1786.4 |
| CAC-10007415-25 | Cayman | Combrestatin A4 3'-O-Phosphate (sodium salt) | 25 mg | 3911.6 |
| CAC-10007415-5 | Cayman | Combrestatin A4 3'-O-Phosphate (sodium salt) | 5 mg | 1001 |
| CAC-10007417-10 | Cayman | 10-Thiastearic Acid | 10 mg | 970.2 |
| CAC-10007417-100 | Cayman | 10-Thiastearic Acid | 100 mg | 7114.8 |
| CAC-10007417-5 | Cayman | 10-Thiastearic Acid | 5 mg | 508.2 |
| CAC-10007417-50 | Cayman | 10-Thiastearic Acid | 50 mg | 4065.6 |
| CAC-10007428-1 | Cayman | N-Arachidonoyl-L-Serine-d8 | 1 mg | 4681.6 |
| CAC-10007428-100 | Cayman | N-Arachidonoyl-L-Serine-d8 | 100 µg | 585.2 |
| CAC-10007428-500 | Cayman | N-Arachidonoyl-L-Serine-d8 | 500 µg | 2633.4 |
| CAC-10007431-1 | Cayman | N-Arachidonoyl Dopamine-d8 | 1 mg | 5544 |
| CAC-10007431-100 | Cayman | N-Arachidonoyl Dopamine-d8 | 100 µg | 693 |
| CAC-10007431-500 | Cayman | N-Arachidonoyl Dopamine-d8 | 500 µg | 3126.2 |
| CAC-10007432-100 | Cayman | FABP3 (human recombinant) | 100 µg | 4989 |
| CAC-10007433-100 | Cayman | FABP5 (mouse recombinant) | 100 µg | 6067 |
| CAC-10007441-1 | Cayman | Transcription Factor PPARα Positive Control | 1 ea | 1601 |
| CAC-10007442-1 | Cayman | Transcription Factor PPARα Primary Antibody | 1 ea | 1201.2 |
| CAC-10007443-1 | Cayman | Transcription Factor PPARδ Positive Control | 1 ea | 1601 |
| CAC-10007444-1 | Cayman | Transcription Factor PPARδ Primary Antibody | 1 ea | 1201.2 |
| CAC-10007448-1 | Cayman | Triacsin C | 1 mg | 6144.6 |
| CAC-10007448-500 | Cayman | Triacsin C | 500 µg | 3234 |
| CAC-10007451-25 | Cayman | PPARδ (human recombinant) | 25 µg | 6221 |
| CAC-10007451-50 | Cayman | PPARδ (human recombinant) | 50 µg | 11272.2 |
| CAC-10007452-10 | Cayman | Vinclozolin M2 | 10 mg | 1108.8 |
| CAC-10007452-25 | Cayman | Vinclozolin M2 | 25 mg | 2633.4 |
| CAC-10007452-5 | Cayman | Vinclozolin M2 | 5 mg | 585.2 |
| CAC-10007452-50 | Cayman | Vinclozolin M2 | 50 mg | 4681.6 |
| CAC-10007457-10 | Cayman | URB602 | 10 mg | 816.2 |
| CAC-10007457-100 | Cayman | URB602 | 100 mg | 6036.8 |
| CAC-10007457-5 | Cayman | URB602 | 5 mg | 431.2 |
| CAC-10007457-50 | Cayman | URB602 | 50 mg | 3449.6 |
| CAC-10007461-1 | Cayman | L-Glutathione, reduced | 1 g | 215.6 |
| CAC-10007461-10 | Cayman | L-Glutathione, reduced | 10 g | 1724.8 |
| CAC-10007461-25 | Cayman | L-Glutathione, reduced | 25 g | 3773 |
| CAC-10007461-5 | Cayman | L-Glutathione, reduced | 5 g | 970.2 |
| CAC-10007464-10 | Cayman | 10-methyl-9-(phenoxycarbonyl) Acridinium fluorosulfonate | 10 mg | 1031.8 |
| CAC-10007464-100 | Cayman | 10-methyl-9-(phenoxycarbonyl) Acridinium fluorosulfonate | 100 mg | 7222.6 |
| CAC-10007464-5 | Cayman | 10-methyl-9-(phenoxycarbonyl) Acridinium fluorosulfonate | 5 mg | 539 |
| CAC-10007464-50 | Cayman | 10-methyl-9-(phenoxycarbonyl) Acridinium fluorosulfonate | 50 mg | 4265.8 |
| CAC-10007466-1 | Cayman | Arachidonic Acid-biotin | 1 mg | 5544 |
| CAC-10007466-100 | Cayman | Arachidonic Acid-biotin | 100 µg | 693 |
| CAC-10007466-500 | Cayman | Arachidonic Acid-biotin | 500 µg | 3126.2 |
| CAC-10007472-1 | Cayman | Transcription Factor Reagent A | 1 ea | 1201.2 |
| CAC-10007475-1 | Cayman | PEPCK Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007517-10 | Cayman | N-Arachidonyl Maleimide | 10 mg | 1262.8 |
| CAC-10007517-100 | Cayman | N-Arachidonyl Maleimide | 100 mg | 9270.8 |
| CAC-10007517-5 | Cayman | N-Arachidonyl Maleimide | 5 mg | 662.2 |
| CAC-10007517-50 | Cayman | N-Arachidonyl Maleimide | 50 mg | 5297.6 |
| CAC-10007518-1 | Cayman | Capsazepine | 1 mg | 385 |
| CAC-10007518-10 | Cayman | Capsazepine | 10 mg | 1478.4 |
| CAC-10007518-5 | Cayman | Capsazepine | 5 mg | 1047.2 |
| CAC-10007518-50 | Cayman | Capsazepine | 50 mg | 6006 |
| CAC-10007527-100 | Cayman | (±)14(15)-EpEDE | 100 µg | 2109.8 |
| CAC-10007527-25 | Cayman | (±)14(15)-EpEDE | 25 µg | 585.2 |
| CAC-10007527-50 | Cayman | (±)14(15)-EpEDE | 50 µg | 1108.8 |
| CAC-10007527-500 | Cayman | (±)14(15)-EpEDE | 500 µg | 9363.2 |
| CAC-10007528-100 | Cayman | (±)14(15)-EpEDE methyl ester | 100 µg | 2109.8 |
| CAC-10007528-25 | Cayman | (±)14(15)-EpEDE methyl ester | 25 µg | 585.2 |
| CAC-10007528-50 | Cayman | (±)14(15)-EpEDE methyl ester | 50 µg | 1108.8 |
| CAC-10007528-500 | Cayman | (±)14(15)-EpEDE methyl ester | 500 µg | 9363.2 |
| CAC-10007531-1 | Cayman | Arachidonoyl Glycine-d8 | 1 mg | 3326.4 |
| CAC-10007531-100 | Cayman | Arachidonoyl Glycine-d8 | 100 µg | 415.8 |
| CAC-10007531-5 | Cayman | Arachidonoyl Glycine-d8 | 5 mg | 14553 |
| CAC-10007531-500 | Cayman | Arachidonoyl Glycine-d8 | 500 µg | 1878.8 |
| CAC-10007534-10 | Cayman | Docosahexaenoyl Ethanolamide | 10 mg | 970.2 |
| CAC-10007534-25 | Cayman | Docosahexaenoyl Ethanolamide | 25 mg | 2294.6 |
| CAC-10007534-5 | Cayman | Docosahexaenoyl Ethanolamide | 5 mg | 508.2 |
| CAC-10007534-50 | Cayman | Docosahexaenoyl Ethanolamide | 50 mg | 4065.6 |
| CAC-10007542-1 | Cayman | KAPA (hydrochloride) | 1 mg | 169.4 |
| CAC-10007542-10 | Cayman | KAPA (hydrochloride) | 10 mg | 1355.2 |
| CAC-10007542-5 | Cayman | KAPA (hydrochloride) | 5 mg | 770 |
| CAC-10007542-50 | Cayman | KAPA (hydrochloride) | 50 mg | 5929 |
| CAC-10007565-100 | Cayman | Tetradecyl Phosphonate | 100 mg | 231 |
| CAC-10007565-1 | Cayman | Tetradecyl Phosphonate | 1 g | 908.6 |
| CAC-10007565-500 | Cayman | Tetradecyl Phosphonate | 500 mg | 539 |
| CAC-10007599-100 | Cayman | Prorenin (human recombinant) | 100 µg | 3911 |
| CAC-10007601-1 | Cayman | 5α-hydroxy-6-keto Cholesterol | 1 mg | 385 |
| CAC-10007601-10 | Cayman | 5α-hydroxy-6-keto Cholesterol | 10 mg | 3465 |
| CAC-10007601-5 | Cayman | 5α-hydroxy-6-keto Cholesterol | 5 mg | 1832.6 |
| CAC-10007602-10 | Cayman | Δ2-cis Eicosenoic Acid | 10 mg | 1262.8 |
| CAC-10007602-100 | Cayman | Δ2-cis Eicosenoic Acid | 100 mg | 9270.8 |
| CAC-10007602-5 | Cayman | Δ2-cis Eicosenoic Acid | 5 mg | 662.2 |
| CAC-10007602-50 | Cayman | Δ2-cis Eicosenoic Acid | 50 mg | 5297.6 |
| CAC-10007608-96 | Cayman | Leptin Receptor (human) EIA Kit | 96 wells | 11226.6 |
| CAC-10007609-96 | Cayman | Leptin (mouse/rat) EIA Kit | 96 wells | 8731.8 |
| CAC-10007610-96 | Cayman | Resistin (human) EIA Kit | 96 wells | 9741.6 |
| CAC-10007612-96 | Cayman | Resistin (rat) EIA Kit | 96 wells | 13959 |
| CAC-10007614-96 | Cayman | FABP4 (human) EIA Kit | 96 wells | 15483.6 |
| CAC-10007619-96 | Cayman | Adiponectin (human) EIA Kit (HS) | 96 wells | 11226.6 |
| CAC-10007620-96 | Cayman | Adiponectin (mouse) EIA Kit | 96 wells | 9741.6 |
| CAC-10007621-96 | Cayman | GFAP (human) EIA Kit | 96 wells | 15483.6 |
| CAC-10007622-10 | Cayman | Δ2-trans Eicosenoic Acid | 10 mg | 1262.8 |
| CAC-10007622-100 | Cayman | Δ2-trans Eicosenoic Acid | 100 mg | 9270.8 |
| CAC-10007622-5 | Cayman | Δ2-trans Eicosenoic Acid | 5 mg | 662.2 |
| CAC-10007622-50 | Cayman | Δ2-trans Eicosenoic Acid | 50 mg | 5297.6 |
| CAC-10007640-96 | Cayman | Cholesterol Fluorometric Assay Kit | 96 wells | 2279.2 |
| CAC-10007640-480 | Cayman | Cholesterol Fluorometric Assay Kit | 480 wells | 6468 |
| CAC-10007652-1 | Cayman | 8-iso Prostaglandin F2α Quant-PAK | 1 ea | 10333.4 |
| CAC-10007653-1 | Cayman | (S)-H-1152 (hydrochloride) | 1 mg | 816.2 |
| CAC-10007653-10 | Cayman | (S)-H-1152 (hydrochloride) | 10 mg | 6036.8 |
| CAC-10007653-5 | Cayman | (S)-H-1152 (hydrochloride) | 5 mg | 3449.6 |
| CAC-10007653-500 | Cayman | (S)-H-1152 (hydrochloride) | 500 µg | 431.2 |
| CAC-10007657-1 | Cayman | 4-hydroxy Hexenal-d3 | 1 mg | 9655.2 |
| CAC-10007657-100 | Cayman | 4-hydroxy Hexenal-d3 | 100 µg | 1832 |
| CAC-10007657-50 | Cayman | 4-hydroxy Hexenal-d3 | 50 µg | 1246.8 |
| CAC-10007657-500 | Cayman | 4-hydroxy Hexenal-d3 | 500 µg | 5774.4 |
| CAC-10007660-1 | Cayman | GPR35 Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10007661-1 | Cayman | GPR35 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007662-10 | Cayman | L-Biopterin | 10 mg | 908.6 |
| CAC-10007662-25 | Cayman | L-Biopterin | 25 mg | 2156 |
| CAC-10007662-5 | Cayman | L-Biopterin | 5 mg | 477.4 |
| CAC-10007662-50 | Cayman | L-Biopterin | 50 mg | 3819.2 |
| CAC-10007663-1 | Cayman | SREBP-2 Polyclonal Antibody | 1 ea | 4296.6 |
| CAC-10007665-1 | Cayman | LDL Receptor Polyclonal Antibody | 1 ea | 3988.6 |
| CAC-10007672-1 | Cayman | LDL Receptor Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007680-96 | Cayman | Semi-Quantitative Biomarker ELISA Component Kit (anti-mouse) | 96 wells | 2574 |
| CAC-10007680-480 | Cayman | Semi-Quantitative Biomarker ELISA Component Kit (anti-mouse) | 480 wells | 9662.4 |
| CAC-10007681-500 | Cayman | Serum Retinol Binding Protein 4 Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10007682-1 | Cayman | Serum Retinol Binding Protein 4 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10007684-96 | Cayman | Prostaglandin D Synthase (lipocalin-type; human) ELISA Kit | 96 wells | 5621 |
| CAC-10007685-384 | Cayman | PPARγ Ligand Screening Assay Kit | 384 wells | 9455 |
| CAC-10007686-1 | Cayman | Acetyl Podocarpic Acid Anhydride | 1 mg | 277.2 |
| CAC-10007686-10 | Cayman | Acetyl Podocarpic Acid Anhydride | 10 mg | 2217.6 |
| CAC-10007686-5 | Cayman | Acetyl Podocarpic Acid Anhydride | 5 mg | 1247.4 |
| CAC-10007686-50 | Cayman | Acetyl Podocarpic Acid Anhydride | 50 mg | 9702 |
| CAC-10007691-10 | Cayman | URB754 | 10 mg | 816.2 |
| CAC-10007691-100 | Cayman | URB754 | 100 mg | 6036.8 |
| CAC-10007691-5 | Cayman | URB754 | 5 mg | 431.2 |
| CAC-10007691-50 | Cayman | URB754 | 50 mg | 3449.6 |
| CAC-10007692-1 | Cayman | Licofelone | 1 mg | 662.2 |
| CAC-10007692-10 | Cayman | Licofelone | 10 mg | 3649.8 |
| CAC-10007692-5 | Cayman | Licofelone | 5 mg | 1986.6 |
| CAC-10007692-50 | Cayman | Licofelone | 50 mg | 16555 |
| CAC-10007697-10 | Cayman | N-Palmitoyl Dopamine | 10 mg | 1108.8 |
| CAC-10007697-100 | Cayman | N-Palmitoyl Dopamine | 100 mg | 8192.8 |
| CAC-10007697-5 | Cayman | N-Palmitoyl Dopamine | 5 mg | 585.2 |
| CAC-10007697-50 | Cayman | N-Palmitoyl Dopamine | 50 mg | 4681.6 |
| CAC-10007704-10 | Cayman | N-(3-hydroxyphenyl)-Arachidonoyl amide | 10 mg | 908.6 |
| CAC-10007704-100 | Cayman | N-(3-hydroxyphenyl)-Arachidonoyl amide | 100 mg | 6683.6 |
| CAC-10007704-5 | Cayman | N-(3-hydroxyphenyl)-Arachidonoyl amide | 5 mg | 477.4 |
| CAC-10007704-50 | Cayman | N-(3-hydroxyphenyl)-Arachidonoyl amide | 50 mg | 3819.2 |
| CAC-10007705-1 | Cayman | α-CEHC | 1 mg | 323.4 |
| CAC-10007705-10 | Cayman | α-CEHC | 10 mg | 2587.2 |
| CAC-10007705-25 | Cayman | α-CEHC | 25 mg | 5667.2 |
| CAC-10007705-5 | Cayman | α-CEHC | 5 mg | 1463 |
| CAC-10007706-1 | Cayman | δ-CEHC | 1 mg | 446.6 |
| CAC-10007706-10 | Cayman | δ-CEHC | 10 mg | 3572.8 |
| CAC-10007706-25 | Cayman | δ-CEHC | 25 mg | 7823.2 |
| CAC-10007706-5 | Cayman | δ-CEHC | 5 mg | 2017.4 |
| CAC-10007707-1 | Cayman | AS-605240 | 1 mg | 385 |
| CAC-10007707-10 | Cayman | AS-605240 | 10 mg | 1355.2 |
| CAC-10007707-25 | Cayman | AS-605240 | 25 mg | 2987.6 |
| CAC-10007707-5 | Cayman | AS-605240 | 5 mg | 770 |
| CAC-10007710-1 | Cayman | PtdIns-(1,2-dipalmitoyl) (ammonium salt) | 1 mg | 6160 |
| CAC-10007710-100 | Cayman | PtdIns-(1,2-dipalmitoyl) (ammonium salt) | 100 µg | 770 |
| CAC-10007710-500 | Cayman | PtdIns-(1,2-dipalmitoyl) (ammonium salt) | 500 µg | 3465 |
| CAC-10007711-1 | Cayman | PtdIns-(4)-P1 (1,2-dioctanoyl) (ammonium salt) | 1 mg | 6160 |
| CAC-10007711-100 | Cayman | PtdIns-(4)-P1 (1,2-dioctanoyl) (ammonium salt) | 100 µg | 770 |
| CAC-10007711-500 | Cayman | PtdIns-(4)-P1 (1,2-dioctanoyl) (ammonium salt) | 500 µg | 3465 |
| CAC-10007712-1 | Cayman | L-902,688 | 1 mg | 2402.4 |
| CAC-10007712-10 | Cayman | L-902,688 | 10 mg | 17679.2 |
| CAC-10007712-5 | Cayman | L-902,688 | 5 mg | 10102.4 |
| CAC-10007712-500 | Cayman | L-902,688 | 500 µg | 1262.8 |
| CAC-10007713-1 | Cayman | HMB-Val-Ser-Leu-VE | 1 mg | 877.8 |
| CAC-10007713-10 | Cayman | HMB-Val-Ser-Leu-VE | 10 mg | 7022.4 |
| CAC-10007713-25 | Cayman | HMB-Val-Ser-Leu-VE | 25 mg | 15369.2 |
| CAC-10007713-5 | Cayman | HMB-Val-Ser-Leu-VE | 5 mg | 3957.8 |
| CAC-10007737-10 | Cayman | Lipoxin A4-d5 | 10 µg | 3017.8 |
| CAC-10007737-100 | Cayman | Lipoxin A4-d5 | 100 µg | 19942.4 |
| CAC-10007737-25 | Cayman | Lipoxin A4-d5 | 25 µg | 6344.2 |
| CAC-10007737-50 | Cayman | Lipoxin A4-d5 | 50 µg | 11487.8 |
| CAC-10007739-10 | Cayman | N-Cyclohexanecarbonylpentadecylamine | 10 mg | 785.4 |
| CAC-10007739-100 | Cayman | N-Cyclohexanecarbonylpentadecylamine | 100 mg | 5821.2 |
| CAC-10007739-5 | Cayman | N-Cyclohexanecarbonylpentadecylamine | 5 mg | 415.8 |
| CAC-10007739-50 | Cayman | N-Cyclohexanecarbonylpentadecylamine | 50 mg | 3326.4 |
| CAC-10007757-1 | Cayman | PtdIns-(4)-P1 (1,2-dihexanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10007757-100 | Cayman | PtdIns-(4)-P1 (1,2-dihexanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10007757-500 | Cayman | PtdIns-(4)-P1 (1,2-dihexanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10007758-1 | Cayman | PtdIns-(5)-P1 (1,2-dioctanoyl) (ammonium salt) | 1 mg | 6160 |
| CAC-10007758-100 | Cayman | PtdIns-(5)-P1 (1,2-dioctanoyl) (ammonium salt) | 100 µg | 770 |
| CAC-10007758-500 | Cayman | PtdIns-(5)-P1 (1,2-dioctanoyl) (ammonium salt) | 500 µg | 3465 |
| CAC-10007759-1 | Cayman | PtdIns-(3,4)-P2 (1,2-dihexanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10007759-100 | Cayman | PtdIns-(3,4)-P2 (1,2-dihexanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10007759-500 | Cayman | PtdIns-(3,4)-P2 (1,2-dihexanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10007762-1 | Cayman | PtdIns-(4,5)-P2 (1,2-dihexanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10007762-100 | Cayman | PtdIns-(4,5)-P2 (1,2-dihexanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10007762-500 | Cayman | PtdIns-(4,5)-P2 (1,2-dihexanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10007763-1 | Cayman | PtdIns-(3,5)-P2 (1,2-dioctanoyl) (sodium salt) | 1 mg | 4928 |
| CAC-10007763-100 | Cayman | PtdIns-(3,5)-P2 (1,2-dioctanoyl) (sodium salt) | 100 µg | 616 |
| CAC-10007763-500 | Cayman | PtdIns-(3,5)-P2 (1,2-dioctanoyl) (sodium salt) | 500 µg | 2772 |
| CAC-10007764-1 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dioctanoyl) (sodium salt) | 1 mg | 5790.4 |
| CAC-10007764-100 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dioctanoyl) (sodium salt) | 100 µg | 723.8 |
| CAC-10007764-500 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dioctanoyl) (sodium salt) | 500 µg | 3264.8 |
| CAC-10007766-100 | Cayman | 19(S)-HETE | 100 µg | 6652.8 |
| CAC-10007766-25 | Cayman | 19(S)-HETE | 25 µg | 1848 |
| CAC-10007766-50 | Cayman | 19(S)-HETE | 50 µg | 3511.2 |
| CAC-10007767-100 | Cayman | 19(R)-HETE | 100 µg | 6652.8 |
| CAC-10007767-25 | Cayman | 19(R)-HETE | 25 µg | 1848 |
| CAC-10007767-50 | Cayman | 19(R)-HETE | 50 µg | 3511.2 |
| CAC-10007777-1 | Cayman | D-myo-Inositol-1-phosphate (sodium salt) | 1 mg | 877.8 |
| CAC-10007777-10 | Cayman | D-myo-Inositol-1-phosphate (sodium salt) | 10 mg | 6468 |
| CAC-10007777-5 | Cayman | D-myo-Inositol-1-phosphate (sodium salt) | 5 mg | 3696 |
| CAC-10007777-500 | Cayman | D-myo-Inositol-1-phosphate (sodium salt) | 500 µg | 462 |
| CAC-10007778-1 | Cayman | D-myo-Inositol-3-phosphate (sodium salt) | 1 mg | 2510.2 |
| CAC-10007778-100 | Cayman | D-myo-Inositol-3-phosphate (sodium salt) | 100 µg | 385 |
| CAC-10007778-5 | Cayman | D-myo-Inositol-3-phosphate (sodium salt) | 5 mg | 7700 |
| CAC-10007778-500 | Cayman | D-myo-Inositol-3-phosphate (sodium salt) | 500 µg | 1355.2 |
| CAC-10007779-1 | Cayman | D-myo-Inositol-2,4,5-triphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10007779-100 | Cayman | D-myo-Inositol-2,4,5-triphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10007779-500 | Cayman | D-myo-Inositol-2,4,5-triphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10007780-1 | Cayman | D-myo-Inositol-1,2,6-triphosphate (sodium salt) | 1 mg | 5544 |
| CAC-10007780-100 | Cayman | D-myo-Inositol-1,2,6-triphosphate (sodium salt) | 100 µg | 693 |
| CAC-10007780-500 | Cayman | D-myo-Inositol-1,2,6-triphosphate (sodium salt) | 500 µg | 3126.2 |
| CAC-10007781-1 | Cayman | D-myo-Inositol-1,3,5-triphosphate (sodium salt) | 1 mg | 4312 |
| CAC-10007781-100 | Cayman | D-myo-Inositol-1,3,5-triphosphate (sodium salt) | 100 µg | 539 |
| CAC-10007781-500 | Cayman | D-myo-Inositol-1,3,5-triphosphate (sodium salt) | 500 µg | 2433.2 |
| CAC-10007782-1 | Cayman | D-myo-Inositol-3,4,5,6-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10007782-100 | Cayman | D-myo-Inositol-3,4,5,6-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10007782-500 | Cayman | D-myo-Inositol-3,4,5,6-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10007783-1 | Cayman | D-myo-Inositol-1,4,5,6-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10007783-100 | Cayman | D-myo-Inositol-1,4,5,6-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10007783-500 | Cayman | D-myo-Inositol-1,4,5,6-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10007784-1 | Cayman | D-myo-Inositol-1,3,4,5,6-pentaphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10007784-100 | Cayman | D-myo-Inositol-1,3,4,5,6-pentaphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10007784-500 | Cayman | D-myo-Inositol-1,3,4,5,6-pentaphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10007793-100 | Cayman | 13,14-dihydro-15-keto Prostaglandin F2α-d4 | 100 µg | 1817.2 |
| CAC-10007793-50 | Cayman | 13,14-dihydro-15-keto Prostaglandin F2α-d4 | 50 µg | 954.8 |
| CAC-10007793-500 | Cayman | 13,14-dihydro-15-keto Prostaglandin F2α-d4 | 500 µg | 7638.4 |
| CAC-10007805-1 | Cayman | Dihydroeponemycin | 1 mg | 3465 |
| CAC-10007805-5 | Cayman | Dihydroeponemycin | 5 mg | 14722.4 |
| CAC-10007806-100 | Cayman | Epoxomicin | 100 µg | 2772 |
| CAC-10007806-25 | Cayman | Epoxomicin | 25 µg | 770 |
| CAC-10007806-250 | Cayman | Epoxomicin | 250 µg | 6160 |
| CAC-10007806-50 | Cayman | Epoxomicin | 50 µg | 1463 |
| CAC-10007812-50 | Cayman | Monoacylglycerol Lipase (human recombinant) | 50 µg | 5451 |
| CAC-10007815-100 | Cayman | 11β-Hydroxysteroid Dehydrogenase | 100 µg | 6067 |
| CAC-10007817-100 | Cayman | Leukotriene A4 Hydrolase (human recombinant) | 100 µg | 6975.6 |
| CAC-10007818-100 | Cayman | Serum Retinol Binding Protein 4 (human recombinant) | 100 µg | 7376 |
| CAC-10007819-96 | Cayman | SREBP-2 Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10007820-1 | Cayman | 5-Lipoxygenase (Phospho-Ser523) Polyclonal Antibody | 1 ea | 6831 |
| CAC-10007823-1 | Cayman | Oleoyl Ethanolamide-d2 | 1 mg | 3449.6 |
| CAC-10007823-100 | Cayman | Oleoyl Ethanolamide-d2 | 100 µg | 431.2 |
| CAC-10007823-5 | Cayman | Oleoyl Ethanolamide-d2 | 5 mg | 15092 |
| CAC-10007823-500 | Cayman | Oleoyl Ethanolamide-d2 | 500 µg | 1940.4 |
| CAC-10007824-1 | Cayman | Palmitoyl Ethanolamide-d4 | 1 mg | 3449.6 |
| CAC-10007824-100 | Cayman | Palmitoyl Ethanolamide-d4 | 100 µg | 431.2 |
| CAC-10007824-5 | Cayman | Palmitoyl Ethanolamide-d4 | 5 mg | 15092 |
| CAC-10007824-500 | Cayman | Palmitoyl Ethanolamide-d4 | 500 µg | 1940.4 |
| CAC-10007839-1 | Cayman | PLC thio-PIP2 (sodium salt) | 1 mg | 11334.4 |
| CAC-10007839-100 | Cayman | PLC thio-PIP2 (sodium salt) | 100 µg | 1416.8 |
| CAC-10007839-500 | Cayman | PLC thio-PIP2 (sodium salt) | 500 µg | 6375.6 |
| CAC-10007848-10 | Cayman | Resolvin E1 | 10 µg | 2525 |
| CAC-10007848-100 | Cayman | Resolvin E1 | 100 µg | 15815.2 |
| CAC-10007848-25 | Cayman | Resolvin E1 | 25 µg | 5173.8 |
| CAC-10007848-50 | Cayman | Resolvin E1 | 50 µg | 9270.2 |
| CAC-10007850-1 | Cayman | 9,11-methane-epoxy Prostaglandin F1α | 1 mg | 4435.2 |
| CAC-10007850-100 | Cayman | 9,11-methane-epoxy Prostaglandin F1α | 100 µg | 554.4 |
| CAC-10007850-500 | Cayman | 9,11-methane-epoxy Prostaglandin F1α | 500 µg | 2494.8 |
| CAC-10007852-100 | Cayman | Pargyline (hydrochloride) | 100 mg | 92.4 |
| CAC-10007852-1 | Cayman | Pargyline (hydrochloride) | 1 g | 739.2 |
| CAC-10007852-500 | Cayman | Pargyline (hydrochloride) | 500 mg | 415.8 |
| CAC-10007852-5 | Cayman | Pargyline (hydrochloride) | 5 g | 3234 |
| CAC-10007853-1 | Cayman | Muraglitazar | 1 mg | 4312 |
| CAC-10007858-100 | Cayman | Leukotriene E4-d5 | 100 µg | 13289.6 |
| CAC-10007858-25 | Cayman | Leukotriene E4-d5 | 25 µg | 4126.6 |
| CAC-10007858-50 | Cayman | Leukotriene E4-d5 | 50 µg | 7299 |
| CAC-10007863-10 | Cayman | 1,2-Dioleoyl-rac-glycerol | 10 mg | 1139 |
| CAC-10007863-100 | Cayman | 1,2-Dioleoyl-rac-glycerol | 100 mg | 3834 |
| CAC-10007863-25 | Cayman | 1,2-Dioleoyl-rac-glycerol | 25 mg | 1678 |
| CAC-10007863-50 | Cayman | 1,2-Dioleoyl-rac-glycerol | 50 mg | 2494.2 |
| CAC-10007867-100 | Cayman | Cylindrospermopsin | 100 µg | 6421.8 |
| CAC-10007867-25 | Cayman | Cylindrospermopsin | 25 µg | 2294.6 |
| CAC-10007867-50 | Cayman | Cylindrospermopsin | 50 µg | 3449.6 |
| CAC-10007867-500 | Cayman | Cylindrospermopsin | 500 µg | 29829.8 |
| CAC-10007868-100 | Cayman | Microcystin-RR | 100 µg | 2186.8 |
| CAC-10007868-50 | Cayman | Microcystin-RR | 50 µg | 1216.6 |
| CAC-10007868-500 | Cayman | Microcystin-RR | 500 µg | 8516.2 |
| CAC-10007875-1 | Cayman | CAY10499 | 1 mg | 169.4 |
| CAC-10007875-10 | Cayman | CAY10499 | 10 mg | 1355.2 |
| CAC-10007875-25 | Cayman | CAY10499 | 25 mg | 2972.2 |
| CAC-10007875-5 | Cayman | CAY10499 | 5 mg | 770 |
| CAC-10007881-1 | Cayman | Transcription Factor NF-κB (human p50) Positive Control | 1 ea | 1601 |
| CAC-10007882-1 | Cayman | Transcription Factor NF-κB 96-Well Strip Plate | 1 ea | 985.6 |
| CAC-10007883-1 | Cayman | Transcription Factor NF-κB (p50) Primary Antibody | 1 ea | 1201.2 |
| CAC-10007884-1 | Cayman | Transcription Factor NF-κB Competitor dsDNA | 1 ea | 985.6 |
| CAC-10007889-96 | Cayman | NF-κB (p65) Transcription Factor Assay Kit | 96 wells | 7145 |
| CAC-10007892-96 | Cayman | Thioredoxin Reductase Colorimetric Assay Kit | 96 wells | 2741.2 |
| CAC-10007895-1 | Cayman | N-3-oxo-dodecanoyl-L-Homoserine lactone | 1 mg | 354.2 |
| CAC-10007895-10 | Cayman | N-3-oxo-dodecanoyl-L-Homoserine lactone | 10 mg | 2833.6 |
| CAC-10007895-5 | Cayman | N-3-oxo-dodecanoyl-L-Homoserine lactone | 5 mg | 1601.6 |
| CAC-10007895-50 | Cayman | N-3-oxo-dodecanoyl-L-Homoserine lactone | 50 mg | 12397 |
| CAC-10007896-10 | Cayman | N-hexanoyl-L-Homoserine lactone | 10 mg | 585.2 |
| CAC-10007896-25 | Cayman | N-hexanoyl-L-Homoserine lactone | 25 mg | 1247.4 |
| CAC-10007896-5 | Cayman | N-hexanoyl-L-Homoserine lactone | 5 mg | 385 |
| CAC-10007896-50 | Cayman | N-hexanoyl-L-Homoserine lactone | 50 mg | 2125.2 |
| CAC-10007897-1 | Cayman | N-hexanoyl-L-Homoserine lactone-d3 | 1 mg | 646.8 |
| CAC-10007897-10 | Cayman | N-hexanoyl-L-Homoserine lactone-d3 | 10 mg | 4743.2 |
| CAC-10007897-5 | Cayman | N-hexanoyl-L-Homoserine lactone-d3 | 5 mg | 2710.4 |
| CAC-10007897-500 | Cayman | N-hexanoyl-L-Homoserine lactone-d3 | 500 µg | 338.8 |
| CAC-10007898-10 | Cayman | N-butyryl-L-Homoserine lactone | 10 mg | 739.2 |
| CAC-10007898-25 | Cayman | N-butyryl-L-Homoserine lactone | 25 mg | 1447.6 |
| CAC-10007898-5 | Cayman | N-butyryl-L-Homoserine lactone | 5 mg | 385 |
| CAC-10007898-50 | Cayman | N-butyryl-L-Homoserine lactone | 50 mg | 2310 |
| CAC-10007899-1 | Cayman | N-butyryl-L-Homoserine lactone-d5 | 1 mg | 646.8 |
| CAC-10007899-10 | Cayman | N-butyryl-L-Homoserine lactone-d5 | 10 mg | 4743.2 |
| CAC-10007899-5 | Cayman | N-butyryl-L-Homoserine lactone-d5 | 5 mg | 2710.4 |
| CAC-10007899-500 | Cayman | N-butyryl-L-Homoserine lactone-d5 | 500 µg | 338.8 |
| CAC-10007900-1 | Cayman | 8,11,14-Eicosatriynoic Acid | 1 mg | 1016.4 |
| CAC-10007900-10 | Cayman | 8,11,14-Eicosatriynoic Acid | 10 mg | 8131.2 |
| CAC-10007900-5 | Cayman | 8,11,14-Eicosatriynoic Acid | 5 mg | 4573.8 |
| CAC-10007901-1 | Cayman | D-erythro-Sphingosine C-15 | 1 mg | 770 |
| CAC-10007901-10 | Cayman | D-erythro-Sphingosine C-15 | 10 mg | 6160 |
| CAC-10007901-25 | Cayman | D-erythro-Sphingosine C-15 | 25 mg | 13475 |
| CAC-10007901-5 | Cayman | D-erythro-Sphingosine C-15 | 5 mg | 3465 |
| CAC-10007902-1 | Cayman | D-erythro-Sphingosine C-17 | 1 mg | 308 |
| CAC-10007902-10 | Cayman | D-erythro-Sphingosine C-17 | 10 mg | 2464 |
| CAC-10007902-25 | Cayman | D-erythro-Sphingosine C-17 | 25 mg | 5390 |
| CAC-10007902-5 | Cayman | D-erythro-Sphingosine C-17 | 5 mg | 1386 |
| CAC-10007903-1 | Cayman | D-erythro-Sphingosine C-20 | 1 mg | 693 |
| CAC-10007903-10 | Cayman | D-erythro-Sphingosine C-20 | 10 mg | 3850 |
| CAC-10007903-5 | Cayman | D-erythro-Sphingosine C-20 | 5 mg | 2310 |
| CAC-10007903-500 | Cayman | D-erythro-Sphingosine C-20 | 500 µg | 385 |
| CAC-10007904-1 | Cayman | Arachidonoyl-1-thio-Glycerol | 1 mg | 938.8 |
| CAC-10007904-10 | Cayman | Arachidonoyl-1-thio-Glycerol | 10 mg | 3310.4 |
| CAC-10007904-25 | Cayman | Arachidonoyl-1-thio-Glycerol | 25 mg | 6529 |
| CAC-10007904-5 | Cayman | Arachidonoyl-1-thio-Glycerol | 5 mg | 2124.6 |
| CAC-10007907-10 | Cayman | D-erythro-Sphingosine C-18 | 10 mg | 539 |
| CAC-10007907-100 | Cayman | D-erythro-Sphingosine C-18 | 100 mg | 3234 |
| CAC-10007907-25 | Cayman | D-erythro-Sphingosine C-18 | 25 mg | 1216.6 |
| CAC-10007907-50 | Cayman | D-erythro-Sphingosine C-18 | 50 mg | 2156 |
| CAC-10007912-100 | Cayman | 20-carboxy Arachidonic Acid | 100 µg | 10148.6 |
| CAC-10007912-25 | Cayman | 20-carboxy Arachidonic Acid | 25 µg | 2818.2 |
| CAC-10007912-50 | Cayman | 20-carboxy Arachidonic Acid | 50 µg | 5359.2 |
| CAC-10007923-10 | Cayman | CUDA | 10 mg | 816.2 |
| CAC-10007923-25 | Cayman | CUDA | 25 mg | 1940.4 |
| CAC-10007923-5 | Cayman | CUDA | 5 mg | 431.2 |
| CAC-10007923-50 | Cayman | CUDA | 50 mg | 3449.6 |
| CAC-10007924-1 | Cayman | Transcription Factor NF-κB (human p65) Positive Control | 1 ea | 1601 |
| CAC-10007925-1 | Cayman | Transcription Factor NF-κB (p65) Primary Antibody | 1 ea | 1201.2 |
| CAC-10007927-10 | Cayman | AUDA | 10 mg | 908.6 |
| CAC-10007927-100 | Cayman | AUDA | 100 mg | 6683.6 |
| CAC-10007927-5 | Cayman | AUDA | 5 mg | 477.4 |
| CAC-10007927-50 | Cayman | AUDA | 50 mg | 3819.2 |
| CAC-10007931-1 | Cayman | 17-phenyl trinor 8-iso Prostaglandin E2 | 1 mg | 2263.8 |
| CAC-10007931-5 | Cayman | 17-phenyl trinor 8-iso Prostaglandin E2 | 5 mg | 10225.6 |
| CAC-10007931-500 | Cayman | 17-phenyl trinor 8-iso Prostaglandin E2 | 500 µg | 1232 |
| CAC-10007938-100 | Cayman | FABP2 (rat recombinant) | 100 µg | 6067 |
| CAC-10007940-100 | Cayman | Prostaglandin F Synthase (human recombinant) | 100 µg | 6452 |
| CAC-10007945-10 | Cayman | D-erythro-Sphinganine | 10 mg | 816.2 |
| CAC-10007945-25 | Cayman | D-erythro-Sphinganine | 25 mg | 1940.4 |
| CAC-10007945-5 | Cayman | D-erythro-Sphinganine | 5 mg | 431.2 |
| CAC-10007945-50 | Cayman | D-erythro-Sphinganine | 50 mg | 3449.6 |
| CAC-10007946-1 | Cayman | Palmitoyl Sphingomyelin | 1 mg | 862.4 |
| CAC-10007946-10 | Cayman | Palmitoyl Sphingomyelin | 10 mg | 6899.2 |
| CAC-10007946-5 | Cayman | Palmitoyl Sphingomyelin | 5 mg | 3880.8 |
| CAC-10007947-1 | Cayman | Lyso-Sphingomyelin | 1 mg | 431.2 |
| CAC-10007947-10 | Cayman | Lyso-Sphingomyelin | 10 mg | 3449.6 |
| CAC-10007947-25 | Cayman | Lyso-Sphingomyelin | 25 mg | 7546 |
| CAC-10007947-5 | Cayman | Lyso-Sphingomyelin | 5 mg | 1940.4 |
| CAC-10007950-100 | Cayman | 15-hydroxy Prostaglandin Dehydrogenase (human recombinant) | 100 µg | 6452 |
| CAC-10007955-1 | Cayman | CAY10498 | 1 mg | 2741.2 |
| CAC-10007955-5 | Cayman | CAY10498 | 5 mg | 12196.8 |
| CAC-10007955-500 | Cayman | CAY10498 | 500 µg | 1524.6 |
| CAC-10007957-1 | Cayman | C-6 NBD-dihydro-Ceramide | 1 mg | 2233 |
| CAC-10007957-10 | Cayman | C-6 NBD-dihydro-Ceramide | 10 mg | 17864 |
| CAC-10007957-5 | Cayman | C-6 NBD-dihydro-Ceramide | 5 mg | 10056.2 |
| CAC-10007958-1 | Cayman | C-12 NBD Ceramide | 1 mg | 2233 |
| CAC-10007958-10 | Cayman | C-12 NBD Ceramide | 10 mg | 17864 |
| CAC-10007958-5 | Cayman | C-12 NBD Ceramide | 5 mg | 10056.2 |
| CAC-10007963-1 | Cayman | E-64 | 1 mg | 246.4 |
| CAC-10007963-10 | Cayman | E-64 | 10 mg | 1971.2 |
| CAC-10007963-25 | Cayman | E-64 | 25 mg | 4312 |
| CAC-10007963-5 | Cayman | E-64 | 5 mg | 1108.8 |
| CAC-10007964-1 | Cayman | E-64c | 1 mg | 754.6 |
| CAC-10007964-10 | Cayman | E-64c | 10 mg | 6036.8 |
| CAC-10007964-25 | Cayman | E-64c | 25 mg | 13213.2 |
| CAC-10007964-5 | Cayman | E-64c | 5 mg | 3403.4 |
| CAC-10007965-10 | Cayman | FK-506 | 10 mg | 816.2 |
| CAC-10007965-100 | Cayman | FK-506 | 100 mg | 6036.8 |
| CAC-10007965-5 | Cayman | FK-506 | 5 mg | 431.2 |
| CAC-10007965-50 | Cayman | FK-506 | 50 mg | 3449.6 |
| CAC-10007974-10 | Cayman | SLF | 10 mg | 2171.4 |
| CAC-10007974-100 | Cayman | SLF | 100 mg | 15276.8 |
| CAC-10007974-5 | Cayman | SLF | 5 mg | 1139.6 |
| CAC-10007974-50 | Cayman | SLF | 50 mg | 9116.8 |
| CAC-10007975-100 | Cayman | (±)11(12)-DiHET-d11 | 100 µg | 8208.2 |
| CAC-10007975-25 | Cayman | (±)11(12)-DiHET-d11 | 25 µg | 2279.2 |
| CAC-10007975-250 | Cayman | (±)11(12)-DiHET-d11 | 250 µg | 18233.6 |
| CAC-10007975-50 | Cayman | (±)11(12)-DiHET-d11 | 50 µg | 4327.4 |
| CAC-10007978-100 | Cayman | 13,14-dihydro-15-keto Prostaglandin D2-d4 | 100 µg | 6375.6 |
| CAC-10007978-25 | Cayman | 13,14-dihydro-15-keto Prostaglandin D2-d4 | 25 µg | 1771 |
| CAC-10007978-50 | Cayman | 13,14-dihydro-15-keto Prostaglandin D2-d4 | 50 µg | 3372.6 |
| CAC-10007980-1 | Cayman | 3,4-DAA | 1 mg | 200.2 |
| CAC-10007980-10 | Cayman | 3,4-DAA | 10 mg | 1601.6 |
| CAC-10007980-5 | Cayman | 3,4-DAA | 5 mg | 908.6 |
| CAC-10007980-50 | Cayman | 3,4-DAA | 50 mg | 7007 |
| CAC-10008012-1 | Cayman | SPD-304 | 1 mg | 677.6 |
| CAC-10008012-10 | Cayman | SPD-304 | 10 mg | 4958.8 |
| CAC-10008012-5 | Cayman | SPD-304 | 5 mg | 2833.6 |
| CAC-10008012-500 | Cayman | SPD-304 | 500 µg | 354.2 |
| CAC-10008014-1 | Cayman | Phorbol 12-myristate 13-acetate | 1 mg | 478.5 |
| CAC-10008014-10 | Cayman | Phorbol 12-myristate 13-acetate | 10 mg | 2640 |
| CAC-10008014-25 | Cayman | Phorbol 12-myristate 13-acetate | 25 mg | 5857.5 |
| CAC-10008014-5 | Cayman | Phorbol 12-myristate 13-acetate | 5 mg | 1551 |
| CAC-10008040-100 | Cayman | (±)14(15)DiHET-d11 | 100 µg | 8208.2 |
| CAC-10008040-25 | Cayman | (±)14(15)DiHET-d11 | 25 µg | 2279.2 |
| CAC-10008040-250 | Cayman | (±)14(15)DiHET-d11 | 250 µg | 18233.6 |
| CAC-10008040-50 | Cayman | (±)14(15)DiHET-d11 | 50 µg | 4327.4 |
| CAC-10008041-1 | Cayman | 20S Proteasome Assay Kit | 1 ea | 4742.6 |
| CAC-10008042-1 | Cayman | 9-Nitrooleate | 1 mg | 4543 |
| CAC-10008042-100 | Cayman | 9-Nitrooleate | 100 µg | 616 |
| CAC-10008042-50 | Cayman | 9-Nitrooleate | 50 µg | 385 |
| CAC-10008042-500 | Cayman | 9-Nitrooleate | 500 µg | 2587.2 |
| CAC-10008043-1 | Cayman | 10-Nitrooleate | 1 mg | 4543 |
| CAC-10008043-100 | Cayman | 10-Nitrooleate | 100 µg | 616 |
| CAC-10008043-50 | Cayman | 10-Nitrooleate | 50 µg | 385 |
| CAC-10008043-500 | Cayman | 10-Nitrooleate | 500 µg | 2587.2 |
| CAC-10008050-1 | Cayman | PtdIns-(5)-P1 (1,2-dihexanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10008050-100 | Cayman | PtdIns-(5)-P1 (1,2-dihexanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10008050-500 | Cayman | PtdIns-(5)-P1 (1,2-dihexanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10008051-480 | Cayman | Acid Phosphatase Colorimetric Assay Kit | 480 wells | 2032.8 |
| CAC-10008052-1 | Cayman | Cholesterol Assay Buffer (10X) | 1 ea | 215.6 |
| CAC-10008052-5 | Cayman | Cholesterol Assay Buffer (10X) | 5 ea | 816.2 |
| CAC-10008053-1 | Cayman | Cholesterol Assay Standard | 1 ea | 215.6 |
| CAC-10008053-5 | Cayman | Cholesterol Assay Standard | 5 ea | 816.2 |
| CAC-10008054-1 | Cayman | Cholesterol Assay Detector | 1 ea | 385 |
| CAC-10008055-1 | Cayman | Cholesterol Assay Horseradish Peroxidase | 1 ea | 215.6 |
| CAC-10008055-5 | Cayman | Cholesterol Assay Horseradish Peroxidase | 5 ea | 816.2 |
| CAC-10008056-1 | Cayman | Cholesterol Assay Oxidase | 1 ea | 385 |
| CAC-10008056-5 | Cayman | Cholesterol Assay Oxidase | 5 ea | 1447.6 |
| CAC-10008057-1 | Cayman | Cholesterol Assay Esterase | 1 ea | 385 |
| CAC-10008057-5 | Cayman | Cholesterol Assay Esterase | 5 ea | 1447.6 |
| CAC-10008097-1 | Cayman | C-12 NBD-dihydro-Ceramide | 1 mg | 2233 |
| CAC-10008097-10 | Cayman | C-12 NBD-dihydro-Ceramide | 10 mg | 17864 |
| CAC-10008097-5 | Cayman | C-12 NBD-dihydro-Ceramide | 5 mg | 10056.2 |
| CAC-10008099-1 | Cayman | PtdIns-(1,2-dioctanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10008099-100 | Cayman | PtdIns-(1,2-dioctanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10008099-500 | Cayman | PtdIns-(1,2-dioctanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10008112-1 | Cayman | Perifosine | 1 mg | 446.6 |
| CAC-10008112-10 | Cayman | Perifosine | 10 mg | 2233 |
| CAC-10008112-25 | Cayman | Perifosine | 25 mg | 5020.4 |
| CAC-10008112-5 | Cayman | Perifosine | 5 mg | 1570.8 |
| CAC-10008115-1 | Cayman | PtdIns-(4,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 1 mg | 7392 |
| CAC-10008115-100 | Cayman | PtdIns-(4,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 100 µg | 924 |
| CAC-10008115-500 | Cayman | PtdIns-(4,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 500 µg | 4158 |
| CAC-10008117-1 | Cayman | Z-LLE-AMC | 1 mg | 539 |
| CAC-10008117-10 | Cayman | Z-LLE-AMC | 10 mg | 3511.2 |
| CAC-10008117-5 | Cayman | Z-LLE-AMC | 5 mg | 1894.2 |
| CAC-10008118-1 | Cayman | Z-LLL-AMC | 1 mg | 539 |
| CAC-10008118-10 | Cayman | Z-LLL-AMC | 10 mg | 3234 |
| CAC-10008118-5 | Cayman | Z-LLL-AMC | 5 mg | 1755.6 |
| CAC-10008119-1 | Cayman | Suc-Leu-Leu-Val-Tyr-AMC | 1 mg | 385 |
| CAC-10008119-10 | Cayman | Suc-Leu-Leu-Val-Tyr-AMC | 10 mg | 1740.2 |
| CAC-10008119-5 | Cayman | Suc-Leu-Leu-Val-Tyr-AMC | 5 mg | 970.2 |
| CAC-10008120-10 | Cayman | Suc-Leu-Tyr-AMC | 10 mg | 754.6 |
| CAC-10008120-25 | Cayman | Suc-Leu-Tyr-AMC | 25 mg | 1447.6 |
| CAC-10008120-5 | Cayman | Suc-Leu-Tyr-AMC | 5 mg | 446.6 |
| CAC-10008120-50 | Cayman | Suc-Leu-Tyr-AMC | 50 mg | 2464 |
| CAC-10008122-1 | Cayman | ent-Prostaglandin F2α | 1 mg | 877.8 |
| CAC-10008122-10 | Cayman | ent-Prostaglandin F2α | 10 mg | 7022.4 |
| CAC-10008122-5 | Cayman | ent-Prostaglandin F2α | 5 mg | 3957.8 |
| CAC-10008123-1 | Cayman | cis-Δ2-11-methyl-Dodecenoic Acid | 1 mg | 1001 |
| CAC-10008123-10 | Cayman | cis-Δ2-11-methyl-Dodecenoic Acid | 10 mg | 8608.6 |
| CAC-10008123-5 | Cayman | cis-Δ2-11-methyl-Dodecenoic Acid | 5 mg | 4512.2 |
| CAC-10008127-1 | Cayman | 15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide | 1 mg | 1878.8 |
| CAC-10008127-10 | Cayman | 15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide | 10 mg | 13798.4 |
| CAC-10008127-5 | Cayman | 15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide | 5 mg | 7884.8 |
| CAC-10008127-500 | Cayman | 15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide | 500 µg | 985.6 |
| CAC-10008128-100 | Cayman | 10(S),17(S)-DiHDHA | 100 µg | 6206.2 |
| CAC-10008128-25 | Cayman | 10(S),17(S)-DiHDHA | 25 µg | 1724.8 |
| CAC-10008128-50 | Cayman | 10(S),17(S)-DiHDHA | 50 µg | 3280.2 |
| CAC-10008128-500 | Cayman | 10(S),17(S)-DiHDHA | 500 µg | 27596.8 |
| CAC-10008131-1 | Cayman | JNJ-10198409 | 1 mg | 323.4 |
| CAC-10008131-10 | Cayman | JNJ-10198409 | 10 mg | 2587.2 |
| CAC-10008131-5 | Cayman | JNJ-10198409 | 5 mg | 1463 |
| CAC-10008131-50 | Cayman | JNJ-10198409 | 50 mg | 11319 |
| CAC-10008132-1 | Cayman | 5-trans-17-phenyl trinor Prostaglandin F2α ethyl amide | 1 mg | 847 |
| CAC-10008132-10 | Cayman | 5-trans-17-phenyl trinor Prostaglandin F2α ethyl amide | 10 mg | 6776 |
| CAC-10008132-25 | Cayman | 5-trans-17-phenyl trinor Prostaglandin F2α ethyl amide | 25 mg | 14830.2 |
| CAC-10008132-5 | Cayman | 5-trans-17-phenyl trinor Prostaglandin F2α ethyl amide | 5 mg | 3819.2 |
| CAC-10008159-10 | Cayman | PtdIns-(4,5)-P2-biotin (sodium salt) | 10 µg | 1986.6 |
| CAC-10008159-100 | Cayman | PtdIns-(4,5)-P2-biotin (sodium salt) | 100 µg | 12920.6 |
| CAC-10008159-25 | Cayman | PtdIns-(4,5)-P2-biotin (sodium salt) | 25 µg | 4712.4 |
| CAC-10008159-50 | Cayman | PtdIns-(4,5)-P2-biotin (sodium salt) | 50 µg | 8146.6 |
| CAC-10008187-1 | Cayman | Dimethylcurcumin | 1 mg | 446.6 |
| CAC-10008187-10 | Cayman | Dimethylcurcumin | 10 mg | 3572.8 |
| CAC-10008187-25 | Cayman | Dimethylcurcumin | 25 mg | 7823.2 |
| CAC-10008187-5 | Cayman | Dimethylcurcumin | 5 mg | 2017.4 |
| CAC-10008188-100 | Cayman | Fatty Acid ethyl ester Standard Pack | 100 mg | 2279.2 |
| CAC-10008196-100 | Cayman | Stearic Acid ethyl ester | 100 mg | 154 |
| CAC-10008196-1 | Cayman | Stearic Acid ethyl ester | 1 g | 462 |
| CAC-10008196-500 | Cayman | Stearic Acid ethyl ester | 500 mg | 385 |
| CAC-10008197-100 | Cayman | Myristic Acid ethyl ester | 100 mg | 231 |
| CAC-10008197-1 | Cayman | Myristic Acid ethyl ester | 1 g | 1617 |
| CAC-10008197-500 | Cayman | Myristic Acid ethyl ester | 500 mg | 1047.2 |
| CAC-10008198-100 | Cayman | Linoleic Acid ethyl ester | 100 mg | 231 |
| CAC-10008198-1 | Cayman | Linoleic Acid ethyl ester | 1 g | 462 |
| CAC-10008198-50 | Cayman | Linoleic Acid ethyl ester | 50 mg | 154 |
| CAC-10008198-500 | Cayman | Linoleic Acid ethyl ester | 500 mg | 385 |
| CAC-10008199-100 | Cayman | Linolenic Acid ethyl ester | 100 mg | 338.8 |
| CAC-10008199-1 | Cayman | Linolenic Acid ethyl ester | 1 g | 1478.4 |
| CAC-10008199-50 | Cayman | Linolenic Acid ethyl ester | 50 mg | 184.8 |
| CAC-10008199-500 | Cayman | Linolenic Acid ethyl ester | 500 mg | 924 |
| CAC-10008200-100 | Cayman | Arachidonic Acid ethyl ester | 100 mg | 908.6 |
| CAC-10008200-25 | Cayman | Arachidonic Acid ethyl ester | 25 mg | 415.8 |
| CAC-10008200-50 | Cayman | Arachidonic Acid ethyl ester | 50 mg | 631.4 |
| CAC-10008200-500 | Cayman | Arachidonic Acid ethyl ester | 500 mg | 2079 |
| CAC-10008201-1 | Cayman | Oleic Acid ethyl ester | 1 g | 462 |
| CAC-10008201-50 | Cayman | Oleic Acid ethyl ester | 50 mg | 154 |
| CAC-10008202-10 | Cayman | Palmitic Acid ethyl ester | 10 g | 693 |
| CAC-10008202-25 | Cayman | Palmitic Acid ethyl ester | 25 g | 1155 |
| CAC-10008202-5 | Cayman | Palmitic Acid ethyl ester | 5 g | 385 |
| CAC-10008203-100 | Cayman | Lauric Acid ethyl ester | 100 mg | 154 |
| CAC-10008203-1 | Cayman | Lauric Acid ethyl ester | 1 g | 539 |
| CAC-10008203-500 | Cayman | Lauric Acid ethyl ester | 500 mg | 385 |
| CAC-10008204-10 | Cayman | Palmitoleic Acid ethyl ester | 10 mg | 169.4 |
| CAC-10008204-100 | Cayman | Palmitoleic Acid ethyl ester | 100 mg | 1355.2 |
| CAC-10008204-50 | Cayman | Palmitoleic Acid ethyl ester | 50 mg | 770 |
| CAC-10008204-500 | Cayman | Palmitoleic Acid ethyl ester | 500 mg | 5929 |
| CAC-10008205-1 | Cayman | D-myo-Inositol-1,4,5-triphosphate (sodium salt) | 1 mg | 924 |
| CAC-10008205-5 | Cayman | D-myo-Inositol-1,4,5-triphosphate (sodium salt) | 5 mg | 4312 |
| CAC-10008205-500 | Cayman | D-myo-Inositol-1,4,5-triphosphate (sodium salt) | 500 µg | 539 |
| CAC-10008206-1 | Cayman | IGFBP5 Blocking Peptide | 1 ea | 1647.8 |
| CAC-10008207-500 | Cayman | IGFBP5 Polyclonal Antibody | 500 µl | 3988.6 |
| CAC-10008282-10 | Cayman | Zafirlukast | 10 mg | 215.6 |
| CAC-10008282-100 | Cayman | Zafirlukast | 100 mg | 1724.8 |
| CAC-10008282-1 | Cayman | Zafirlukast | 1 g | 12936 |
| CAC-10008282-500 | Cayman | Zafirlukast | 500 mg | 7546 |
| CAC-10008284-1 | Cayman | N-acetyl-2-carboxy Benzenesulfonamide | 1 mg | 200.2 |
| CAC-10008284-10 | Cayman | N-acetyl-2-carboxy Benzenesulfonamide | 10 mg | 1601.6 |
| CAC-10008284-5 | Cayman | N-acetyl-2-carboxy Benzenesulfonamide | 5 mg | 908.6 |
| CAC-10008284-50 | Cayman | N-acetyl-2-carboxy Benzenesulfonamide | 50 mg | 7007 |
| CAC-10008294-1 | Cayman | ent-Prostaglandin E2 | 1 mg | 877.8 |
| CAC-10008294-10 | Cayman | ent-Prostaglandin E2 | 10 mg | 7022.4 |
| CAC-10008294-5 | Cayman | ent-Prostaglandin E2 | 5 mg | 3957.8 |
| CAC-10008313-1 | Cayman | GW 610 | 1 mg | 261.8 |
| CAC-10008313-10 | Cayman | GW 610 | 10 mg | 2094.4 |
| CAC-10008313-5 | Cayman | GW 610 | 5 mg | 1185.8 |
| CAC-10008313-50 | Cayman | GW 610 | 50 mg | 9163 |
| CAC-10008317-10 | Cayman | N-Cyclohexanecarbonyltetradecylamine | 10 mg | 785.4 |
| CAC-10008317-100 | Cayman | N-Cyclohexanecarbonyltetradecylamine | 100 mg | 5821.2 |
| CAC-10008317-5 | Cayman | N-Cyclohexanecarbonyltetradecylamine | 5 mg | 415.8 |
| CAC-10008317-50 | Cayman | N-Cyclohexanecarbonyltetradecylamine | 50 mg | 3326.4 |
| CAC-10008318-10 | Cayman | Montelukast (sodium salt) | 10 mg | 215.6 |
| CAC-10008318-100 | Cayman | Montelukast (sodium salt) | 100 mg | 1724.8 |
| CAC-10008318-50 | Cayman | Montelukast (sodium salt) | 50 mg | 970.2 |
| CAC-10008318-500 | Cayman | Montelukast (sodium salt) | 500 mg | 7546 |
| CAC-10008319-10 | Cayman | Pranlukast | 10 mg | 215.6 |
| CAC-10008319-100 | Cayman | Pranlukast | 100 mg | 1724.8 |
| CAC-10008319-1 | Cayman | Pranlukast | 1 g | 12936 |
| CAC-10008319-500 | Cayman | Pranlukast | 500 mg | 7546 |
| CAC-10008321-1 | Cayman | trans-Δ2-11-methyl-Dodecenoic Acid | 1 mg | 431.2 |
| CAC-10008321-10 | Cayman | trans-Δ2-11-methyl-Dodecenoic Acid | 10 mg | 3449.6 |
| CAC-10008321-5 | Cayman | trans-Δ2-11-methyl-Dodecenoic Acid | 5 mg | 1940.4 |
| CAC-10008321-50 | Cayman | trans-Δ2-11-methyl-Dodecenoic Acid | 50 mg | 15092 |
| CAC-10008333-1 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid methyl ester | 1 mg | 1293 |
| CAC-10008333-10 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid methyl ester | 10 mg | 6144 |
| CAC-10008333-5 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid methyl ester | 5 mg | 3726.2 |
| CAC-10008335-1 | Cayman | all-cis-4,7,10,13,16-Docosapentaenoic Acid | 1 mg | 539 |
| CAC-10008335-10 | Cayman | all-cis-4,7,10,13,16-Docosapentaenoic Acid | 10 mg | 4312 |
| CAC-10008335-25 | Cayman | all-cis-4,7,10,13,16-Docosapentaenoic Acid | 25 mg | 9440.2 |
| CAC-10008335-5 | Cayman | all-cis-4,7,10,13,16-Docosapentaenoic Acid | 5 mg | 2433.2 |
| CAC-10008346-10 | Cayman | Gabapentin | 10 mg | 462 |
| CAC-10008346-100 | Cayman | Gabapentin | 100 mg | 3696 |
| CAC-10008346-25 | Cayman | Gabapentin | 25 mg | 1093.4 |
| CAC-10008346-50 | Cayman | Gabapentin | 50 mg | 2079 |
| CAC-10008349-1 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid | 1 mg | 1293 |
| CAC-10008349-10 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid | 10 mg | 6144 |
| CAC-10008349-5 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid | 5 mg | 3726.2 |
| CAC-10008350-1 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid ethyl ester | 1 mg | 693 |
| CAC-10008350-10 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid ethyl ester | 10 mg | 5544 |
| CAC-10008350-5 | Cayman | 9(Z),11(E),13(E)-Octadecatrienoic Acid ethyl ester | 5 mg | 3126.2 |
| CAC-10008351-1 | Cayman | Propidium Iodide Solution | 1 ea | 338.8 |
| CAC-10008370-1 | Cayman | AL 8810 methyl ester | 1 mg | 877.8 |
| CAC-10008370-10 | Cayman | AL 8810 methyl ester | 10 mg | 7022.4 |
| CAC-10008370-5 | Cayman | AL 8810 methyl ester | 5 mg | 3957.8 |
| CAC-10008377-1 | Cayman | α-Tocotrienol | 1 mg | 323.4 |
| CAC-10008377-10 | Cayman | α-Tocotrienol | 10 mg | 2587.2 |
| CAC-10008377-25 | Cayman | α-Tocotrienol | 25 mg | 5667.2 |
| CAC-10008377-5 | Cayman | α-Tocotrienol | 5 mg | 1463 |
| CAC-10008385-1 | Cayman | Prostaglandin D2 methyl ester | 1 mg | 1001 |
| CAC-10008385-5 | Cayman | Prostaglandin D2 methyl ester | 5 mg | 4188.8 |
| CAC-10008385-500 | Cayman | Prostaglandin D2 methyl ester | 500 µg | 523.6 |
| CAC-10008390-1 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dihexanoyl) (ammonium salt) | 1 mg | 4928 |
| CAC-10008390-100 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dihexanoyl) (ammonium salt) | 100 µg | 616 |
| CAC-10008390-500 | Cayman | PtdIns-(3,4,5)-P3 (1,2-dihexanoyl) (ammonium salt) | 500 µg | 2772 |
| CAC-10008394-1 | Cayman | PtdIns-(3)-P1 (1,2-dioctanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10008394-100 | Cayman | PtdIns-(3)-P1 (1,2-dioctanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10008394-500 | Cayman | PtdIns-(3)-P1 (1,2-dioctanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10008396-1 | Cayman | PtdIns-(3,5)-P2 (1,2-dihexanoyl) (sodium salt) | 1 mg | 4928 |
| CAC-10008396-100 | Cayman | PtdIns-(3,5)-P2 (1,2-dihexanoyl) (sodium salt) | 100 µg | 616 |
| CAC-10008396-500 | Cayman | PtdIns-(3,5)-P2 (1,2-dihexanoyl) (sodium salt) | 500 µg | 2772 |
| CAC-10008398-1 | Cayman | PtdIns-(3,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10008398-100 | Cayman | PtdIns-(3,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 100 µg | 770 |
| CAC-10008398-500 | Cayman | PtdIns-(3,5)-P2 (1,2-dipalmitoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10008400-1 | Cayman | PtdIns-(3,4)-P2 (1,2-dioctanoyl) (sodium salt) | 1 mg | 6160 |
| CAC-10008400-100 | Cayman | PtdIns-(3,4)-P2 (1,2-dioctanoyl) (sodium salt) | 100 µg | 770 |
| CAC-10008400-500 | Cayman | PtdIns-(3,4)-P2 (1,2-dioctanoyl) (sodium salt) | 500 µg | 3465 |
| CAC-10008418-1 | Cayman | D-myo-Inositol-4,5-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008418-100 | Cayman | D-myo-Inositol-4,5-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008418-500 | Cayman | D-myo-Inositol-4,5-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008419-1 | Cayman | D-myo-Inositol-2,4-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008419-100 | Cayman | D-myo-Inositol-2,4-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008419-500 | Cayman | D-myo-Inositol-2,4-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008422-1 | Cayman | D-myo-Inositol-1,5,6-triphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008422-100 | Cayman | D-myo-Inositol-1,5,6-triphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008422-500 | Cayman | D-myo-Inositol-1,5,6-triphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008423-1 | Cayman | D-myo-Inositol-2,3,5-triphosphate (ammonium salt) | 1 mg | 6036.8 |
| CAC-10008423-100 | Cayman | D-myo-Inositol-2,3,5-triphosphate (ammonium salt) | 100 µg | 754.6 |
| CAC-10008423-500 | Cayman | D-myo-Inositol-2,3,5-triphosphate (ammonium salt) | 500 µg | 3403.4 |
| CAC-10008424-1 | Cayman | D-myo-Inositol-2,5,6-triphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008424-100 | Cayman | D-myo-Inositol-2,5,6-triphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008424-500 | Cayman | D-myo-Inositol-2,5,6-triphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008425-1 | Cayman | D-myo-Inositol-3,4,5-triphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008425-100 | Cayman | D-myo-Inositol-3,4,5-triphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008425-500 | Cayman | D-myo-Inositol-3,4,5-triphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008426-1 | Cayman | L-myo-Inositol-1,4,5-triphosphate (sodium salt) | 1 mg | 11211.2 |
| CAC-10008426-100 | Cayman | L-myo-Inositol-1,4,5-triphosphate (sodium salt) | 100 µg | 1401.4 |
| CAC-10008426-500 | Cayman | L-myo-Inositol-1,4,5-triphosphate (sodium salt) | 500 µg | 6314 |
| CAC-10008427-1 | Cayman | D-myo-Inositol-1,4,6-triphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008427-100 | Cayman | D-myo-Inositol-1,4,6-triphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008427-500 | Cayman | D-myo-Inositol-1,4,6-triphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008435-1 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2α | 1 mg | 2125.2 |
| CAC-10008435-10 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2α | 10 mg | 17001.6 |
| CAC-10008435-5 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2α | 5 mg | 9563.4 |
| CAC-10008436-1 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2β | 1 mg | 4573.8 |
| CAC-10008436-100 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2β | 100 µg | 693 |
| CAC-10008436-500 | Cayman | 8-iso-17-phenyl trinor Prostaglandin F2β | 500 µg | 2602.6 |
| CAC-10008437-1 | Cayman | D-myo-Inositol-4-phosphate (ammonium salt) | 1 mg | 13552 |
| CAC-10008437-100 | Cayman | D-myo-Inositol-4-phosphate (ammonium salt) | 100 µg | 1694 |
| CAC-10008437-500 | Cayman | D-myo-Inositol-4-phosphate (ammonium salt) | 500 µg | 7623 |
| CAC-10008438-1 | Cayman | D-myo-Inositol-1,4-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008438-100 | Cayman | D-myo-Inositol-1,4-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008438-500 | Cayman | D-myo-Inositol-1,4-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008439-1 | Cayman | D-myo-Inositol-1,2-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008439-100 | Cayman | D-myo-Inositol-1,2-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008439-500 | Cayman | D-myo-Inositol-1,2-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008441-1 | Cayman | D-myo-Inositol-1,5-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008441-100 | Cayman | D-myo-Inositol-1,5-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008441-500 | Cayman | D-myo-Inositol-1,5-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008442-1 | Cayman | D-myo-Inositol-1,3,4,6-tetraphosphate (ammonium salt) | 1 mg | 5544 |
| CAC-10008442-100 | Cayman | D-myo-Inositol-1,3,4,6-tetraphosphate (ammonium salt) | 100 µg | 693 |
| CAC-10008442-500 | Cayman | D-myo-Inositol-1,3,4,6-tetraphosphate (ammonium salt) | 500 µg | 3126.2 |
| CAC-10008443-1 | Cayman | D-myo-Inositol-1,3-diphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008443-100 | Cayman | D-myo-Inositol-1,3-diphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008443-500 | Cayman | D-myo-Inositol-1,3-diphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008444-1 | Cayman | D-myo-Inositol-1,2,5,6-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008444-100 | Cayman | D-myo-Inositol-1,2,5,6-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008444-500 | Cayman | D-myo-Inositol-1,2,5,6-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008445-1 | Cayman | 3-methoxy Limaprost | 1 mg | 1262.8 |
| CAC-10008445-10 | Cayman | 3-methoxy Limaprost | 10 mg | 9270.8 |
| CAC-10008445-5 | Cayman | 3-methoxy Limaprost | 5 mg | 5297.6 |
| CAC-10008445-500 | Cayman | 3-methoxy Limaprost | 500 µg | 662.2 |
| CAC-10008448-1 | Cayman | D-myo-Inositol-1,2,3,4-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008448-100 | Cayman | D-myo-Inositol-1,2,3,4-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008448-500 | Cayman | D-myo-Inositol-1,2,3,4-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008449-1 | Cayman | D-myo-Inositol-1,2,3,5-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008449-100 | Cayman | D-myo-Inositol-1,2,3,5-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008449-500 | Cayman | D-myo-Inositol-1,2,3,5-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008450-1 | Cayman | D-myo-Inositol-1,2,3,6-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008450-100 | Cayman | D-myo-Inositol-1,2,3,6-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008450-500 | Cayman | D-myo-Inositol-1,2,3,6-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008451-1 | Cayman | D-myo-Inositol-1,2,4,5-tetraphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008451-100 | Cayman | D-myo-Inositol-1,2,4,5-tetraphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008451-500 | Cayman | D-myo-Inositol-1,2,4,5-tetraphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008452-1 | Cayman | D-myo-Inositol-1,2,4,5,6-pentaphosphate (sodium salt) | 1 mg | 13552 |
| CAC-10008452-100 | Cayman | D-myo-Inositol-1,2,4,5,6-pentaphosphate (sodium salt) | 100 µg | 1694 |
| CAC-10008452-500 | Cayman | D-myo-Inositol-1,2,4,5,6-pentaphosphate (sodium salt) | 500 µg | 7623 |
| CAC-10008453-1 | Cayman | D-myo-Inositol-1,2,3,5,6-pentaphosphate (sodium salt) | 1 mg | 9732.8 |
| CAC-10008453-100 | Cayman | D-myo-Inositol-1,2,3,5,6-pentaphosphate (sodium salt) | 100 µg | 1216.6 |
| CAC-10008453-500 | Cayman | D-myo-Inositol-1,2,3,5,6-pentaphosphate (sodium salt) | 500 µg | 5482.4 |
| CAC-10008455-1 | Cayman | D-myo-Inositol-2,3,5,6-tetraphosphate (sodium salt) | 1 mg | 6036.8 |
| CAC-10008455-100 | Cayman | D-myo-Inositol-2,3,5,6-tetraphosphate (sodium salt) | 100 µg | 754.6 |
| CAC-10008455-500 | Cayman | D-myo-Inositol-2,3,5,6-tetraphosphate (sodium salt) | 500 µg | 3403.4 |
| CAC-10008456-1 | Cayman | D-myo-Inositol-2,3,4,5-tetraphosphate (ammonium salt) | 1 mg | 13552 |
| CAC-10008456-100 | Cayman | D-myo-Inositol-2,3,4,5-tetraphosphate (ammonium salt) | 100 µg | 1694 |
| CAC-10008456-500 | Cayman | D-myo-Inositol-2,3,4,5-tetraphosphate (ammonium salt) | 500 µg | 7623 |
| CAC-10008463-500 | Cayman | ApoA1 Polyclonal Antibody | 500 μl | 3988.6 |
| CAC-10008477-2.5 | Cayman | Creatinine Sodium Borate | 2.5 ml | 107.8 |
| CAC-10008477-12.5 | Cayman | Creatinine Sodium Borate | 12.5 ml | 400.4 |
| CAC-10008478-7.5 | Cayman | Creatinine Surfactant | 7.5 ml | 107.8 |
| CAC-10008478-37.5 | Cayman | Creatinine Surfactant | 37.5 ml | 400.4 |
| CAC-10008492-1 | Cayman | Adipose Triglyceride Lipase Blocking Peptide | 1 ea | 1647.8 |
| CAC-10008494-1 | Cayman | γ-Tocotrienol | 1 mg | 323.4 |
| CAC-10008494-10 | Cayman | γ-Tocotrienol | 10 mg | 2587.2 |
| CAC-10008494-25 | Cayman | γ-Tocotrienol | 25 mg | 5667.2 |
| CAC-10008494-5 | Cayman | γ-Tocotrienol | 5 mg | 1463 |
| CAC-10008513-1 | Cayman | δ-Tocotrienol | 1 mg | 323.4 |
| CAC-10008513-10 | Cayman | δ-Tocotrienol | 10 mg | 2587.2 |
| CAC-10008513-25 | Cayman | δ-Tocotrienol | 25 mg | 5667.2 |
| CAC-10008513-5 | Cayman | δ-Tocotrienol | 5 mg | 1463 |
| CAC-10008517-10 | Cayman | Tienilic Acid | 10 mg | 1509.2 |
| CAC-10008517-25 | Cayman | Tienilic Acid | 25 mg | 4019.4 |
| CAC-10008517-5 | Cayman | Tienilic Acid | 5 mg | 893.2 |
| CAC-10008517-50 | Cayman | Tienilic Acid | 50 mg | 7145.6 |
| CAC-10008518-1 | Cayman | 4-hydroxy Diclofenac | 1 mg | 1960.2 |
| CAC-10008518-10 | Cayman | 4-hydroxy Diclofenac | 10 mg | 12751.2 |
| CAC-10008518-5 | Cayman | 4-hydroxy Diclofenac | 5 mg | 7345.8 |
| CAC-10008519-5 | Cayman | 6β-hydroxy Testosterone | 5 mg | 1324.4 |
| CAC-10008520-1 | Cayman | 4-hydroxy Tolbutamide | 1 mg | 431.2 |
| CAC-10008520-10 | Cayman | 4-hydroxy Tolbutamide | 10 mg | 3449.6 |
| CAC-10008520-25 | Cayman | 4-hydroxy Tolbutamide | 25 mg | 7546 |
| CAC-10008520-5 | Cayman | 4-hydroxy Tolbutamide | 5 mg | 1940.4 |
| CAC-10008539-1 | Cayman | 8-iso-15-keto Prostaglandin F2β | 1 mg | 4573.8 |
| CAC-10008539-100 | Cayman | 8-iso-15-keto Prostaglandin F2β | 100 µg | 693 |
| CAC-10008539-500 | Cayman | 8-iso-15-keto Prostaglandin F2β | 500 µg | 2602.6 |
| CAC-10008581-100 | Cayman | Myristoleic Acid methyl ester | 100 mg | 739.2 |
| CAC-10008581-1 | Cayman | Myristoleic Acid methyl ester | 1 g | 3465 |
| CAC-10008581-50 | Cayman | Myristoleic Acid methyl ester | 50 mg | 385 |
| CAC-10008581-500 | Cayman | Myristoleic Acid methyl ester | 500 mg | 2510.2 |
| CAC-10008585-1 | Cayman | 5-cis Iloprost | 1 mg | 3126.2 |
| CAC-10008585-10 | Cayman | 5-cis Iloprost | 10 mg | 23069.2 |
| CAC-10008585-5 | Cayman | 5-cis Iloprost | 5 mg | 13182.4 |
| CAC-10008585-500 | Cayman | 5-cis Iloprost | 500 µg | 1647.8 |
| CAC-10008588-1 | Cayman | 5-cis-15(R)-Iloprost | 1 mg | 3126.2 |
| CAC-10008588-10 | Cayman | 5-cis-15(R)-Iloprost | 10 mg | 23069.2 |
| CAC-10008588-5 | Cayman | 5-cis-15(R)-Iloprost | 5 mg | 13182.4 |
| CAC-10008588-500 | Cayman | 5-cis-15(R)-Iloprost | 500 µg | 1647.8 |
| CAC-10008593-1 | Cayman | PSN375963 | 1 mg | 200.2 |
| CAC-10008593-10 | Cayman | PSN375963 | 10 mg | 1601.6 |
| CAC-10008593-25 | Cayman | PSN375963 | 25 mg | 3511.2 |
| CAC-10008593-5 | Cayman | PSN375963 | 5 mg | 908.6 |
| CAC-10008594-1 | Cayman | PSN632408 | 1 mg | 323.4 |
| CAC-10008594-10 | Cayman | PSN632408 | 10 mg | 2587.2 |
| CAC-10008594-25 | Cayman | PSN632408 | 25 mg | 5667.2 |
| CAC-10008594-5 | Cayman | PSN632408 | 5 mg | 1463 |
| CAC-10008596-100 | Cayman | (±)5(6)-EET Ethanolamide | 100 µg | 3988.6 |
| CAC-10008596-25 | Cayman | (±)5(6)-EET Ethanolamide | 25 µg | 1108.8 |
| CAC-10008596-50 | Cayman | (±)5(6)-EET Ethanolamide | 50 µg | 2032.8 |
| CAC-10008597-100 | Cayman | 8(9)-EET Ethanolamide | 100 µg | 3988.6 |
| CAC-10008597-25 | Cayman | 8(9)-EET Ethanolamide | 25 µg | 1108.8 |
| CAC-10008597-50 | Cayman | 8(9)-EET Ethanolamide | 50 µg | 2109.8 |
| CAC-10008598-100 | Cayman | 11(12)-EET Ethanolamide | 100 µg | 3988.6 |
| CAC-10008598-25 | Cayman | 11(12)-EET Ethanolamide | 25 µg | 1108.8 |
| CAC-10008598-50 | Cayman | 11(12)-EET Ethanolamide | 50 µg | 2109.8 |
| CAC-10008599-100 | Cayman | 14(15)-EET Ethanolamide | 100 µg | 3988.6 |
| CAC-10008599-25 | Cayman | 14(15)-EET Ethanolamide | 25 µg | 1108.8 |
| CAC-10008599-50 | Cayman | 14(15)-EET Ethanolamide | 50 µg | 2109.8 |
| CAC-10008602-100 | Cayman | 20-HETE Ethanolamide | 100 µg | 10472 |
| CAC-10008602-25 | Cayman | 20-HETE Ethanolamide | 25 µg | 2910.6 |
| CAC-10008602-50 | Cayman | 20-HETE Ethanolamide | 50 µg | 5528.6 |
| CAC-10008609-1 | Cayman | S-NEPC | 1 mg | 231 |
| CAC-10008609-10 | Cayman | S-NEPC | 10 mg | 1848 |
| CAC-10008609-25 | Cayman | S-NEPC | 25 mg | 4050.2 |
| CAC-10008609-5 | Cayman | S-NEPC | 5 mg | 1047.2 |
| CAC-10008610-1 | Cayman | Epoxy Fluor 7 | 1 mg | 554.4 |
| CAC-10008610-10 | Cayman | Epoxy Fluor 7 | 10 mg | 4435.2 |
| CAC-10008610-5 | Cayman | Epoxy Fluor 7 | 5 mg | 2494.8 |
| CAC-10008610-50 | Cayman | Epoxy Fluor 7 | 50 mg | 19404 |
| CAC-10008612-1 | Cayman | azido-FTY720 | 1 mg | 3203.2 |
| CAC-10008612-100 | Cayman | azido-FTY720 | 100 µg | 400.4 |
| CAC-10008612-5 | Cayman | azido-FTY720 | 5 mg | 14014 |
| CAC-10008612-500 | Cayman | azido-FTY720 | 500 µg | 1801.8 |
| CAC-10008613-1 | Cayman | GW 7647 | 1 mg | 431.2 |
產品咨詢
當前位置：
地址：上海市奉賢區金大公路8218號1幢
郵箱：1006909781@qq.com
傳真：QQ1006909781